Validation of the National Lung Cancer Audit database and analysis of the information it contains by Rich, Anna
Rich, Anna (2012) Validation of the National Lung 
Cancer Audit database and analysis of the information it 
contains. DM thesis, University of Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/29747/1/575414.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
Validation of the National Lung Cancer 
Audit database and analysis of the 
information it contains. 
Dr Anna Rich MA, MRCP 
MEDICAL LlBRARY 
QUEENS MEDICAL CENTRE 
Thesis submitted to the University of Nottingham 
for the degree of Doctor of Medicine 
July 2011 
Abstract 
Introduction 
Lung cancer Is the commonest cause of cancer related death In men and women 
In England. In 2004 the National Lung Cancer Audit (NLCA) was created, as a 
national non-mandatory contemporary dataset of clinical features of Individuals 
with lung cancer In part to Identify variations In clinical practice and outcomes. 
The main aims of this dissertation are to determine the validity and 
representativeness of this dataset and then to Investigate what factors Influence 
access to surgery and chemotherapy and subsequent survival. In addition I 
have taken the opportunity afforded by this large dataset to describe the natural 
history of lung cancer In young adults (20-40 years). 
Methods 
In order to establish If the dataset was representative, I created a measure of 
case ascertainment at the level of an NHS Trust, and examined the distribution 
of patient features and outcomes for varying levels of case ascertainment. 
I have then quantified the Impact of patient and NHS Trust level features on 
access to surgery In people with non-small cell lung cancer and access to 
chemotherapy In people with small cell lung cancer using multivariate logistic 
regression. I have also conducted a series of survival analyses using Cox 
regression. 
Results 
I have found no evidence that patient features vary systematically according to 
levels of case ascertainment In the NLCA. 
Age, sex, performance status, stage and co-morbidity all Influenced the 
likelihood of having surgery for people with non-small cell lung cancer. Those 
patients first seen In a thoracic surgical centre where more likely to receive 
surgery than patients seen at peripheral centres (adjusted OR 1.51, 95% CI 
1.16, 1.97), and surgery had a significant benefit on mortality (adjusted HR 
0.41, 95% CI 0.39, 0.44). Although the resection rate was higher for patients 
first seen at a surgical centre (17% v 12%) these patients did equally well after 
surgery suggesting they were not a higher risk group. 
Individuals with small cell lung cancer first seen In a hospital with a high 
participation In clinical trials, (>5% of expected lung cancer patients being 
entered into clinical trials), were more likely to receive chemotherapy (adjusted 
OR 1.42, 95% CI 1.06, 1.90). Chemotherapy was associated with an 
Improvement In survival (adjusted HR 0.51, 95% CI 0.46, 0.56), and amongst 
those patients receiving chemotherapy, mortality was not affected by the trial 
status of the hospital where they were first seen. In limited stage small cell 
disease, those patients who had chemo-radiotherapy had an Improved survival 
compared with those patients who received chemotherapy alone (adjusted HR 
0.72, 95% CI 0.62, 0.84). 
This dataset of English patients with lung cancer contains one of the largest 
cohorts of young adults (20-40 years) with lung cancer (N=583). I have been 
able to demonstrate that the majority present with a good performance status (0 
or 1 in 80% of those with PS recorded), but advanced (stage IV) disease at 
diagnosis (55% of those with stage recorded). Those who have surgery have a 
survival profile simIlar to their older counterparts. 
Conclusion 
The National Lung Cancer Audit is a representative, contemporary cohort of 
people with lung cancer, which can provide valuable information for health 
service research in lung cancer. I have found evidence that there is variation in 
access to treatment based on the facilities or the performance of Individual NHS 
Trusts. My results suggest that by improving access to thoracic surgery for 
those individuals with non-small cell lung cancer we may be able to raise the 
resection rate and Improve five year survival. The pattern is similar for people 
with sma" cell lung cancer and access to chemotherapy. 
What this research cannot explain Is the aetiology for this variation, and where 
In the diagnostic pathway changes need to be made to improve the active 
management and access to potentially curative regimes. As the audit matures 
with more detailed information on NHS Trust level care, further analyses will be 
possible to try and determine more clearly what explains these variations, and 
how we might intervene to reduce them. 
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Chapter one: Introduction 
1 
Introduction 
Lung cancer In England and Wales 
The aim of this MD Is to examine a national dataset, evaluate Its validity and 
then analyse the data within It, to assess how patient and hospital features 
Influence treatment and survival for Individuals with lung cancer In England. The 
aim of this chapter Is to set the scene by describing the epidemiology of lung 
cancer nationally and Internationally, and commenting on Important Government 
Initiatives that have been designed to Improve the standard of care for 
Individuals with lung cancer In England and Wales. The development of the 
National Lung Cancer Audit was driven by concerns that widespread Inequality In 
lung cancer outcome existed In England. Data generated by the National Lung 
Cancer Audit have formed the basis for the analysis throughout this thesis. 
1.1 Epidemiology 
Lung cancer remains one of the leading causes of preventable death In the 21st 
century despite the knowledge of Its aetiology, and the dramatic fall In smoking 
rates over the past three decades. More than 40,500 Individuals are diagnosed 
with lung cancer each year In the United Kingdom (1). The Incidence rate for 
lung cancer Increased In men until the late 1980's and has gradually fallen since. 
In women the Incidence overall has remained stable over the past two decades, 
but In women aged over 75 years the Incidence has continued to rise (2). This 
trend In lung cancer Incidence mirrors the pattern of smoking In the United 
Kingdom, with a 20 year lag phase (3). The prevalence of smoking In young 
middle aged men has halved between 1950 and 1990 (4), and the death rate 
from lung cancer (between the ages 35-54 years) has fallen even more sharply, 
suggesting a reduction In the risk for those who continued smoking too. The 
Incidence of lung cancer In women has not begun to fall yet, and It remains the 
leading cause of cancer related mortality In women. 
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1.1.1 Histology 
Lung cancer has four main groups of histology: squamous cell, adenocarcinoma, 
large cell and small cell carcinoma. These account for >90% of all lung cancers. 
Changes In the relative frequency of these different tumours have occurred over 
time, and world-wide adenocarcinoma has become the commonest type of lung 
cancer, above squamous cell carcinoma (3). The dose-response relationship 
between smoking and lung cancer Is steepest for small cell carcinoma closely 
followed by squamous cell carcinoma, and there appears to be a link between 
adenocarcinoma and peripheral lesions, in contrast to squamous cell carcinoma 
and central lesions (3). 
1.1.2 Survival 
Survival from lung cancer remains poor, which is primarily related to late 
presentation of this aggressive disease, and the advanced stage of the disease at 
diagnosis which limits the treatment options. It Is generally accepted that only a 
third of patients are potentially curable at diagnosis, In other words have 
localised disease and are fit enough to receive radical treatment. In these 
patients with Stage Ia or Ib disease, the five year survival figures are 54-80% 
and 38-65% respectively. 
Survival figures In England and Wales from 2000-2001, suggest that 25% of 
men and 26% of women were alive a year after diagnosis. This Is a dramatic 
Improvement compared with the one year survival In 1971-76 of 15% and 13% 
respectively. However, five year survival has Improved very little over the same 
tl mefra me. In 1971-76 the five year survival for men and women was 4%, and 
In 2000-01 It was 7% (5). This apparent discrepancy between one and five year 
survival may reflect a combination of Improved diagnostic practice and better 
chemotherapy, so that whilst the majority of Individuals have Incurable disease 
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at diagnosis (and fall to survive five years), they may show partial response to 
chemotherapy and survive between one and two years from diagnosis. 
Doll published evidence In 2005 which showed that the mortality rate of lung 
cancer In men In the UK Is comparable with other economically equivalent 
European countries, whilst for women the UK has one of the highest mortality 
rates (6). However, Coleman et al have published data from several national 
cancer Registries which show higher mortality In England, Northern Ireland and 
Wales compared with Australia, Canada and several Scandinavian countries, 
regardless of sex. This was particularly relevant for the first year after diagnosis 
and for those Individuals aged >65 years at diagnosis (7). Deaths within the 
first year of diagnosis suggest late presentation of lung cancer patients In the 
UK. 
1.1.3 Race and Ethnlclty 
There Is evidence from the Cancer Reform Strategy (CRS) Equality Impact 
Assessment (8) document that smoking levels are higher In Black and Minority 
Ethnic (BME) communities compared with the national average, and that the 
uptake of 'Stop smoking' services Is low In these communities. There appears to 
be lower cancer mortality In these groups. This can be partially explained by the 
younger age profile, and the fact that some older patients will return to their 
country of birth to die. There Is also evidence that Individuals from these ethniC 
groups are underrepresented In cancer research. The reason for this Is not 
clear. In England and Wales, Individuals from the White-British race group are 
more likely than Individuals from BME groups to attend screening programmes 
and to be referred under the two week walt system (8). 
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1.1.4 Socioeconomic status 
In developed countries it has been noted that lung cancer Is more common 
amongst Individuals from lower socioeconomic classes (9, 10) and those who are 
less educated (11). In Canada, the risk of lung cancer In both sexes is inversely 
related to Income, education, and social class even after adjustment for cigarette 
smoking (12). It has also been observed that those from lower socioeconomic 
classes present later and hence will have a worse prognosis. A difference of 
1.4% In 5 year survival has been reported between Individuals In the most 
affluent sections of society In England and Wales compared with those In the 
most deprived sections of society (5). 
The CRS Equality Impact Assessment (8) reported several features relating to 
lung cancer, smoking and socioeconomic status. Lung cancer Incidence In 
England and Wales Is significantly higher In deprived groups compared with more 
affluent groups; and the prevalence of smoking Is 29% In manual groups 
compared with 19% In non-manual groups. An encouraging finding was that the 
'Stop smoking' services have been most successful In the most deprived areas of 
England and Wales. 
1.1.5 Worldwide 
Lung cancer Is the most commonly diagnosed cancer worldwide, but there Is 
marked regional variation In Incidence. The areas with the highest Incidence 
rate are the developed countries of North America, Europe, Australia and for 
men the former Soviet Union, whilst for women China Is a country with a high 
Incidence rate (13). Although diagnostic techniques and coding of cancer 
registrations will affect the reliability of this Information, It Is widely accepted 
that lung cancer remains a disease of developed countries. It Is Interesting to 
note that African-Americans have one of the highest Incidence rates In the world 
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(3) despite Africa Itself being a low Incidence area. This suggests environmental 
factors playa much larger role than genetics, In the aetiology of lung cancer. In 
the past ten years much more has been understood about the molecular biology 
of lung cancers, and this has led to the production of novel targeted therapies 
Including several epidermal growth factor receptor (EGFR) tyrosine kinase 
Inhibitors (14), and vascular endothelial growth factor (VEGF) Inhibitors (15). 
1.1.6 Historical Information relating to lung cancer and smoking 
The Increase In the Incidence of lung cancer In England and Wales began In the 
first half of the 20th century. Doll reported a fifteen-fold Increase In the annual 
number of deaths attributed to lung carcinoma between 1922 and 1947 (612 to 
9,287 respectively) (16). Although some of this Increase could be accounted for 
by the population Increase, standardised death rates showed that this could not 
be the main cause for the Increase. In 1901-20 the death rate for lung cancer In 
men was 1.1 per 100,000 and 0.7 per 100,000 In women. By 1936-39 this had 
Increased to 10.6 and 2.5 per 100,000 respectively (17). This Increase In deaths 
attributed to lung cancer was also reported In other European countries, North 
America, Australia and parts of south east Asia (16). Two main theories were 
offered for this Increase In the Incidence of lung cancer, namely atmospheric 
pollution (car exhaust fumes, coal fires and Industrial plants), and smoking of 
tobacco. Although tobacco had been used for centuries, It was thought that the 
Introduction of manufactured cigarettes In the 20th century, with addictive 
properties, led to a more sustained pattern of exposure which was the cause of 
the rise In lung cancer Incidence. 
In 1950, approximately 80% of men and 40% of women were smoking, and that 
same year Doll and Hili published the results of a case-control study, which 
Included 709 patients with lung cancer and an equal number of age and sex 
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matched controls (16). In those patients with lung cancer, few were non-
smokers and the majority of smokers fell Into the 'heavier smoking' categories. 
In 1951 Doll and Hill began a longitudinal cohort study amongst doctors on the 
medical register In the United Kingdom. Questionnaires were completed which 
reported current smoking status, age of Initial smoking, method of smoking and 
amount of tobacco consumed (18). A total of almost 35,000 male doctors were 
recruited, and their smoking habits as well as cause specific mortality have been 
monitored periodically until 2001, a total of fifty years. Excess mortality was 
associated with neoplastic, vascular and respiratory disease (19). The results 
showed that men born between 1900-30, who smoked cigarettes, died on 
average about ten years younger than lifelong non-smokers. The study also 
showed that the age at which smokers stopped affected the years of life 
expectancy that an Individual could expect to gain: 3, 6, 9 and 10 years, If men 
stopped smoking at age 60, SO, 40 and 30 years respectively. The cohort has 
also revealed a progressive Increase In the smoker v non-smoker death rate 
ratio at the end of the 20th century, with a three-fold death rate ratio In men 
surviving between the ages of 70-90 years. 
The cause of death amongst this cohort of male doctors can be divided Into three 
main groups: vascular (Including Ischaemlc heart disease and cerebrovascular 
disease), neoplastic, and respiratory disease which accounted for 55%, 21% and 
9% of the deaths respectively. Within the subgroup who died of a neoplastic 
process, lung cancer accounted for 20% of deaths. Doll reports that a quarter of 
the excess mortality amongst smokers Is accounted for by lung cancer or chronic 
obstructive pulmonary disease (COPD), and a further quarter by Ischaemlc heart 
disease (IHD). 
Since 1950 the prevalence of smoking has fallen steadily for men, reported as 
36% In 2000, whilst the peak level of smoking In women did not occur until 
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1970, when 50% of women smoked, and by 2000 this level had fallen to 28% 
(4). Worldwide, approximately 30% of young adults become smokers, but In the 
U.K this figure Is lower at 23%. A report from Peto et al In 2000, reported that 
mortality from smoking In the first half of the 21st century will be affected 
predominantly by the number of smokers who quit rather than by the number of 
young adults who start (4). 
It Is known that the risk of lung cancer Is related to the duration of smoking and 
the number of cigarettes smoked per day. Whilst cigar and pipe smoking are 
linked to lung cancer, their Influence Is less than cigarettes; and this Is thought 
to be due to differences In frequency and In the depth of Inhalation. Smokers of 
any age can reduce their risk of lung cancer by quitting, and If this Is achieved 
by middle-age, then almost 90% of the risk attributable to lung cancer can be 
avoided (4). 
There have been a number of Initiatives to reduce the public health Impact of 
smoking. These Include: filtered and low tar cigarettes, stronger advice 
warnings on packets, smoking cessation workshops, quit-lines, a ban on 
cigarette advertising at all sporting events, and In July 2007 the ban on smoking 
In all public places Including workplaces, restaurants and pubs In England. 
Nicotine replacement therapy has also been a major advance In helping those 
Individuals who are trying to quit smoking achieve long term cessation. A 
Cochrane review article In 2008 states that nicotine replacement therapy 
Increases the chance of quitting by 50 to 70%, and this Is true regardless of the 
type of replacement therapy used (20). 
1.2 Comparison with International data; European and North American 
There have been a number of European collaborations regarding cancer survival 
since 1999, EUROCARE 1-4. These studies Incorporate data from 47 cancer 
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registries In 21 countries, and Include 4 regional registries from England. The 
latest paper, EUROCARE-4 (21), was published In 2007, and used period analysis 
to report survival data. The relative 5 year survival for lung cancer across the 
U.K was reported as 8.4% In England, 10.4% In Wales, 8.2% In Scotland, 10.7% 
Northern Ireland, and 10.9% In the Republic of Ireland. The highest rate of 5 
year survival for lung cancer was In central Europe, with a rate of 13.4%. There 
are also noted differences In lung cancer resection rates, which for the U.K. are 
quoted as 11%, compared with 17% for the rest of Europe and 21% for North 
America (5). 
The Surveillance, Epidemiology and End Results (SEER) programme (22) In 
America Is a registry linked dataset recording Information on all cancers, 
Including stage at diagnosis, and covers approximately 26% of the population of 
the United States. It produces statistical reports covering all cancers and 
Includes data from 1973 onwards, with links to the National Longitudinal 
Mortality Study which provides socioeconomic and demographic Information. 
The latest figures for 5 year survival for lung cancer In America are 13% for men 
and 17% for women (22). 
An International benchmarking project Is underway, using Registry data from six 
countries Including the United Kingdom, Australia, Canada, Denmark, Sweden 
and Norway. The first results have been published and they confirm that the UK 
has the lowest lung cancer survival data of these countries, with a 5 year 
survival rate of 9% (7). 
1.3 Department of Health Initiatives to address lung cancer care 
Despite a National Health Service that Is free at point of access, medical 
professionals with a good reputation both clinically and for research, England and 
Wales have appeared to lag behind other European countries and North America 
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In terms of outcome measures for lung cancer. There have therefore been a 
number of government policy changes over the past 15 years which have tried 
to address Inequalities In the system and to Improve clinical standards across 
England and Wales. These policy documents and the establishment of the 
National Lung Cancer Audit are outlined below. 
1.3.1 Lung Cancer Audit (1999) (23) 
The Clinical Effectiveness and Evaluation Unit (CEEU) of the Royal College of 
Physicians of London produced an Internal Report funded by the Department of 
Health In August 1999. This document Included the findings on 1600 patients 
from 48 National Health Service (NHS) Trusts In England, Wales and Northern 
Ireland. The patients were those on whom a bronchoscopy had been performed 
for suspected lung cancer, and the follow-up period was 6 months. Although the 
cohort Is not adequate for definitive evaluations on treatment offered and 
survival, there were several observations of Interest. The first was that more 
than a third of patients with suspected lung cancer were not referred directly by 
their General Practitioner (GP), but entered the lung cancer pathway via an 
alternative route. Another observation, linked with the 'process' of managing 
Individuals with suspected lung cancer, was the variation and length of time 
between points along their pathway, for example bronchoscopy and the Initiation 
of treatment. Both these pOints were addressed In "commitment 2" of the NHS 
Cancer Plan (24) (see below). It was also noted that for this specific cohort, 
those without a histological diagnosis at four weeks, two thirds failed to have 
any proven histology at six months. The results In this document were not 
published in a peer reviewed journal; but, as the first national audit addressing 
lung cancer care In the United Kingdom, It was a useful exercise which did 
produce evidence of Inequality around the country and which has Informed the 
Clinical Effectiveness and Evaluation Unit (CEEU) of the Royal College of 
Physicians who, In partnership with The Information Centre, established the 
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National Lung Cancer Audit in 2004. The first full year of data collection of the 
National Lung Cancer Audit (NLCA) was 2005, and Initially recruitment was slow. 
However, over the past 5 years there has been a steady Improvement with every 
NHS Trust In England having participated at some pOint, and the vast majority 
now upload data on people with lung cancer as part of routine clinical practice. 
In the Annual report of 2010 (based on data from 2009), the level of case 
ascertainment was reported to be 95%, and the data completeness has also 
increased, with data on histology, performance status and stage reported as 
being 78%, 79% and 82% complete (25). It is now mandated that all NHS 
Trusts should partiCipate In the NLCA, and the NLCA has been endorsed by the 
National Institute of Health and Clinical Excellence (NICE) Lung cancer guideline 
In 2005 (26). 
1.3.2 The NHS Cancer Plan (2000) (24) 
Published In September 2000 'The NHS Cancer Plan' was designed to layout the 
strategies by which the Department of Health Intended to Improve cancer 
services across England and Wales, and, In so dOing, address the Inequalities 
that exist in InCidence, survival and provision of cancer care around the country 
and In comparison with other European countries. It had four main alms; 
• To save more lives. 
• To ensure people with cancer get the right professional support and care 
as well as the best treatments. 
• To tackle the Inequalities In health that mean unskilled workers are twice 
as likely to die from cancer as professionals. 
• To build for the future through Investment In the cancer workforce, 
through strong research, and through preparation for the genetiCS 
revolution, so that the NHS never falls behind In cancer care again. 
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It also had 3 specific new commitments, namely: to reduce smoking rates, to 
create targeted waiting times for new referrals with suspected cancer, and to 
Invest an extra £50 million by 2004 In hospices and specialist palliative care. 
There were a number of areas In which the proposals would affect lung cancer 
care specifically. Addressing the burden of cancer which results from smoking 
was one of the key areas discussed. Methods to control smoking related cancer 
burden included: a ban on tobacco advertising, the Introduction of smoking 
cessation services and nicotine replacement therapy (NRT) on preSCription, 
which have subsequently become available 'over-the-counter', and enforcing the 
law on the sale of tobacco products to under 16 year olds. Screening services 
for lung cancer were also mentioned, and a national pilot feasibility study Is 
underway with funding from the Health Technology Assessment Scheme. A 
number of new national bodies were created such as the National Institute for 
Health and Clinical Excellence (NICE) which have produced recommendations on 
the structure of lung cancer services and the drugs that should be available, 
regardless of one's place of residence In an attempt to eradicate the 'postcode 
lottery'. The Commission for Health Improvement (CHI) was also created. This 
has been Involved with the Peer Review process to evaluate If recommendations 
made by the Department of Health are actually being translated to the public. 
The National Cancer Research Institute (NCRI) was established to ensure high 
level research, and a specific recommendation was made to support audit 
database development for all cancer sites. 
1.3.3 Cancer Reform Strategy (2007) (27) 
Published in 2007 the Cancer Reform Strategy was designed to build on the 
progress made since the NHS Cancer Plan In 2000, and, with a strict tlmeframe, 
to implement Improvements within the next five years. Cancer mortality had 
fallen by 17% between 1996 and 2005, and survival rates were Improving for a 
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number of cancers (for example, breast and bowel), although not for lung 
cancer. The creation of multi-disciplinary teams (Cancer Plan 2000) made a 
huge difference to the patient pathway (28), from suspicion of cancer to the 
Instigation of a management plan (29); and the generation of specialist cancer 
nurses has Improved the patients' experience (30, 31). Almost all patients are 
seen within two weeks of referral from their GP, and more than 99% receive 
their first treatment within a month of diagnosis, compared with 31% In 2000 
(29). But there remain areas of need, In particular the rise In the Incidence rate 
of cancer as people live longer, and the Increase In people living beyond the 
disease, which leads to an Increase In disease prevalence. The Cancer Reform 
Strategy set out to address these challenges and Is divided Into ten key areas of 
change. Six areas of change are designed to Improve cancer outcomes: 
• Preventing cancer 
Over half of all cancers could be prevented through changes to lifestyle; these 
Include smoking cessation, avoiding obesity and excess alcohol consumption. 
• Diagnosing cancer earlier 
The CRS alms to achieve this by using a combination of Increased public 
awareness and cancer screening, whilst ensuring cancer walt targets are met. 
• Ensuring better treatment 
There Is a shortage of radiotherapy facilities which needs to be addressed, 
alongside concerns regarding the delay In uptake of new cancer drugs, and 
encouraging new surgical techniques. 
• Living with and beyond cancer 
Communication Is the main priority here, both directly with health professionals 
and also by using other media formats. 
• Reducing cancer Inequalities 
There are persisting Inequalities In cancer Incidence and survival on many levels, 
Including sex, age, ethnlclty, religion, and socioeconomic class. To tackle this, 
the CRS recommends better data collection, research, and sharing best practice. 
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• Delivering care In the most appropriate setting 
This Involves the creation of service models that can be adapted for Individual 
Trust situations whilst ensuring the key components remain. 
Four areas of change are designed to ensure Improved delivery of this care: 
• Using Information to Improve quality and choice 
Improving the collection and publication of Information should lead to service 
Improvement and strengthen the commissioning from Primary Care Trusts. 
• Stronger commissioning 
The needs of every population will differ, and so there needs to be more 
focussed planning at a local level on the services that should be commissioned 
from the NHS Trusts serving that population. 
• Funding world class cancer care 
The government has made various pledges regarding funding, but has stressed 
the need for primary care trusts (PCTs) to ensure that money Is spent wisely, 
and NHS Trusts are cost effective. 
• Building for the future 
This aim Is over-arching, but It makes special mention of national data collection, 
and the creation of the National Cancer Intelligence Network (NCIN). The 
funding for research on data collated by the NCIN will come from the National 
Cancer Research Institute (established by the Cancer Plan 2000). 
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1.4 Natlona' audit changing practice 
The Royal College of Physicians, London, Is committed to clinical audit as a 
means of Improving provision of healthcare and Is Involved In several national 
audits. These Include the Inflammatory Bowel disease Audit; Multiple Sclerosis 
Audit; the COPO Audit; the Myocardial Ischaemia National Audit Project and the 
National Sentinel Stroke Audit. The latter Is a good example of a large national 
audit being used to evaluate current medical practice, create standards to which 
NHS Trusts can be measured and then re-evaluatlng NHS Trust performance. 
Over time, changes In the structure of health care can be evaluated, and 
national health policy Informed. 
1.4.1 Stroke 
The National Sentinel Audit of Stroke was established In 1998, and has been 
completed every two years since then. In 1998 all NHS Trusts In England, Wales 
and Northern Ireland completed the survey. The results of the audit, which look 
at consecutive patients seen over a two month period every other year, have 
been used to Inform national policy In terms of the National Clinical Guidelines 
for Stroke (2004) and the NICE guidelines of 2008. In 2005 Irwin et ai, 
published some of the results of the first 3 rounds of the Audit (1998, 1999 and 
2001/02) and demonstrated that the standard of care achieved on a specialist 
Stroke Unit exceeded that on a general ward, but that there had been a 
reduction In the likelihood of a patient being managed on a Stroke Unit (32). 
There have now been seven rounds of the audit process and over the last 10 
years several changes have occurred: specialist Stroke Units are now universal, 
and the Importance of Specialist Stroke Nurses has been highlighted; and 
several centres now offer thrombolytic therapy. The Audit report describes the 
shortcomings as well as the Improvements In the system (33). Two related 
Audits have now been established, the UK Carotid Interventions Audit, and the 
Stroke Improvement National Audit Programme. 
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1.5 Thesis plan 
This MD thesis Is based on the research I performed as part of a Royal College of 
Physicians (RCP) research fellowship, the aim of which was to evaluate the data 
within the National Lung Cancer Audit (NLCA). The Initial application for the 
research fellowship was designed by Dr David Baldwin and Prof. Richard Hubbard 
in collaboration with Dr Lalla Tata, Dr Catherine Free and myself. The main aim 
of the research was to assess the validity of the NLCA dataset, and then to use 
the data within It to try and Investigate the potential causes of Inequality In lung 
cancer care across England. In order to achieve this, a period of training In 
research methods, both epidemiology and statistics was required. There were 
two other elements to the fellowship, extended training In the clinical aspects of 
lung cancer care, and training In clinical effectiveness. In terms of extended 
clinical training I had a number of tutorials with Dr Baldwin discussing a range of 
topics within the field of lung cancer care (appendix 1). I also attended clinics 
with the allied specialities, thoracic surgeons, oncologists and specialist nurses. 
I also attended theatre to observe surgical procedures and have been trained to 
perform EndoBronchial UltraSound guided lymph node biopsies (EBUS). Clinical 
Effectiveness Is a measure of how well an Intervention works not just for the 
Individual but for the wider population, and my training In this Included: 
Attending Network level Lung cancer meetings, and presenting my 
research at local Lung Cancer meetings. 
Spending a day at the RCP Clinical Effectiveness and Evaluation Unit 
(CEEU)i meeting with members of all the different audit teams. 
Spending a day with Dr Peter Lachman and the Change Management 
team at Great Ormond Street Hospital to hear about their work. 
Finally I was Invited to join the Guideline Development Group (GOG) of 
the NICE Lung cancer guideline update, with the specific role of writing the 
Needs Assessment chapter, and In so doing describing the current state of lung 
cancer epidemiology In England and Wales. 
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The main alms of the research were to using existing datasets to assess the 
validity of the NLCA dataset, and then to go on to Interrogate the dataset to try 
and answer specific clinical questions regarding the geographical variation In 
lung cancer outcomes that have been reported In the past (23). In order to 
answer whether geographical Inequality Is primarily due to patient features, a 
robust marker of co-morbidity was required. I have been able to link the NLCA 
with Hospital Episode Statistics (HES) and calculate a composite score of co-
morbidity, the Charlson Index (34) for this cohort of English patients with lung 
cancer, and Incorporate this Into regreSSion models to assess Its Independent 
Influence on outcome measures. I have also tried to quantify the features of 
NHS Trusts across England, for example whether or not they are surgical or 
radiotherapy centres; and I have tried to establish which features of both 
patients and the hospitals where they are first seen have the greatest Influence 
on clinical outcomes of lung cancer. To ensure clinical relevance I have analysed 
the use of surgery In patients with non-small cell lung cancer only, and the use 
of chemotherapy In patients with small cell lung cancer only. The National Lung 
Cancer Audit contains a large number of young adults with the disease, and this 
provided a unique opportunity to describe the pattern of disease and outcomes 
observed In this young and economically viable population. 
During the course of the research period, three separate datasets were 
downloaded from the Information Centre for Health and Social Care, and I have 
used these at different pOints within this thesis. 
Dataset 1: Downloaded on 17th November 2008. 
Includes all patients first seen between 1st January 2004 & 31st December 2007. 
Dataset 2: Linked with HES. Downloaded on 30th September 2009. 
Includes all patients first seen between 1st January 2004 & 31st December 2008. 
Dataset 3: Downloaded on 30th January 2010. 
Includes all patients first seen between 1st January 2004 & 31st December 2008. 
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1.6 Chapter outline (dataset used) 
Chapter 2: Needs Assessment of the NICE Lung Cancer Update 2011 (3) 
This Is an Independent piece of work using the NLCA dataset to describe the 
current patterns of lung cancer demography In England and Wales. 
Chapter 3: Description and validation of the NLCA dataset (1) 
This was the first step In the research project, and describes the use of existing 
national datasets (ONS, HES) to try and establish If the NLCA Is a representative 
and unbiased cohort of patients. 
Chapter 4: Validating the NLCA using cancer Registry data (1) 
This chapter describes the use of cancer Registry data to repeat the validation 
process of chapter 3, and to assess the Influence of soclo-economlc status on 
clinical outcomes. 
Chapter 5: Linking the NLCA to Hospital Episode Statistics (2) 
This chapter will describe the process of cleaning the linked data and generating 
a composite score for co-morbidity. There is also a description of how features 
of NHS Trusts were generated. 
Chapter 6: Inequalities In outcomes for non-small cell lung cancer: the 
influence of clinical characteristics and features of the local lung cancer service 
(2) 
Chapter 7: How do patient and hospital features Influence outcomes In sma" 
cell lung cancer In England (2) 
Chapter 8: Young adults with lung cancer: a different disease entity? (3) 
This Is a descriptive report of the features of young adults who are diagnosed 
with lung cancer. I have also looked specifically at survival post-surgery for 
those with NSCLC, to allow comparison with published literature. 
Chapter 9: Future research 
This chapter describes proposals for future research In order to build on the 
research carried out so far, and to try and answer some of the questions raised 
during the course of this research fellowship. 
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Throughout my formal period of research I was supported by a steering group 
which was chaired by Prof Anne Tattersfield, who offered an Impartial opinion on 
the direction of the project and advice regarding publications. The members of 
the steering group Included my MD supervisors; Prof Richard Hubbard, Dr Lalla 
Tata, and Dr David Baldwin. Dr Catherine Free who had been a co-applicant on 
the Initial fellowship application was also on the group. Other members of the 
group were: Dr Mlck Peake, as the director of the National Lung Cancer Audit; Dr 
Roz Stanley, Project Manager of the NLCA; and Dr Paul Beckett, Associate 
Director, Clinical Effectiveness and Evaluation Unit, Royal College of Physicians, 
London. I was also supported by a lay member Mr Ken Purslow, who ensured 
the project direction was pertinent to patients and their carers. 
The Ideas regarding the validation and analysis of the NLCA dataset were 
primarily generated by Prof Hubbard, Dr Baldwin, Dr Tata and myself. I 
performed all the data management, cleaning and statistical analysis of the data. 
I have written this document and been lead author on three papers which have 
arisen from this work, which have been accepted for publication In peer reviewed 
journals. The co-authors on the papers were: U Tata, CM Free, RA Stanley, MD 
Peake, DR Baldwin and RB Hubbard. 
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Chapter Two: Needs Assessment of the NICE Lung Cancer Update 2011 
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2.1 Introduction 
During my research period I was Invited by the Guideline Development Group of 
the National Collaborating Centre for Cancer (NCC-C) to produce the Needs 
Assessment for the NICE Lung Cancer Update 2011. This was an excellent 
opportunity to participate In the creation of a NICE guideline and fitted nicely 
within the alms of my RCP fellowship. The scope of the guideline had already 
been agreed (appendix 2). The remit of the Needs Assessment was to provide 
the context for this guideline update, to describe the burden of disease and to 
assess whether variation exists In the treatment and outcome for Individuals with 
lung cancer In England and Wales. Given my knowledge of the National Lung 
Cancer Audit dataset, I was In an Ideal position to describe the results of this 
unselected and contemporary cohort. However, the NLCA only contains 
Individuals diagnosed with lung cancer In England, and so I had to obtain 
permission to receive the corresponding years (2006-2008 Inclusive) of data 
from Cancer Network Information System Cymru (CANISC) In Wales. 
Data from within the NLCA were used not only for the Needs Assessment but 
also for the Health Economic component, and I was able to work closely with Dr 
Sarah Willis (health economist commissioned by NICE) to provide the numbers 
and proportions from within the dataset to furnish her economic models. Finally, 
In order to assess the facilities available at NHS Trusts across England and 
Wales, I created and distributed, via an on-line survey programme, a 
questionnaire for all Lung Cancer Lead Physicians. This primarily looked at the 
diagnostic and therapeutic facilities available, as well as the role of the lung 
cancer speCialist nurse. It describes the on-going variation In access to 
diagnostic and therapeutic facilities, which may well Influence clinical outcomes. 
What follows Is the Needs Assessment chapter as It appears In the NICE Lung 
Cancer Update 2011. 
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2.2 Needs Assessment 
The following chapter provides a summary of the full Needs Assessment that was 
carried out as part of the evidence review for this guideline. It Includes 
Information regarding the epidemiology of lung cancer regionally, nationally and 
Internationally. This guideline update Is not a comprehensive review of all 
aspects of lung cancer management but Is limited to priority areas that were 
Identified before and during the scoping exercise that were thought to be key 
topics that might help Improve the overall standard and equity of care provided 
geographically. The purpose of this chapter therefore Is to provide the context 
for the guideline, to describe the burden of disease and to assess whether 
variation exists In the treatment and outcome for Individuals with lung cancer In 
England and Wales. We shall Illustrate the need for Improved diagnostic and 
staging procedures, and the link to selecting patients for their optimal therapy 
for Improving survival and quality of life; whilst addressing the Important Issues 
of Informed patient choice. 
Since the 2005 NICE Guideline on Diagnosis and Treatment of lung cancer was 
published, the National Lung Cancer Audit has been established, and accrual has 
Increased steadily over the past five years. It Is estimated that the Audit 
gathered Information on 85% of the Incident cases of lung cancer In England and 
Wales In 2008 (35). It Is the largest contemporary, non-registry, clinical 
database of lung cancer patients In Europe, with over 100,000 patients In total. 
It Is a non-mandatory dataset of clinical and soclo-demographlc features, and 
also records details of the treatment received. The dataset has been shown to 
be unbiased and representative of lung cancer patients In England (36). These 
data have been used within this NICE Lung Cancer Update along with 
contemporary data from Cancer Network Information System Cymru (CANISC) 
In Wales to describe the current demographics of Individuals with lung cancer In 
England and Wales; the patterns of treatment they receive and their survival. 
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Other Information sources Include the National Cancer Intelligence Network 
(NCIN), the National Cancer Registry, and the British Society of Cardlothoracic 
Surgery. 
This NICE Lung Cancer Update has Included a revision of several sections from 
the original guideline In 2005 (26), and provided the opportunity to assess the 
progress that has been made over the last five years, and Identify areas that 
have shown no Improvement. In 2002 there were 29,000 deaths from lung 
cancer, and It was the second most common cause of cancer related death In 
women. In 2008, there were more than 35,000 deaths (5), and It Is now the 
leading cause of cancer related death In men and women. There has been an 
encouraging Improvement In 1 year survival compared with the data quoted In 
the 2005 guideline; although regional variation In this outcome measure perSists 
(37). Regional variation was also described In 5 year survival, but contemporary 
data from the NLCA will not be available until 2011. The proportion of the 
overall patient cohort with small cell lung cancer was estimated as 20% In 2005. 
Current data reports the proportion having fallen to around 11% of all reported 
lung cancers (18% of histologically confirmed lung cancers). Data from 1986-
1994 (North Yorkshire Cancer Registry Information Services) demonstrated that 
34% of patients had no histological confirmation of their lung cancer (38), and 
this figure has fallen very little over the last 15 years. 
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2.2.1 Incidence 
The incidence of lung cancer in England and Wales is believed to be 47.4 per 
100,000 population (5). Data from ONS showed a total of 34,897 incident cases 
in England and Wales in 2008. It is the second commonest cancer in men, after 
prostate and, in women, after breast cancer. The prognosis is very poor with a 
mortality rate of 40.1/100,000 population. The prevalence reflects this poor 
prognosis with an estimate of 65,000 individuals living with lung cancer in 2008. 
In the 2005 NICE Lung Cancer Guideline (26), deaths from lung cancer were 
believed to be the commonest cause of cancer related deaths in men, and the 
second most common cause in women. However, lung cancer has since become 
the commonest cause of cancer related death in both sexes. 
Comparison within the European Union reveals that the incidence in men is 
similar to most of western Europe and lower than most of eastern Europe. The 
incidence in women is amongst the highest in the European Union (figure 2.1) . 
. <57.1 
. 57.2 - 82.8 
82.9 - 108.4 
(a) Males 
• <13.9 
. 14 - 22.2 
22.3 - 30.6 
(b) Females 
Figure 2.1: Age-standardised incidence rates in the European Union (2000) ; 
Reproduced with the permission of Cancer Research UK. 
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2.2.2 Sex variation 
The majority of individuals with lung cancer are male, and th is is almost certa inly 
a direct reflection of the proportion of smokers that are male. However, the 
proportion of men who smoke has fallen by 26% since the mid 1970's (39) and 
there has been a similar decline in the proportion of women who smoke over the 
same timeframe (figure 2.2) . There is known to be a twenty year lag phase 
between smoking and the onset of lung cancer and so changes in the pattern of 
smoking between the sexes is a precursor of changes in the sex ratio amongst 
individuals with lung cancer (figure 2.2). The peak prevalence of smoking in 
young women was only reached in the 1990's, and so the incidence of lung 
cancer amongst older women has only recently stabilised. The male:female ratio 
was >6: 1 in 1973 compared with 1.5: 1 in 2008 (35). 
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1975-2005 (Reproduced by kind permission of Cancer Research UK) . 
25 
20 
0 
"'0 CD O Q.o 
CD -
_ 0 
ClIO 
0:: .... 
There Is also evidence from the National Lung Cancer Audit that females have 
better overall survival than males, with an adjusted hazard ratio of 0.89, 
p<O.OOl (95% confidence Intervals, 0.88, 0.91) (36). This result Indicates that 
women with lung cancer are 11% less likely to die than men, and this 
observation has been Identified In a number of other populations (40,41). 
2.2.3 Histological subtypes 
Obtaining a histological diagnosis for a lung tumour Is usually necessary to 
ensure the most appropriate treatment regime Is considered. If targeted 
treatment Is an option, It Is vital that samples and their analysis are adequate to 
allow Identification of histological subtypes and specific mutations that directly 
determine suitability for specific treatments. 
There Is evidence from the National Lung Cancer Audit that a significant 
proportion of patients are diagnosed on the basis of clinical examination and 
radiological Investigations alone, without histological evidence. The proportion of 
patients for whom this was the case Is 23% In England and 32% In Wales (2006-
08); which refiects some Improvement on English data from 1986-94 of 34% 
(38). It Is acknowledged that some patients do not require a histological 
diagnosis where they are either too unwell for active treatment or a decision to 
proceed to curative surgery has been made prior to histological confirmation, but 
for the majority histology should be confirmed. It Is not possible to say what the 
histological confirmation rate should be but the Guideline Development Group 
(GOG) agreed with the Department of Health recommendation of around 80%. 
The NLCA shows that this Is not the case across NHS Trusts In England with the 
median Histological Confirmation Rate being only 63% (interquartile range 47 to 
72%) (36). 
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The prevalence of the different subtypes has changed with time, which is 
believed to be due to the temporal change in smoking prevalence, and also the 
use of filters and low tar cigarettes. Small cell lung cancer is believed to be most 
closely linked to smoking pack history, and the proportion of all lung cancers due 
to small cell has decreased from 20 to 10% (42). In 1950 the ratio of 
adencarcinoma :squamous cell carcinoma was 1: 18; but in 1994 was reported as 
1: 1.3 (43). This increase in adenocarcinoma was seen in both sexes and all 
ethnic groups. 
Data from the National Lung Cancer Audit demonstrate contemporary results for 
the variation in histological types, although these data are missing in 40% of the 
English and 32% of the Welsh cohorts. 
• Non-small cell (N =32,432, 78%) 
• Small cell (N=7,307, 18%) 
• Carcinoid (N=236, 0.6%) 
• Other (N=l,650, 4%) 
Figure 2.3: Histological subtypes In proven primary lung cancer; NLCA (England 
and Wales) 2010. 
The NLCA holds data for the breakdown of subgroups of Non-small cell lung 
cancer, which highlights the increase in prevalence of adenocarcinoma, and also 
the large proportion of patients in whom an exact histological subtype is missing, 
Non-small cell "Not otherwise specified" (NOS) . 
27 
• Non-small cell NOS (N =11,496, 35%) 
• Squamous cell (N=10,350, 32%) 
• Adenocarcinoma (N=8,568, 26%) 
• Bronchoalveolar cell (N=582, 2%) 
• Carcinoma-in-situ (N=139, 0.4%) 
• Large cell carcinoma (N=l,164, 4%) 
• Mixed NSCLC (N=133, 0.4%) 
Figure 2.4: Subgroups of non-small cell lung cancer in England and Wales 
(N = 32,432; NLCA 2006-08). 
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2.2.4 Soclo-economlc status (SES) 
A number of papers have been published which Indicate that there Is an 
Increased Incidence of lung cancer In Individuals from the lowest level of socio-
economic strata, the least affluent group (9-11). Historically this difference has 
been attributed to the Increased rate of smoking In the least affluent group (9), 
and there Is evidence that histological subtypes vary with SES reflecting the 
variable Influence of smoking on specific histological subtypes (44). However, 
other factors will be involved Including diet, nature of employment (manual vs 
professional), and educational attainment (11, 12, 45). Differences also exist 
between Individuals from different SES In terms of access to health services and 
health seeking behaviour (46). Crawford et al found individuals from the most 
deprived group were less likely to receive a histological diagnosis (47). Shack et 
al (48) noted that the gradient In incidence of lung cancer across socio-economlc 
groups In England was more marked In the North East, the North West and 
Yorkshire and Humber regions. Data from the National Cancer Intelligence 
Network Illustrates a more than two fold variation In age standardised Incidence 
rate In both men and women between the most and least affluent strata (figure 
2.5). 
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Figure 2.5: Age standardised incidence rate (per 100,000) across quintiles of 
socio-economic status (Reproduced by kind permission of NCIN). 
As well as the increase in incidence of lung cancer in the least affluent socia l 
group, there is evidence that these individuals present with more advanced 
disease (45, 49) and demonstrate a reduced uptake of resection for lung cancer 
(46, 47, 50). Data using Hospital Episode Statistics (HES) between 1992-95 
demonstrated a 40% reduction in the use of surgery between the least 
compared with the most affluent group of patients with lung cancer (unadjusted 
OR 0.58, 95% confidence interval 0.48, 0.70) (50). However this figure may be 
misleading as it is not adjusted for age, sex, performance status, or stage . 
Contemporary data (2005-2008) from the NLCA demonstrated no variation in 
the use of surgery in proven NSCLC, based on socio-economlc status, with an 
adjusted OR of 1.11 (95% confidence interval 0.96, 1.27) (36). Jack et al 
(2006) reported a lower rate of chemotherapy use in patients within the South 
East region from the least affluent group (51), which has been reproduced using 
contemporary data from the NLCA (36). However, in neither study was social 
deprivation linked to poorer survival (36, 51). Data from the NLCA 
demonstrated no variation in the use of radiotherapy for the overall cohort of 
patients with lung cancer, based on socio-economic status (36). 
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2.2.5 Ethnic variation 
There is evidence of variation in the incidence of lung cancer amongst ethnic 
groups in England and Wales, which is related to demographic features, socio-
economic deprivation and smoking prevalence. Black and minority ethnic groups 
(BME), have higher than average smoking rates, and are more likely to be from 
deprived areas with increased unemployment and lower levels of educational 
attainment (8, 52). Evidence from America demonstrated that African -
Americans were more likely to present with advanced stage of lung cancer than 
Caucasians, which was related to socio-economic status rather than directly to 
ethnicity (45). In contrast race was an independent risk factor for advanced 
stage at presentation in breast and prostate cancer (45). In England and Wales, 
an increase in relative mortality was found in migrant individuals with lung 
cancer from Jamaica (52). Differences also exist in terms of accessing health 
services such as smoking cessation and screening between ethnic groups, with 
White-British individuals more likely to present via a two-week wait appointment 
than individuals from BME groups (8). There is also evidence that individuals 
from BME groups are underrepresented in cancer research (8) . 
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Figure 2.6: Variation in age standardised relative male survival at 1 and 3 years 
by major ethnic groups in England and Wales (Reproduced with kind permission 
of NCIN). 
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Asian individuals with lung cancer have a significantly higher percentage survival 
at 1 and 3 years compared with white patients, regardless of age. There was no 
significant difference in relative survival between BME groups at 1 or 3 years. 
Similar results were seen for women as for men. 
Given potential cultural and language barriers for individuals from BME groups 
accessing lung cancer services within the NHS, it is very important that every 
effort is made to ensure that each component of the patient pathway is clear and 
user-friendly. 
2.2.6 Stage and Performance status 
The stage of lung cancer at diagnosis Is crucially important in terms of 
determining which patients have potentially curable disease, and which do not. 
Stage Is also an Important determinant of prognosis. The routine use of CT 
scans of the thorax and upper abdomen along with PET-CT has Improved the 
accuracy of staging. Recently the International Association for the Study of Lung 
Cancer group (IASLC) has produced a revised TNM staging system that has been 
adopted by the Union Internatlonale Contre Ie Cancer (UICC). Plans are already 
underway to collect more accurate staging data and relate this to prognosis to 
produce a yet more accurate staging system. Information regarding stage of 
disease at presentation Is not collected by the Cancer Registries but Is collected 
within the NLCA and CANISC, although these data are Incomplete. Stage data 
were missing In 46% English and 30% Welsh patients overall, and In 27% and 
17% of English and Welsh patients with proven NSCLC respectively. 
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• IA-B (N=5,770, 14%) 
• IIA-B (N=2,523, 6%) 
• IliA (N=4,292, 11%) 
.IIIB (N=8,530, 21%) 
_ IV (N=19,377, 48%) 
Figure 2.7: Stage at presentation in those patients with stage recorded 
(N = 40,492). NLCA (England and Wales) 2006-08. 
Table 2.1 demonstrates that across England and Wales a significant proportion of 
each age group presents with late stage metastatic disease. As a proportion of 
those patients with stage recorded, the youngest age groups have a similar 
burden of advanced disease to other groups, with the most elderly (>80 years) 
having significantly less. A significant proportion of people who are economically 
active and more likely to have dependent children will present with advanced 
disease. Late presentation in the younger age group will be multi - factorial but 
may reflect fear or ignorance on the part of young adults, and a lack of clinical 
suspicion in healthcare professionals. 
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Table 2.1: Frequency of Stage IV disease based on age groups in England and 
Wales (2006-08) . Data provided by NLCA and CANISC 
Age groups (years) N 0/0* 0/0* if stage recorded 
20-40 95 27 58 
41-50 615 27 51 
51-60 2807 29 52 
61-70 5682 27 48 
71-80 6711 26 47 
>80 years 3397 24 45 
% * percentage of each age group with Stage IV disease 
Data are also collected by the NLCA and CANISC on performance status at 
diagnosis, although these data were missing in 38% of the English and 23% of 
the Welsh cohorts. Figure 2.8 demonstrates that as age increases so does the 
proportion of patients with performance status 3 or 4 at diagnosis. This will 
have implications on the treatment options available to elderly patients. 
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Figure 2.8: Variation in performance status at diagnosis based on patient age 
group (N = 46,897). NLCA (England and Wales) 2006-08. 
Information on co -morbidities is not reliable within the NLCA, and so work is on -
going to link the NLCA dataset to other datasets, such as Hospital Episode 
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Statistics (HES), in order to evaluate the potential influence of patient co-
morbidity and outcome measures for lung cancer. This work is described in 
Chapter 5 and incorporated into the analyses in Chapters 6-8. 
2.2.7 Treatment received 
Data from the NLCA (total for this analysis 67,730 records) show that overall 
13.5% of patients are recorded as receiving treatment with curative intent, 
52.5% treatment with palliative intent and 17.7% supportive care only. In 
16.3% no treatment was specified or data were missing. 
2.2.7.1 Surgery remains the mainstay of treatment with curative intent for 
NSCLC. Data from the NLCA for England reports an overall resection rate of 
11 %, which for the subgroup of patients with proven NSCLC rises to 14%. The 
data for Wales, indicates a resection rate of 6% overall, rising to 9% in proven 
NSCLC patients. Within this subgroup, the use of surgery varies according to 
age group of the patient as illustrated in figure 2.9. 
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Figure 2.9: Proportion of patients with proven NSCLC receiving surgery in 
England and Wales based on age (N = 3,998). Data from NLCA and CANISC 
(2006-2008). 
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The resection rate In proven NSCLC patients appears to drop above the age of 
70 years, and there Is evidence that even adjusting for stage and performance 
status, those over 75 years are significantly less likely to be treated surgically, 
than those less than 65 years (36, 53, 54). It Is known that as age Increases so 
does the level of co-morbid Illness (55), however It Is Important to ensure that 
patient's treatment Is planned on the basis of their clinical state, Including co-
morbidities and performance status etc, not simply their chronological age. 
Recent published evidence based on operation codes recorded in Hospital 
Episode Statistics (HES) shows no Increase In the rate of resection for lung 
cancer In England and Wales between 1999 and 2006 (46). In view of the fact 
surgical resection Is the main component of potentially curative treatment, this Is 
disappointing, and does Illustrate apparent differences In practice between other 
parts of Europe and North America (17% and 21% resection rates respectively) 
(56). 
There are data on the number and type of resections being performed In surgical 
centres throughout Great Britain and Ireland, and these are shown below as 
figures 2.10 and 2.11. These data demonstrate that there Is significant 
variability In the number of resections being performed In different surgical 
centres, although It Is not known how much this reflects differences In patient 
population, or surgical practice. 
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Figure 2.10: Number of resections for primary lung cancer at surgical centres in 
Great Britain and Ireland (Reproduced by kind permi ssion of Society of 
Cardiothoracic Surgery-Data 2005-2008). 
There is no clear evidence as to what the 'optimal' number of resections per 
surgical centre should be. Anecdotally the theory is that fewer centres 
performing more resections would reduce the post-operative mortality and 
improve the long-term survival. There is evidence from America which describes 
a difference of >5% adjusted mortality rate between low volume and high 
volume institutions for pneumonectomies (57), whilst the effect on lobectomy 
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adjusted mortality was <2%. However, research from Britain in 2003 found no 
such link between the number of lobectomies performed by an individual 
surgeon and in-hospital mortality (58). Of note, 40% of the 102 surgeons 
performed <24 lobectomies per year, which is a reflection of the fact that the 
majority of lobectomies were performed by cardiothoracic, not pure thoracic, 
surgeons at the time of this study. 
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Figure 2.11: Types of resection for primary lung cancer at surgical centres in 
Great Britain and Ireland (Reproduced by kind permission of Society of 
Cardiothoracic Surgery-Data 2005-08). 
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There is also evidence that the type of procedure performed for lung cancer 
resection varies at different surgical centres (figure 2.11). The 2005 NICE 
guideline (26) states that the procedure of choice in stage I or II NSCLC should 
be lobectomy, rather than pneumonectomy, and figure 2.11 confirms the low 
proportion of patients that underwent pneumonectomy. Only three surgical 
centres had >20% of resections recorded as pneumonectomies. 
2.2.7.2 Chemotherapy is the mainstay of treatment for small cell lung cancer, 
ideally used with concurrent radiotherapy. Overall 64% of English and 48% of 
Welsh patients with proven small cell lung cancer received chemotherapy. 
However, evidence of chemo-radiation was only found in 12% of English and 
28% of Welsh patients with small cell lung cancer. There is variation in the use 
of chemotherapy based on the age of a patient as illustrated in figure 2.12 
below. 
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Figure 2.12: Proportion of patients with proven small cell lung cancer receiving 
chemotherapy in England and Wales based on age (N = 4,530). Data from NLCA 
and CANISC (2006-2008). 
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The NLCA 2009 Annual report published evidence that demonstrated variation in 
the proportion of patients with small cell lung cancer receiving chemotherapy 
across the Cancer Networks in England and Wales (35) (figure 2.13). 
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Figure 2.13: Proportion of patients with small cell lung cancer receiving 
chemotherapy at level of Cancer Network (England and Wales). Data provided 
by NLCA. 
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2.2.7.3 Radiotherapy can be used in all histological subtypes and with both 
curative and palliative intent. It is not possible to differentiate accurately the 
treatment intent from data held within the NLCA, and so figure 2.14 illustrates 
the variation in use of radiotherapy with age for the whole cohort, regardless of 
histology. 
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Figure 2.14: Proportion of overall cohort receiving radiotherapy in England and 
Wales based on age (N = 73,730). Data from NLCA and CANISe (2006-2008). 
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2.2.8 Survival 
The prognosis from lung cancer is poor, and it is the commonest cause of cancer 
related death in England and Wales, as well as worldwide. The median survival 
for individuals with lung cancer in England, is 203 days (interquartile range 62 to 
545 days), and this is illustrated in figure 2.15 below. 
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Figure 2.15: Kaplan-Meier curve demonstrating overall survival of English 
patients with lung cancer (N = 67,730). Data from NCLA (2006-08). 
Evidence from the EUROCARE-4 (21) report suggests there is significant 
variation in the 5 year survival rate across European countries, with a relative 5 
year survival in England and Wales of 8.4% and 10.4% respectively. The mean 
5 year survival rate for all countries within EUROCARE-4 was 10.9%, and for 13 
registries within the American Surveillance Epidemiology and End Result (SEER) 
dataset was 15.7%. Survival rates were highest in Scandinavia, Belgium and 
Switzerland. It was noted, that for all areas, except central Europe, but 
including England and Wales, 5 year survival rates in lung cancer increased 
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between 1991 and 2002. No adjustment can be made for stage of disease at 
presentation within EUROCARE-4, and this may be an Important limitation of the 
study. 
There Is evidence from a recent paper comparing national lung cancer survival 
between England, Sweden and Norway that the excess mortality observed In 
England Is primarily caused by excess deaths within the first three months after 
diagnosis (59). The comparisons of excess mortality between the countries for 
years 1-2, and 2-5 years post diagnosis showed very little variation. There was 
evidence that English patients were older than their Scandinavian counterparts. 
No histological data were used In this study, but previous research has not 
demonstrated any significant variation between European countries (44). This 
study was based on registry data, and It was not possible to compare stage of 
disease, nor patient co-morbidity, and both these features will Influence the 
proportion of patients receiving treatment with curative Intent and their overall 
survival. Therefore the high rate of early death In Individuals diagnosed with 
lung cancer In England could be the result of a number of features: advanced 
stage of disease at presentation; poor performance status and co-morbidity; 
access to healthcare being via a primary care physician rather than direct to 
secondary care; or different attitudes towards and rates of anti-cancer 
treatment. 
The lack of histological data for a large proportion of patients has already been 
mentioned, and may well be due In part to poor data entry to the NLCA. 
However, It may reflect ambivalence amongst clinicians to ensure a histological 
diagnosis Is made In patients who are not candidates for radical treatment. 
Therefore It Is Interesting to note that the survival curves for these two 
subgroups of patients, those with and those without a histological diagnosis, 
show early divergence with confluence latterly (figure 2.16). The median 
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survival for those with a histological diagnosis is 217 days (interquartile range 71 
to 527 days), compared to a median survival of 158 days (interquartile range 43 
to 513 days) for those without histology recorded. Cox regression analysis 
reveals a small but significant benefit for those patients with, compared to those 
without, a histological diagnosis (unadjusted hazard ratio 0.93, 95% confidence 
interval 0.91, 0.94, p<O.OOl). This is despite it being likely that obtaining a 
histological diagnosis lengthens the time to diagnosis and hence shortens 
survival time in the histology confirmed group. The most likely explanation for 
this observation is that fitter patients are more likely to be offered chemotherapy 
with a resultant short term survival benefit. Ensuring that all NHS Trusts offer 
the same proportion of their patients active treatment, might confer a 
meaningful improvement in median survival; via a modest reduction in early 
deaths . 
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Figure 2.16: Kaplan-Meier curve demonstrating the variation in survival based on 
whether data is entered on histology in NLCA (England only data, N= 67,730) . 
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It is possible to illustrate the effect of surgery on those patients with proven 
NSCLC who were performance status 0 or 1, and who had a stage recorded of 
IA-UB. Although the numbers are relatively small, N=2,753, the Kaplan-Meier 
survival curve demonstrates a stark variation in their observed outcome (figure 
2.17). 
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Figure 2.17: Kaplan-Meier curve demonstrating the observed outcome of a 
subgroup of patients with proven NSCLC, stage IA-UB, and performance status 
0-1 (England only; N= 2,753, of whom 1,698 had surgery, and 1,055 did not) . 
Data from NLCA. 
This highlights the need to proactively stage patients accurately and to assess 
their fitness for surgery, and if required optimise their co-morbidities prior to 
surgery, given the improved outcome observed in these patients after surgery. 
45 
2.2.8.1 One year survival 
There has been a dramatic improvement in one year survival for individuals with 
lung cancer over the last 10 years. This may reflect improved cancer services 
within the National Health Service secondary to recommendations within the 
National Cancer Plan (24), and the Cancer Reform Strategy (27) in England and 
the Designed to Tackle Cancer in Wales Strategic Framework (60). 
Contemporary data reveals 32% of male patients and 35% female patients 
survive to one year in England, and 33% male and 37% female Welsh patients 
survive to one year (figure 2.18). These contemporary data suggest that one 
year survival in England and Wales is now approaching the figure of 37% quoted 
as 'good practice' in the EUROCARE-4 publication (21). 'Good practice' is based 
on the highest one year survival rates of countries with 100% registration in 
EUROCARE-4. 
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Figure 2.18: One year survival data for England and Wales (2006-2008); Data 
from NLCA and CANISe. 
However, the improvement in overall percentage of patients alive one year after 
diagnosis conceals the geographical variation that has been described between 
Primary Care Trusts (PCT) in England ranging from 15.4% to 43.7% (37). This 
apparent discrepancy in survival will be influenced by the total number of 
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patients, patient features, the infrastructure of the health service (specifically 
the availability of diagnostic and treatment facilities in individual PCTs) but 
importantly, may be influenced by the approach the local MDT takes to selection 
of patients for active treatment. 
2.2.8.2 Five year survival 
The percentage of patients surviving to 5 years, by definition cured, remains low, 
7% for males and 9% for females. Although this has improved over the last 40 
years, it remains lower than comparable European and North American countries 
(21). 
10 
9 +---------------------------------__ ___ 
~ ~~ ~ 8 + - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - ~ ~ - - -
> 
~ ~ 7 + - - - - - - - - - - - - - - - - - - - - - - - - - - - - - ~ ~ ~ ~ ~
.... 
"' ~ ~ 6 + + - - - - - - - - - - - - - - - - - - - - - - - - ~ ~ ~ ~ - - - - -
. ~ ~ 5 
:::J 
\II 
GI 4 
bO 
nJ 
E 3 +--------------------------------------
GI 
~ ~ 2 +--------------------------------------
0.. 
1 +--------------------------------------
o + + - - ~ r _ - - ~ - - - - ~ - - - - . _ - - ~ - - - - _ r - - _ _ . .
-+-Men 
Legend: * 5 year survival data incomplete for patients diagnosed in 2006 
Figure 2.19: Five year survival data over time (Reproduced with kind permission 
of Cancer Research UK). 
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2.3 Facilities available at NHS Trusts In England and Wales 
As part of the Needs Assessment exercise an online survey was distributed to all 
lung cancer MDT leads at NHS Trusts In England, and all Local Health Boards In 
Wales (appendix 3). The lung cancer leads were Invited to complete the survey 
which primarily focussed on the composition of the multi-disciplinary team 
(MDT), and the diagnostic and therapeutic facilities available within their Trust or 
their cancer Network. The response rate was 101 (66%) In England and 6 
(43%) In Wales. The NHS In Wales underwent a major reorganisation In October 
2009, with the formation of seven Local Health Boards from the previous 
configuration of Local Health Boards and Trusts. Each new Local Health Board 
therefore encompasses several MOTs. 
Cancer MOTs, which were recommended In the NHS Cancer Plan In England (24), 
and In the Cameron Report In Wales (61) have been adopted across all cancer 
sites. The aim was to provide a body of experience and breadth of knowledge 
such that patients under Investigation for cancer could be rapidly assessed and 
the appropriate treatment started at the earliest opportunity. There are no fixed 
criteria on which medical disciplines should comprise the MDT, and the National 
Cancer Peer Review Programme In England (which Is led by the National Cancer 
Action Team, NCAT) have recommended that all personnel deemed relevant to 
the decision making process should be Involved either In person or via 
video/teleconferencing. The majority of lung cancer MOTs would Include a chest 
physician, radiologist, pathologist, and specialist nurse; as well as oncologists, 
surgeons and members of the palliative care team If available. The Peer Review 
Programme provides Important Information on the number, structure, function 
and quality of all cancer MOTs across England. Between 2004 and 2008, peer 
reviews of cancer services were carried out In each cancer network, for each 
cancer site. The process has been modified over the last 6 years, and now 
occurs on an annual basis, Involves a degree of self assessment, and there are 
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32 measures to which a lung Cancer MDT Is assessed for compliance. There are 
currently 161 lung cancer MOTs across 157 English NHS Trusts, and 14 MOTs In 
Wales. 
In Wales the Welsh Assembly Government launched the National Cancer 
Standards In 2005, Including lung cancer (62), with the objective that 
compliance should be achieved by March 2009. The National Cancer Standards 
have provided NHS Wales with a clear set of quality requirements that have been 
central to the Welsh Assembly Governments Cancer Policy since 2005 (60). 
Compliance to these standards has been determined by using Information 
provided by self assessment by NHS Trusts In Wales and the most recent data 
were published In 2009. 
The survey distributed by the NICE GOG revealed that between 90-100% of 
MOTs In England and Wales had a respiratory physician, chest radiologist, 
pathologist, speCialist nurse and clinical oncologist on the MDT. However, only 
80% of MOTs had a medical oncologist, and 85% had a thoracic surgeon on the 
MDT. 
Of those English and Welsh MOTs responding to the survey, all now have an MDT 
co-ordinator, 95% have an electronic database, and 65% have a data 
administrator. These figures suggest that the lung cancer MDT Is now an 
established component of every NHS Trust and the majority have adequate 
support staff. 
The analyses described In the remainder of the Needs Assessment use only the 
on-line results from lung cancer leads at English NHS Trusts, because the 
number of Welsh responses would not allow appropriate statistical analysis nor 
could they be merged with the English responses. 
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2.3.1 Lung Cancer Specialist Nurses 
The workload of the Specialist nurse was also evaluated in th e survey, and 
revealed significant variation in the number of new cases allocated to each full 
time equivalent (FTE) nurse, and the number of additional t asks they are 
expected to perform. 
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The responsibilities of the specialist nurse can vary, and often Involve 
Inappropriate tasks that reduce the time they can spend with patients, their 
families and carers. The table below lists some of the tasks performed by 
Specialist nurses In England. 
Table 2.2: Duties of a Specialist Lung Cancer Nurse 
Duties of the Specialist nurse 
Telephone support 
Nurse-led clinics 
Support groups 
0/0 of nurses 
100 
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Only 44% of Specialist nurses have secretarial support, and 57% have formal 
cover arrangements for sick leave. 
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2.3.2 Access to diagnostic and endobronchial therapeutic facilities 
The results of this NICE lung cancer GDG survey reveal wide variation in the 
availability of diagnostic facilities at NHS Trusts in England (figure 2.22) and at 
the level of Cancer Networks (figure 2.23) . Consequently some patients will be 
expected to travel considerable distances to undergo diagnostic procedures and 
for which there may be a moderate delay of more than 2 weeks (figures 2.24 
and 2.25, England only data). 
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Figure 2.22: Endobronchial diagnostic facilities available at an NHS Trust. 
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Figure 2.23: Endobronchial diagnostic faciliti es available within a Cancer 
Network. 
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Figure 2.24: Distance required to access certain diagnostic and therapeutic 
services. 
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2.3.3 PET scanning 
Over the past 15 years a number of publications have supported the use of FDG-
PET scanning to assist the staging process of lung cancer. The 2005 NICE 
Guidelines for Diagnosis and Treatment of Lung Cancer (26) recommended the 
use of this imaging modality, and the availability of PET-CT scanners has become 
almost universal. However, this availability may be at the level of the Cancer 
Network, rather than at individual NHS Trusts (see figure 2.26-2.28, England 
only data). 
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Figure 2.27: Distance travelled to access a PET scanner. 
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Figure 2.28: Interval between referral and access to PET scanning. 
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2.3.4 Pathological services 
The importance of increasing the histological confirmation rate has already been 
emphasised, but it is also important that there is not an unnecessary delay in 
obtaining the histological report as this will delay the final diagnostic and 
therapeutic decision of the MDT. Results from the survey of lung cancer leads 
revealed 80% of diagnostic samples are returned within 5 days, i.e. within a 
working week, ensuring the result is available for the next MDT meeting. 
2.3.5 Pulmonary rehabilitation services 
There was good availability of pulmonary rehabilitation services across English 
lung cancer MDTs who completed the survey, with 78% NHS Trusts having 
access to this service, and 79% of Cancer Networks (figure 2.29). 92% of NHS 
Trusts reported a patient would not have to travel more than 25 miles to receive 
this service, although 86% stated that there would be a delay of more than 2 
weeks to access this service. 
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Figure 2.29: Proportion of NHS Trusts and Cancer Networks with pulmonary 
rehabilitation services (England only data). 
55 
2.3.6 Access to treatment facilities 
There is significant variation in the treatment facilities available at individual NHS 
Trusts. Amongst the 157 NHS Trusts in England there are only 31 Cardiothoracic 
surgical centres and 49 Radiotherapy centres. Figure 2.30 Illustrates the 
variation in treatment facilities available at the level of an individual NHS Trust; 
although the majority of treatments are available within a Cancer Network 
(figure 2.31). There may well be a significant distance to travel and delay to 
receive the recommended treatment modality (figure 2.32 and 2.33 below, 
England only data). 
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Figure 2.31: Treatment facilities available within a Cancer Network. 
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modalities. 
There have been a number of publications which suggest th at the further a 
pati ent with cancer must travel to a treatment centre the less likely they are to 
undergo treatment (47, 54). Amongst patients with lung cancer in North ern 
England; the adjusted odds ratio for receiving surgery, chemotherapy and 
radioth erapy, was 0.76 (95% CI 0.68, 0.85), 0.70 (95% CI 0. 63, 0.79), and 
0.86 (95% CI 0.80, 0.91) respectively, for those living furth est, compared with 
those living closest, to the treatment centre (54). 
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Therefore, whilst specialised treatment centres may have Increased expertise as 
the high throughput of patients will Increase experience, this benefit must be 
balanced with the potential Impact that fewer, centralised, specialised centres 
may result In reduced uptake of treatment by Individuals In remote areas. 
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Chapter Three: Description and Initial validation of the NLCA dataset 
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3.1 Introduction 
Before any conclusions can be drawn from analysis of data within the National 
Lung Cancer Audit, the validity of the dataset needs to be tested, proven, and 
accepted by the medical profession. Anecdotally, the main concern levied at the 
dataset arises from the fact that data entry Is non-mandatory and hence 
Incomplete. This may result In data that are not truly representative of the 
spectrum of disease. There Is marked variation between NHS Trusts In the 
amount of data entered Into the dataset (63). For those NHS Trusts with 
Incomplete data entry, It Is Important to ensure that data are not biased In terms 
of the type of patients selected for Inclusion In the audit. 
The aim of this chapter Is to describe the basic properties of the data within the 
NLCA dataset and to look for evidence of variation depending on the level of NHS 
Trust reporting. In order to do this, I used funnel plots to examine the variation 
In patient demographics based on the actual number of patients entered Into the 
NLCA by each NHS Trust. I will then describe the creation of an 
observed: expected ratio of Individuals with lung cancer for every NHS Trust. 
This allows me to divide all NHS Trusts Into strata based on this measure of case 
ascertainment. The actual dataset used during this validation process (chapters 
3 and 4) was downloaded on 17th November 2008, and Includes all patients first 
seen up to the 31st December 2007. Other sources of data for comparison 
Included the Office of National Statistics (ONS) and Hospital Episode Statistics 
(HES). In May 2009, I was given access to the most recent data from Thames 
cancer Registry, the national Registry for Lung, and this allowed me to perform 
additional analyses (Including survival analyses) which are reported In Chapter 4. 
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3.2 Methods 
3.2.1 The NLCA dataset 
The National Lung Cancer Audit database, commissioned by the Healthcare 
Commission and then HQIP (Healthcare Quality Improvement Partnership), was 
established In July 2004, In a partnership between the NHS Information Centre 
and the Royal College of Physicians. It has been formally acknowledged and 
supported by the National Institute for Clinical Excellence (NICE) guidelines on 
"The Diagnosis and Treatment of Lung Cancer" (2005) (26). 
3.2.1.1 Data collection and the NLCA population 
Data are entered Into NLCA from Individual NHS Trusts In England, usually via 
the lung cancer multi-disciplinary team, and are collected via the Open Exeter 
portal. The Individuals collecting and uploading the Information Include 
respiratory physicians, lung cancer speCialist nurses, lung cancer co-ordlnators 
and speCialist audit data managers. Data entry follows a pro-forma which can be 
accessed on line at: 
http://www.lc.nhs.uk/webflles/Servlces/NCASp/Cancer/New0J020web0J020docume 
nts%20(Lyng)/LUCADA%20proforma%20y3%20+%20Key%20Flelds.doc. Data 
can be entered periodically, and the closing date for Inclusion In the annual 
report Is the 30th June the following year. However, data entry Is never closed, 
and so an NHS Trust could upload Information on patients covering a number of 
years In one go, although not all would be Included In the relevant annual report. 
It Is possible for a patient to have their first hospital attendance at one NHS 
Trust and then to receive their treatment at another NHS Trust, and so 
Information about the diagnostic and treatment pathway of one patient can be 
entered by two or more NHS Trusts. The latest entry chronologically overwrites 
all preceding entries regarding that one particular patient. 
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The patient population In the NLCA database consists of all Individuals receiving 
a diagnosis of lung cancer; be that with proven histology or by clinical means 
alone. It also Includes Individuals who have lung cancer reported on a death 
certificate, for which no formal diagnosis was made ante-mortem. 
3.2.1.2 Data cleaning 
The Initial dataset downloaded and delivered to Nottingham University for the 
purposes of this research fellowship Included all patients within the dataset who 
had had their first hospital appointment before 31st December 2007. It Included 
67,824 patients. An Important first step In data cleaning was the creation of 
start and end dates for survival analyses which will be performed In all 
subsequent chapters. The date of diagnosis, where present, was used as the 
start date. In the absence of this a surrogate date of diagnosis was calculated 
using an alternative available date In the following sequential order: date of first 
NHS Trust appointment, date of referral from general practitioner, and, finally, 
the date of the multi-disciplinary team meeting where a decision on patient 
treatment was made (figure 3.1). Using the median number of days for the 
whole cohort between the date of diagnosis (where available) and each of the 
alternative dates, a surrogate date of diagnosis was Interpolated and hence a 
surrogate start date for people without an actual start date (figure 3.2). It was 
not possible to calculate a start date In 3,962 Individuals (6%) and they were 
excluded from the cohort, leaving 63,862 patients. An end date was generated 
using either the date of death (obtained from the Personal Demographics 
Service), or the date the dataset was downloaded, which was the 17th November 
2008. Data were Incorporated Into the statistical programme Stata SE version 
10 (Stata corp. TX USA) and this was used for all subsequent analyses. 
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7,844 
67,824 
Original patient cohort 
59,980 
"Missing" date of diagnosis Date of diagnosis present 
3,195 
Date of first NHS Trust appointment 
244 
Date of referral from GP 
443 
Date of M Dr meeti ng 
Summary; 
59,980 had date of diagnosis present 
3,822 have surrogate date of diagnosis 
Therefore 63,862 have a "start" date calculated 
3,962 (5.80/0) are unable to have a start date calculated. 
Figure 3.1: Flow diagram depicting the method used to calculate start date. 
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Figure 3.2: Diagram illustrating the median intervals between key dates in the patient pathway which were used to 
interpolate a "start" date if the date of diagnosis was missing. 
In the remaining cohort there were two individuals without a sex ascribed, and a 
further 74 who had an age at diagnosis of less than 30 years and in whom it was 
felt that either the data may be unreliable or that their disease was not 
representative of the overall cohort, and these two groups of individuals were 
also excluded. This left a total of 63,786 patients with a start date calculated, a 
sex assigned, and over the age of 30 years at diagnosis. 
Patients may receive their diagnosis and treatment in more than one NHS Trust. 
For this evaluation a patient was assigned to the NHS Trust at which they had 
their first appointment. This would allow subsequent analysis of possible 
Inequalities in treatment offered and survival based on the NHS Trust at which a 
patient is first seen. A total of 3,039 (5%) patients had "unknown" as the NHS 
Trust at which they were first seen and so they were excluded from this analYSiS, 
leaving a total of 60,747 patients. 
3.2.2 Examining the data based on NHS Trust size using funnel plots 
Conventionally used to evaluate publication bias of studies included In meta-
analyses, a funnel plot is a scatter plot of treatment effect against a measure of 
study size. A symmetrical inverted funnel shape, with most studies lying evenly 
to both sides of a central estimate of treatment effect, and larger studies lying 
closest to the peak of the funnel, suggests no evidence of publication or 
reporting bias. 
In this setting a funnel plot was created to examine the effect of NHS Trust size, 
I.e. the number of patients who had their first appointment at each NHS Trust, 
on six key patient features. These features were selected on the basis that they 
might reveal evidence of bias in the patients being selected for inclusion In the 
NLCA dataset. The features chosen were: sex, mean age at diagnosis, 
proportion of patients over 80 years, proportion of patients with a histological 
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diagnosis, proportion of patients with early stage disease (la-IlIa, according to 
the Union Internatlonale Contre Cancer version 6) and the proportion of patients 
with curative treatment Intent. 
3.2.3 Creating a measure of case ascertainment for each NHS Trust 
To quantify the level of data completeness, In other words case ascertainment, 
at the level of an NHS Trust, an observed:expected ratio was calculated. The 
level of an NHS Trust was chosen as this Is the level of Interest for clinicians. 
However there are no published data on the expected number of lung cancer 
patients at this level, Instead the level of a Primary Care Trust (PCT) Is often 
used. The NLCA dataset contains Information on the number of patients within 
each Primary Care Trust, based on a patient's postcode and so this formed the 
"observed" number of patients within each PCT. Data from the Office of National 
Statistics (ONS) and then Hospital Episode Statistics (HES) were used to 
estimate an "expected" number of patients for each PCT. This allowed a two 
stage process to be undertaken, firstly to create an observed:expected ratio at 
the level of a Primary Care Trust (PCT), and then to extrapolate this to the level 
of an NHS Trust. 
3.2.3.1 Using data from the Office of National Statistics 
In the absence of definitive data from Cancer Registry, unavailable Initially, data 
from The Office of National Statistics (ONS) were used. Data from the 2005 
annual report of Cancer Incidence were used, as the most up-to-date at the time 
of study (64). These data of lung cancer Incidence (per 100,000 population) are 
recorded In age/sex strata nationally. The ONS also has data for the population 
of each of the 152 primary care trusts (PCTs) for the same age/sex strata. It Is 
therefore possible to use direct standardisation to calculate the expected number 
of Individuals with lung cancer for each of these PCTs, for each age/sex stratum. 
This Information was then reduced to create an expected number of patients of 
each sex for each PCT. 
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However, lung cancer Incidence Is not distributed equally across England, and so 
It was necessary to account for this geographical variation. The Office of 
National Statistics documents the variation In lung cancer Incidence across the 
nine Government Office regions, and states the national rate for each sex. Table 
3.1 Illustrates these data, and the reglonal:natlonal ratio for each Government 
office. Government offices were linked to primary care trusts and the 
regional: national ratio was used to correct the expected number of patients at 
each PCT, accounting for geographical variation In lung cancer Incidence. The 
expected number of men and women were then totalled to generate an overall 
expected number of lung cancer patients for each PCT. Using the NLCA data 
("observed" numbers) an observed:expected ratio at the level of a PCT could 
now be created. 
Table 3.1: Regional variation In lung cancer Incidence (ONS 2005)(64) 
Government Office Region Male* Female* Male R:N Female R:N 
North East 102.5 78.5 1.41 1.55 
North West 90.3 67.9 1.24 1.34 
Yorkshire and the Humber 80.2 60.7 1.1 1.2 
East Midlands 76.6 49.4 1.05 0.98 
West Midlands 75.8 45.1 1.04 0.89 
East 67.2 44.4 0.92 0.88 
London 54.8 39.6 0.75 0.78 
South East 62.4 41.9 0.86 0.83 
South West 70.7 46.0 0.97 0.91 
England 72.9 50.6 
* Directly age-standardised Incidence rate using European standard population 
(per 100,000). R:N reglonal:natlonal ratio 
To translate our primary care trust results to the level of an NHS Trust, websltes 
of both primary care trusts and NHS Trusts were researched, and primary care 
trusts were mapped to the NHS Trusts from which they commission services. 
Whilst 93 (61%) of the 152 primary care trusts commissioned services from a 
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single NHS Trust, 25 primary care trusts used two NHS Trusts, a further 27 used 
three, five used four, and two primary care trusts had a total of five NHS Trusts 
from whom they commissioned services. Where an NHS Trust was associated 
with multiple primary care trusts, the mean primary care trust 
observed:expected ratio was calculated. NHS Trusts were then stratified by 
generating quartlles of the observed:expected ratios. 
3.2.3.2 Using data from Hospital Episode Statistics (HES) 
In order to try and strengthen the stratification of NHS Trusts, a second method 
was used to generate an observed:expected ratio at this level. Hospital Episode 
Statistics (HES) are mandatorily collected nationally and Include data on 
admissions and out-patient appOintments at NHS Trusts (65). Data are available 
on the annual number of admissions to NHS Trusts and the total number of 
admissions for all the Trusts within a StrategiC Health Authority (SHA). It Is 
therefore possible to create a proportion of admissions for each NHS Trust within 
a StrategiC Health Authority. 
Table 3.2: Extract from HES detailing acute admissions within one SHA (2006/7) 
Number P r o ~ o r t l o n * *
East Midlands Strategic Health Authority 958,315 
Chesterfield Royal Hospital NHS Foundation Trust 64,995 0.07 
Sherwood Forest Hospitals NHS Foundation Trust 71,251 0.07 
Kettering General Hospital NHS Trust 67,538 0.07 
Northampton General Hospital NHS Trust 82,362 0.09 
Derby Hospitals NHS Foundation Trust 126,325 0.13 
United Lincolnshire Hospitals NHS Trust 134,515 0.14 
University Hospitals of Leicester NHS Trust 217,524 0.23 
Nottingham University Hospitals NHS Trust 193 805 0.20 
Legend: * proportion of all acute admiSSions In the SHA seen In each NHS Trust 
The Office of National Statistics publishes the actual number of lung cancer 
patients for each Government Office region, and these map almost directly to 
Strategic Health Authorities. The only exception Is the Government Office for the 
South East, which Includes the South Central and South East coast SHAs. 
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Therefore the total number of admissions for these two SHAs were combined and 
the proportion for each Individual NHS Trust recalculated. 
Table 3.3: Number of lung cancer patients In each SHA/Government region 
Strategic Health Authorities/Government Offices 
East Midlands 
East of England 
London 
North East 
North West 
South Central and South East 
South West 
West Midlands 
Yorkshire and Humber 
Number 
2718 
3092 
3515 
2300 
5396 
4251 
2953 
3223 
3589 
Assuming that the proportion of admissions and the proportion of lung cancer 
patients at each NHS Trust, within each SHA, were virtually equal, It was 
possible to calculate an expected number of lung cancer patients for each NHS 
Trust. 
Table 3.4: Extract of table describing process of combining HES and ONS data 
Number of Expected number 
acute lung cancer 
admissions ProDortlon * Datlents 
East Midlands Strategic Health Authority gs8,315 2718 
Chesterfield Royal Hospital NHS Foundation Trust 64,995 0.07 184 
Sherwood Forest Hospitals NHS Foundation Trust 71,251 0.07 202 
Kettering General Hospital NHS Trust 67,538 0.07 192 
Northampton General Hospital NHS Trust 82,362 0.09 234 
Derby Hospitals NHS Foundation Trust 126,325 0.13 358 
United Lincolnshire Hospitals NHS Trust 134,515 0.14 382 
University Hospitals of Leicester NHS Trust 217,524 0.23 617 
Nottingham University Hospitals NHS Trust 19380S 0.20 550 
The data from NLCA again provided the "observed" number of patients for each 
NHS Trust based on the Trust at which they had been first seen. Therefore It 
was possible to create a second observed:expected ratio for each NHS Trust 
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using HES data, and then to stratify these by creating quartiles of the 
observed: expected ratios. 
3.2.3.3 Comparing the level of agreement between NHS Stratification 
derived using data from ONS and HES 
NHS Trusts were divided Into four equal groups by creating quartiles of the 
observed:expected ratios which had been created using ONS data (mapped from 
PCTs to NHS Trusts) and using HES data. The level of agreement between these 
two methods was evaluated by creating a table of concordance, calculating a 
weighted Kappa value, and generating a Bland-Altman plot. 
3.2.4 Assessing the accuracy of NLCA to provide observed cases 
A written request was sent to the lead lung cancer physician and the lung cancer 
audit manager at 40 NHS Trusts, ten from each of the four strata generated 
using data from ONS and HES. These were randomly selected by the data 
manager at the Information Centre In Leeds. A copy of the letter Is Included In 
Appendix 4. They were asked to report the number of patients with lung cancer 
who had been first seen at their NHS Trust between 1st January and 31st 
December 2007. This figure was then compared with the number of patients 
within the NLCA dataset for the same time period. 
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3.3 Results 
There were 67,824 patients In the first dataset downloaded from the NLCA. 
After cleaning the dataset to ensure all patients had a start date, a sex assigned, 
were aged over 30 years and had an NHS Trust where they were first seen, the 
total number of individuals remaining was 60,747. There are 157 NHS Trusts in 
England, and all except 2 had entered patients at some point into the NLCA. 
There were 13 NHS Trusts who had entered more than 1000 patients (the 
largest having entered 2054), and 23 that had entered less than 100 patients. 
3.3.1 Results of Funnel plots 
Figures 3.3 to 3.8 depict the funnel plots created for this cohort. The inverted 
symmetrical funnel shape is depicted in Figures 3.3, 3.4, and 3.5, with the 
largest NHS Trusts tending towards the mean value, which illustrates no 
suggestion of bias for these features on the basis of NHS Trust "size" alone. 
Figures 3.6 to 3.8 do not depict the traditional inverted 'funnel' shape. There are 
a few small NHS Trusts (with less than 10 patients) who appear to have all their 
patients with either a histological diagnosis, early disease, or being offered 
curative treatment. But If this were a more widespread deliberate technique to 
skew the data, for example recording only their patients with early disease and 
curative Intent, there would have been a more pronounced pattern on these 
graphs with a high frequency of dots In the bottom right hand corner (figures 3.6 
to 3.8), which Is not the case. 
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Figure 3.3: Scatter plot illustrating the distribution of sex depending on size 
of NHS Trust. 
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Figure 3.4: Scatter plot Illustrating the distribution of mean age at diagnosis 
depending on size of NHS Trust. 
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Figure 3.5: Scatter plot illustrating the proportion of patients over the age of 80 
years depending on size of NHS Trust. 
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Figure 3.6: Scatter plot illustrating the proportion of patients with a histological 
diagnosis depending on size of NHS Trust. 
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Figure 3.7: Scatter plot illustrating the proportion of patients with early stage 
disease (la - IlIa) depending on size of NHS Trust . 
0 
0 •• 
L() 
..... 
..-
Cf) 
2 • 
.- • 
CJ) 
J: • Z 0 • • 
I.- 0 ... QJ 0 
0. • • Cf) •• •• 
-c: 
• • QJ •• :;::: , ... • ro 
0. ..... 
-
0 ~ ~ \. . • 0 0 
I.-
L() :, . ~ ~ .... • QJ 
.0 ." r.f •• E ··1 .. • ::l 
z ~ \ \ ... \l:: , • • • 
0 ..... • • 
.. • 
0 .2 .4 .6 .8 
Proportion of patients with curative treatment intent 
Figure 3.8: Scatter plot Illustrating the proportion of patients with curative 
treatment intent depending on size of NHS Trust. 
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3.3.2 Results of case ascertainment 
3.3.2.1 Observed:expected ratios at the level of peT using ONS data 
The median observed:expected ratio for a primary care trust was 0.56 
(interquartile range (IQR) 0.37 to 0.77). It was possible to calculate an annual 
figure for the three years 2005 to 2007, which showed a steady improvement in 
case ascertainment. In 2005 the median observed:expected ratio was 0.43 (IQR 
0.14 to 0.67), in 2006 it was 0.64 (IQR 0.36 to 0.85), and in 2007 the median 
observed:expected ratio was 0.71 (IQR 0.49 to 0.94). The distribution of 
observed: expected ratios across primary care trusts are depicted graphically in 
figure 3.9. 
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Figure 3.9: Histogram depicting the range of observed:expected ratios across 
primary care trusts (peTs) using data from ONS. 
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3.3.2.2 Observed:expected ratios at the level of NHS Trusts 
The median observed:expected ratio at the level of an NHS Trust, via the 
mapping method described in 3.2.3.1, was 0.56 (interquartile range 0.37 to 
0.72), and the distribution is depicted graphically in figure 3.10. 
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Figure 3.10: Histogram depicting the range of observed: expected ratios across 
NHS Trusts created via mapping technique from PCT observed :expected ratios. 
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3.3.2.3 Observed:expected ratios for NHS Trusts using HES data 
The median observed:expected ratio at the level of an NHS Trust was 0.53 (IQR 
0.30 to 0.87). Again there was evidence of improved data completeness yea r on 
year, with a median observed:expected ratio in 2005 of 0.3 2 (IQR 0.05 to 0.75), 
and a median value of 0.75 (IQR 0.38 to 0.96) in 2007. 
II) 
Cii 
o 
C"') 
2 0 
I-N 
C/) 
J: 
Z 
-o 
~ ~
c 0 ~ ~ T"" 
0-
~ ~
u.. 
o .5 1 
Observed:expected ratios 
1.5 
Figure 3.11: Histogram depicting the range of observed: expected ratios across 
NHS Trusts created using data from HES. 
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3.3.3 Comparing the NHS Trust strata created via these two methods 
In order to compare NHS Trust stratification using ONS and HES data, a table of 
concordance was created, see Table 3.5. Further comparisons of similarity were 
performed using weighted Kappa values and by generating a Bland-Altman plot 
(figure 3.12). 
Table 3.5: Comparison of NHS Trust strata created using ONS and HES data 
NHS Trust strata calculated using HES data 
J!U) 1 z l!o 1 23 
U en 
c: 2 10 
U '= 3 4 ti 
... ..., 4 1 
IV 
U) "5 IV 'Missing' 0 z : ~ . . . , ,
z"',: Total 38 
NHS Trust stratum; 
2 3 4 'Missing' Total 
12 3 1 0 39 
16 6 4 0 36 
10 19 7 1 41 
1 10 27 2 41 
0 0 0 11 11 
39 38 39 14 168 
l=quartlle with highest observed:expected ratio, 
4=quartlle with lowest observed:expected ratio. 
The weighted Kappa value for NHS Trust strata using these two methods was 
0.70 (actual agreement 93.9%, expected agreement 79.5%), which confirms a 
high level of agreement for these two methods. 
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Figure 3.12: Bland-Altman plot depleting the comparison between ONS and HES 
methods for calculating observed:expected (0: E) ratios for NHS Trusts. 
Note: Mean = -O.15 and Standard Deviation =O.27 
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3.3.4 Result of the observed cases of lung cancer (postal request) 
A total of 26 responses were received, 65% of the number requested. Figure 
3.13 depicts the relationship between observed cases as per the postal request, 
and those reported in the NLCA. The correlation coefficient was 0.828, showing 
a high level of agreement. Of note, the NHS Trusts with greatest disparity 
between both sources of observed cases were those in the 4th stratum, in other 
words the NHS Trusts from the lowest stratum of case ascertainment, as per 
observed: expected ratios. The NLCA contained fewer cases than were reported 
by the NHS Trusts themselves. 
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Figure 3.13: Scatter plot depicting the relationship between observed cases of 
lung cancer In 2007, reported directly from the NHS Trusts, or In the NLCA. 
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3.4 Discussion 
There was no strong evidence that key demographic features varied based on 
the number of cases reported at each NHS Trust (I.e. the size of the NHS Trust). 
There was no evidence that centres reporting a small number of cases were 
reporting only those with specific features, such as early stage and good 
performance status In whom surgery was possible. 
In order to quantify data completeness, an observed:expected ratio was 
calculated, and NHS Trusts stratified on this basis. In the absence of cancer 
Registry data and published data with an expected number of lung cancer cases 
at the level of an NHS Trust, It was necessary to use published data from ONS, 
(and perform a mapping process from primary care trusts to NHS Trusts), and 
HES data (based on acute admissions to an NHS Trust) as comparators. There 
was a high level of agreement on the stratificatIon of NHS Trusts by these two 
methods. 
The next step would be to evaluate the differences between patients within these 
NHS Trust strata to establish If there was any evidence of bias, on the basis of 
an observed:expected ratio acting as a marker of case ascertainment. 
In May 2009, data from the Thames cancer Registry was provided. This Is the 
gold standard record of lung cancer Incidence In England. These data are held at 
the level of a PCT and so the mapping process performed In Chapter 3 was 
repeated. Chapter 4 describes the variation observed In patient features, access 
to treatment and survival across strata of NHS Trusts based on case 
ascertainment. 
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Chapter Four: Validating the NLCA using Cancer Registry data 
82 
4.1 Introduction 
Outcome measures for lung cancer In the UK are worse than those In 
comparable European and North American countries (21), but the reasons for 
this are unclear. The National Lung Cancer Audit (NLCA) was established In 
2004 to Identify possible Inequalities within the National Health Service (NHS) 
and highlight the potential for service improvements. 
The NLCA database is a record of detailed clinical Information of individuals 
diagnosed with lung cancer in England and Wales. As such It is a unique 
dataset, offering more detailed Information on lung cancer patients than the 
large registry linked datasets of both Europe (EUROCARE-4) and America (SEER, 
Surveillance Epidemiology and End Results programme) (66). NHS Trusts are 
requested to upload Information on all lung cancer patients, but data entry Is 
non-mandatory and this has raised concerns about the validity of the database 
because of the potential bias which could arise if patients were 'selected' for 
Inclusion In the audit. 
The alms of this chapter were two-fold; firstly to determine whether 
demographic and outcome data from Individual NHS Trusts held In the NLCA are 
Infiuenced by the level of data completeness; and secondly to describe the 
features of people with lung cancer currently In England and to determine 
whether the socio-economic status of an Individual with lung cancer contributes 
to either the treatment they receive or their overall survival. 
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4.2 Methods 
4.2.1 Description of data entry Into NLCA 
Data used In this chapter were entered Into the NLCA dataset as per section 
3.2.1, and the same data cleaning process was used as described In 3.2.1.2. 
4.2.2 Observed:Expected ratios: Case ascertainment 
An observed:expected ratio was calculated as described In section 3.2.3, except 
that to generate an expected number of patients, data from the Thames Cancer 
Registry (Dr H M"lIer) were used. These are mandatory records of lung cancer 
Incidence and were reported at the level of a primary care trust. 50 after 
creation of an observed : expected ratio for each primary care trust, the mapping 
technique employed In section 3.2.3.1 was repeated. 
NHS Trusts were divided Into four equal groups on the basis of their 
ascertainment of lung cancer cases by creating quartlles of the 
observed:expected ratios. In order to assess the validity of the dataset, I 
examined the distribution across these NH5 Trust quartlles of the following key 
patient features: sex, age at diagnosis, performance status at diagnosis (as 
classified by the Eastern Cooperative Oncology Group), basis of diagnosis (e.g. 
histology of the primary tumour, cytology), histology of the tumour, pre-
treatment stage of the tumour (as classified by the American Joint Committee on 
Cancer and Union Internatlonale Contre Ie Cancer version 6), treatment modality 
used, and median number of days survived from diagnosis. I used a chi square 
test for trend to determine whether the proportion of missing data for each 
variable Increased as data completeness decreased. A similar approach was 
used for the other non missing data by recodlng each variable Into a binary 
variable as follows: performance status 011 versus performance status 2/3/4, 
diagnosis made by histology versus diagnosis made by another approach, non-
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small cell histology versus small cell histology, stage I and II versus stage III 
and IV. 
I used logistic regression to assess the variation In MDT treatment Intent across 
the NHS Trust quartiles of data completeness, and constructed a model which 
was adjusted for all patient features. 
4.2.3 Access to curative or active palliative treatment 
The NLCA contains Information on the treatment decision of the multi-
disciplinary team in terms of curative (surgery or radical radiotherapy), or active 
palliative treatment (chemo or radiotherapy). It also records the option of best 
supportive care for Individuals In whom symptom relief was the most appropriate 
management. An option of no specific anti-cancer treatment could be recorded 
and for some patients this data field was missing. Logistic regression was used 
to assess the variation In treatment being offered to patients across the NHS 
Trust strata, and on the basis of the key patient features. Curative treatment 
was compared to all other treatment options. A similar analysis was conducted 
for active palliative treatment, although patients referred for curative treatment 
were excluded from the baseline comparator group. Multivariate logistic 
regression was used to construct a model which was fully adjusted for all patient 
and NHS Trust strata. 
4.2.4 Soclo-economlc status and the receipt of specific treatments 
The NLCA dataset also contains the details of each Individual patient's Lower 
Super Output Area (LSOA), which Is a geographical unit (encompassing 
approximately 1500 homes) derived from their postcode. Every LSOA can be 
linked with the Townsend score for deprivation, and this is usually divided into 
qulntlles to simplify analyses; 1 Is most affluent and qulntlle 5 represents the 
least affluent qulntile of society. The Townsend qulntlle was the marker of socio-
economic status used throughout the remainder of this research. In order to 
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evaluate the potential Influence of soclo-economlc status on treatment received, 
the dates of either: surgery, chemotherapy, or radiotherapy were used, and 
binary variables created to allow logistic regression to be performed. Cox 
regression was used to assess the Influence of soclo-economlc status on overall 
survival. For both these regression analyses a similar modelling strategy, 
adjusting for patient features, was used to that outlined above, and In addition 
the final model was clustered by NHS Trust to ensure data entry at Individual 
NHS Trusts did not Influence the results. 
4.2.5 Evaluating patient survival 
For survival analyses the start and end dates described In section 3.2.1.2 were 
used. Cox regression analyses were performed to calculate hazard ratios (HR) 
across the NHS Trust strata and for each of the key patient features Individually. 
A multivariate model was then constructed to adjust mutually for all key patient 
features and NHS Trust strata. The proportional hazards assumptions for this 
model were checked by Inspecting Nelson-Aaleen plots. 
4.2.6 Comparison of NHS Trust strata with previous estimations using 
data from ONS and HES 
The strata of NHS Trusts created using data from the Cancer Registry were 
compared to those previously created (see Chapter 3) using data from Office of 
National Statistics and Hospital Episode Statistics. Weighted Kappa values were 
calculated to evaluate the level of agreement between these different methods of 
creating NHS Trust strata. 
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4.3 Results 
4.3.1 Overall cohort analysis 
The NLCA subset Initially contained 67,824 patients at English NHS Trusts with 
their first hospital attendance before 1st January 2008. As described In section 
3.2.1.2, a total of 60,747 patients remained after the data cleaning process. A 
further 688 were dropped as they were first seen at an NHS Trust that could not 
be linked to Registry data, primarily because of changes In Infrastructure over 
time. This left 60,059 patients for analysis: 21,976 from 2007, 18,229 from 
2006, 12,910 from 2005, and 6944 from 2004. The median age at diagnosis 
was 71 years (Interquartile range 64 to 78 years) and the majority were male 
(59%) (table 4.1). The commonest histological subgroup was non-small cell 
lung cancer, contributing 39% of the cohort; 10% were proven small cell cancer, 
a further 3% had mesothelioma. A total of 44% of the cohort had no histology 
data recorded, of whom 50% had a clinical diagnosis of lung cancer, whilst the 
other half appear to have had histology or cytology sought, but the specific 
result Is missing from the NLCA record. The majority of patients (36%) received 
active palliative treatment, with 9% of the overall cohort receiving treatment 
with a curative Intent. 
4.3.2 Observed:expected ratios: results of case ascertainment 
The median observed:expected ratio for NHS Trusts was 0.52 (Interquartlle 
range 0.37 to 0.71). There was evidence that this figure had Improved over the 
four years that the NLCA had been established. NHS Trusts In the top stratum 
reported a median of 0.85 of expected cases (Interquartile range 0.80 to 0.91), 
representing 40% of the overall patient cohort. The corresponding values for 
the second, third and fourth quartlles which comprised 30%, 21% and 9% of the 
overall patient cohort, respectively, are listed In table 4.1. 
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Table 4.1: Distribution of key patient features for the overall cohort, and NHS 
Trust strata based on case ascertainment. 
Trust strata Highest OlE 2 3 Lowest O:E Total 
Number of Trusts 39 39 39 40 157 
Median 0: E ratio 0.85 0.63 0.46 0.31 0.52 
(IQR) (0.8,0.91) (0.56, 0.68) (0.43, 0.48) (0.23, 0.35) (0.37,0.71) 
Number of patients 24261 17980 12498 5320 60059 
Sex 
Male 14449 (60) 10583 (59) 7417 (59) 3244 (61) 35693 (59) 
Female 9812 (40) 7397 (41) 5081 (41) 2076 (39) 24366 (41) 
Age at diagnosis 
Median (IQR) years 72 (64 to 79) 71 (63 to 78) 71 (63 to 78) 71 (63 to 78) 71 (64 to 78) 
Performance status (PS) 
PS 0 3596 (15) 1921 (11) 1284 (10) 633 (12) 7434 (12) 
PS 1 6023 (25) 3135 (17) 1757 (14) 893 (17) 11808 (20) 
PS 2 3595 (15) 2307 (13) 1171 (9) 538 (10) 7611 (13) 
PS 3 2751 (11) 1964 (11) 956 (8) 355 (7) 6026 (10) 
PS 4 986 (4) 648 (4) 339 (3) 95 (2) 2068 (3) 
Don't know 2874 (12) 3272 (18) 3458 (28) 997 (19) 10601 (18) 
"Missing" 4436 (18) 4733 (26) 3533 (28) 1809 (34) 14511 (24) 
aasls of diagnosis 
Histology 13522 (56) 9103 (51) 4861 (39) 2824 (53) 30310 (51) 
Cytology 2365 (10) 1571 (9) 1775 (14) 428 (8) 6139 (10) 
Clinical 5691 (23) 3741 (21) 3115 (25) 644 (12) 13191 (22) 
Tumour markers 2 (0) 6 (0) 27 (0) 2 (0) 37 (0) 
Death Certificate 56 (0) 9 (0) 18 (0) 0 (0) 83 (0) 
Don't know 351 (1) 1598 (9) 959 (8) 326 (6) 3234 (5) 
"Missing" 2274 (9) 1952 (11) 1743 (14) 1096 (21) 7065 (12) 
HIstology of prImary tumour 
Non Small cell 10168 (42) 6603 (37) 4267 (34) 2095 (39) 23133 (39) 
Small cell 2636 (11) 1585 (9) 1064 (9) 491 (9) 5776 (10) 
Carcinoid 67 (0) 39 (0) 31 (0) 15 (0) 152 (0) 
Mesothelioma 918 (4) 535 (3) 343 (3) 179 (3) 1975 (3) 
Other 948 (4) 559 (3) 634 (5) 241 (5) 2382 (4) 
"Missing" 9525 (39) 8659 (48) 6159 (49) 2301 (43) 26641 (44) 
Stage of tumour 
IA 707 (3) 520 (3) 289 (2) 173 (3) 1689 (3) 
IB 1173 (5) 711 (4) 348 (3) 249 (5) 2481 (4) 
I1A 127 (1) 73 (0) 40 (0) 33 (1) 273 (0) 
liB 702 (3) 439 (2) 252 (2) 177 (3) 1590 (3) 
IlIA 1476 (6) 844 (5) 448 (4) 291 (5) 3059 (5) 
IIIB 2914 (12) 1592 (9) 898 (7) 576 (11) 5980 (10) 
IV 6595 (27) 3661 (2) 1962 (16) 1060 (20) 13278 (22) 
Occult 22 (0) 34 CO) 8 CO) 1 (0) 65 (0) 
Uncertain 1124 (5) 1628 (9) 965 (8) 531 (10) 4248 (7) 
"Missing" 9421 (39) 8478 (47) 7288 (58) 2229 (42) 27416 (46) 
MDT treatment Intent 
No specific anti-cancer 1256 (5) 885 (5) 568 (5) 223 (4) 2932 (5) 
Curative Intent 2421 (10) 1475 (8) 1044 (8) 527 (10) 5467 (9) 
Palliative Intent 9936 (41) 5914 (33) 4041 (32) 1510 (28) 21401 (36) 
Best supportive Care 3854 (16) 1943 (11) 1224 (10) 376 (7) 7397 (12) 
Don't know 651 (3) 3026 (17) 1018 (8) 334 (6) 5029 (8) 
"Missing" 6143 (25) 4737 (26) 4603 (37) 2350 (44) 17833 (30) 
Survival 
Median (days) 193 201 200 223 203 
IQR (days) 58-522 61-527 60-566 70-547 62-545 
One year survival (%) 31.3 31.5 32.3 31.9 31.6 
Legend: IQR Interquartlle range; ( ) percentage 
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There was a proportion of missing data present for each of the key patient 
variables and In general this proportion tended to Increase as the level of data 
completeness decreased (table 4.2). There was also some evIdence of variation 
In the non-missing data between these quartlles. For example, people In NHS 
Trusts with the lowest quartile of data completeness tended to have a more 
favourable disease stage and to be more likely to have their diagnosis made on 
the basis of histology. However, although the p values for these analyses were 
small, reflecting the large size of the dataset, the absolute differences In the 
proportions were small. In contrast distribution of good versus poor 
performance status and non-small cell versus small cell lung cancer was very 
similar across all four quartlles. 
Table 4.2: Chi square analyses for missing data and key patient variables 
(having excluded missing data) by quartile of data completeness at NHS Trusts. 
Trust quartlles Highest 2 3 Lowest O:E C h l ~ ~ for O:E trendlRl 
Performance status 
Missing/don't know 30% 45% 56% 53% <0.001 
0/1 57% 51% 55% 61% 0.94 
2/3/4 43% 49% 45% 39% 
Basis of diagnosis 
Missing/don't know 11% 20% 22% 27% <0.001 
Histology 63% 63% 50% 72% <0.001 
Other 37% 37% 50% 28% 
Histology 
Missing 39% 48% 49% 43% <0.001 
Non-small cell 79% 81% 80% 81% 0.06 
Small cell 21% 19% 20% 19% 
Stage 
Missing/uncertain 43% 56% 66% 52% <0.001 
I/I! 20% 23% 22% 25% <0.001 
III/IV 80% 77% 78% 75% 
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4.3.3 Access to curative and active palliative treatment 
The results of logistic regression analyses assessing access to curative and active 
palliative treatment across NHS Trust strata are depicted In Tables 4.3 and 4.4 
respectively. There was little variation In referral for curative treatment across 
all four NHS Trust strata of ascertainment, which became even smaller after key 
patient features were Included In the model. There was a progressive decline In 
the likelihood of curative treatment being offered as age Increased, with an 
adjusted odds ratio (OR) of 0.30 (95% CI 0.26, 0.34) for the qulntlle of oldest 
age (>81 years) compared with the youngest age group «61 years). There was 
a marked reduction In the likelihood of being offered curative treatment once an 
Individual was classed as performance status 2 (adjusted odds ratio 0.28, 95% 
CI 0.25, 0.32), and once their tumour was staged as IlIa or above (adjusted 
odds ratio 0.18, 95% CI 0.15, 0.21). Table 4.4 shows the results of logistic 
regression for referral for active palliative treatment once those patients referred 
for curative treatment (n=5467) had been removed. It shows there was an 
apparent reduction In the likelihood of active palliative treatment being used In 
the stratum with lowest observed:expected ratios (adjusted OR 0.72, 95% CI 
0.66, 0.77). There was a progressive decline In the likelihood of active palliative 
treatment being used as age at diagnosis Increased (adjusted OR In oldest 
qulntile (>81 years) 0.63, 95% CI 0.59, 0.67). There was no variation In the 
likelihood of active palliative treatment being used In patients with performance 
status 0-2, but there was a reduction for those patients with performance status 
3 and 4 (adjusted OR 0.41, 95% CI 0.36, 0.46 for performance status 4). In 
contrast, odds ratios Increased for patients staged IIa or greater, with patients 
staged as IIIb having a four-fold Increased likelihood of receiving active palliative 
treatment compared with those with stage Ia disease (adjusted OR 3.95, 95% CI 
3.29, 4.74). Patients with metastatic spread (stage IV), had a slightly lower 
adjusted odds ratio of 3.68 (95% CI 3.0, 4.39). 
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Table 4.3: Logistic Regression analyses of curative treatment; NHS Trust strata 
and key patient features 
Absolute no. of Unadjusted OR Adjusted ~ ~ ~* * 
oatlents (%) * (95% CIl (95% CI 
Trust strata based on O:E ratio 
Highest O;E 2421 (10) 
2 1475 (8) 0.81 (0.75-0.86) 0.83 (0.77-0.90) 
3 1044 (8) 0.82 (0.76-0.89) 1.03 (0.94-1.12) 
Lowest O:E 527 (10) 0.99 (0.90-1.10) 0.97 (0.86-1.09) 
Sex 
Male 3233 (9) 
Female 2234 (9) 1.01 (0.96-1.07) 1.03 (0.96-1.10) 
Age qulnt/le 
1 (30-61 years) 1408 (12) 
2 (62-69 years) 1603 (12) 0.97 (0.90-1.0S) 0.92 (0.84-1.01) 
3 (70-74 years) 1026 (10) 0.82 (0.75-0.89) 0.77 (0.69-0.85) 
4 (75-80 years) 1046 (8) 0.65 (0.60-0.70) 0.63 (0.57-0.70) 
5 (81-101 years) 384 (4) 0.27 (0.24-0.31) 0.30 (0.26-0.34) 
Performance status (PS) 
PS 0 1687 (23) 
PS 1 1738 (15) 0.59 (0.55-0.63) 0.73 (0.67-0.79) 
PS 2 392 (5) 0.18 (0.16-0.21) 0.28 (0.25-0.32) 
PS 3 75 (1) 0.04 (0.03-0.05) 0.08 (0.07-0.11) 
PS 4 6 (0) 0.01 (0.00-0.02) 0.03 (0.01-0.06) 
PS not known 890 (8) 0.31 (0.29-0.34) 0.48 (0.43-0.53) 
"Missing" 679 (5) 0.17 (0.15-0.18) 0.32 (0.29-0.36) 
Basis of diagnosis 
Histology of tumour 3743 (13) 
Histology of metastases 58 (3) 0.17 (0.12-0.22) 0.33 (0.25-0.43) 
Cytology 507 (8) 0.58 (0.53-0.64) 0.73 (0.65-0.81) 
Clinical (Investigations) 727 (8) 0.53 (0.48-0.57) 0.76 (0.67-0.86) 
Clinical (no 114 (3) 0.22 (0.18-0.26) 0.34 (0.27-0.43) 
Investigations) 
Tumour markers 5 (14) 1.01 (0.39-2.60) 1.35 (0.48-3.79) 
Death certificate only 0 (0) 
Don't know 136 (4) 0.28 (0.24-0.34) 0.28 (0.23-0.34) 
"Missing" 177 (3) 0.17 (0.14-0.19) 0.21 (0.18-0.25) 
HlstolOllY of tumour 
Non Small Cell 3175 (14) 
Small Cell 290 (5) 0.33 (0.29-0.38) 0.45 (0.39-0.52) 
Carcinoid 71 (47) 5.51 (4.00-7.59) 3.32 (2.25-4.90) 
Mesothelioma 70 (4) 0.23 (0.18-0.29) 0.21 (0.17-0.28) 
"Other" histology 272 (11) 0.81 (0.71-0.92) 0.85 (0.73-0.98) 
"Missing" 1589 (6) 0.40 (0.37-0.42) 0.78 (0.70-0.86) 
Stage of tumour 
Stage Ia 749 (44) 
Stage Ib 1006 (41) 0.86 (0.76-0.97) 0.84 (0.73-0.97) 
Stage IIa 117 (43) 0.94 (0.73-1.21) 0.83 (0.62-1.10) 
Stage lIb 510 (32) 0.60 (0.52-0.70) 0.52 (0.45-0.61) 
Stage lIla 466 (15) 0.23 (0.20-0.26) 0.18 (0.15-0.21) 
Stage IIIb 395 (7) 0.09 (0.08-0.10) 0.07 (0.06-0.08) 
Stage IV 250 (2) 0.02 (0.02-0.03) 0.02 (0.02-0.03) 
Occult 12 (l8) 0.28 (0.lS-0.54) 0.34 (0.17-0.67) 
Uncertain 522 (12) 0.18 (0.15-0.20) 0.20 (0.17-0.23) 
"Missing" 1440 (5) 0.07 (0.06-0.08) 0.11 (0.10-0.12) 
Legend: The comparator variables are the first subgroup of each patient feature. 
* percentage of patients from each subgroup referred for curative treatment. 
** Odds Ratio adjusted for all other features listed In the table. 
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Table 4.4: Logistic regression for active palliative treatment; NHS Trust strata 
and key patient features 
Absolute no. of Unadjusted OR Adjusted OR** 
patients (% \ * (95% ell (95% en 
Trust strata based on o:e ratio 
Highest O:E 9936 (41) 
2 5914 (33) 0.67 (0.64-0.70) 0.84 (0.81-0.88) 
3 4041 (32) 0.65 (0.62-0.68) 0.94 (0.89-0.99) 
Lowest O:E 1510 (28) 0.55 (0.52-0.59) 0.72 (0.66-0.77) 
Sex 
Male 12954 (36) 
Female 8447 (35) 0.93 (0.90-0.96) 0.98 (0.94-1.02) 
Age qulntlle 
1 (30-61 years) 4697 (39) 
2 (62-69 years) 5369 {39} 0.96 {0.91-1.01} 0.95 (0.89-1.00) 
3 (70-74 years) 3815 {27} 0.85 (0.80-0.90) 0.87 (0.81-0.92) 
4 (75-80 years) 4463 (34) 0.73 (0.69-0.n) 0.80 (0.75-0.85) 
5 (81-101 years) 3057 (28) 0.51 (0.48-0.54) 0.63 (0.59-0.67) 
Performance status (PS) 
PS 0 2872 (39) 
PS 1 5816 (49) 1.37 (1.28-1.46) 1.33 (1.24-1.43) 
PS 2 3689 (48) 1.05 (0.97-1.12) 1.13 (1.04-1.22) 
PS 3 2211 (37) 0.59 (0.55-0.64) 0.70 (0.64-0.76) 
PS 4 498 {24} 0.32 {0.28-0.36} 0.41 (0.36-0.46) 
PS not known 3374 {32} 0.53 (0.50-0.57) 0.70 (0.65-0.76) 
"Missing" 2941 (20) 0.27 (0.25-0.29) 0.43 (0.40-0.46) 
Basis of diagnOSis 
Histology of tumour 12576 (45) 
Histology of metastases 1373 (59) 1.45 (1.33-1.58) 1.34 (1.22-1.47) 
Cytology 2805 (46) 0.92 (0.87-0.98) 0.98 (0.92-1.04) 
Clinical (Investigations) 2686 (28) 0.39 (0.37-0.41) 0.77 (0.71-0.83) 
Clinical (no Investigations) 839 (24) 0.30 (0.28-0.33) 0.60 (0.55-0.67) 
Tumour markers 15 (41) 0.82 (0.41-1.64) 1.51 (0.74-3.09) 
Death certificate only 6 (7) 0.07 (0.03-0.17) 0.12 (0.05-0.29) 
Don't know 461 (14) 0.16 (0.15-0.18) 0.21 (0.19-0.24) 
"Missing" 700 (10) 0.11 (0.10-0.11) 0.21 (0.19-0.23) 
Histology of tumour 
Non Small Cell 10259 (44) 
Small Cell 3225 (56) 1.35 (1.27-1.43) 1.46 (1.36-1.56) 
Carcinoid 18 (12) 0.27 (0.16-0.46) 0.31 (0.18-0.54) 
Mesothelioma 1037 (53) 1.13 (1.03-1.24) 1.30 (1.18-1.44) 
"Other" histology 867 (36) 0.66 (0.60-0.72) 0.84 (0.76-0.93) 
"Missing" 5995 (23) 0.30 (0.29-0.31) 0.62 (0.59-0.67) 
Stage of tumour 
Stage Ia 70 (4) 
Stage Ib 414 (17) 1.77 (1.45-2.16) 1.63 (1.32-2.01) 
Stage lIa 42 (15) 1.67 (1.12-2.47) 1.32 (0.88-2.00) 
Stage lIb 415 (26) 2.91 (2.37-3.58) 2.48 (2.00-3.09) 
Stage lIla 1203 (39) 3.92 (3.26-4.71) 3.08 (2.54-3.73) 
Stage IIIb 2971 (50) 5.15 (4.32-6.13) 3.95 (3.29-4.74) 
Stage IV 6495 (49) 4.50 (3.80-5.34) 3.68 (3.08-4.39) 
Occult 11 (17) 1.19 (0.60-2.35) 0.99 (0.49-2.02) 
Uncertain 1455 (34) 2.90 (2.43-3.47) 2.91 (2.41-3.51) 
"Missing" 8225 (30) 2.10 (1.77-2.48) 2.71 (2.27-3.23) 
Legend: Patients receiving curative treatment (N=5467) were excluded from 
this analysis. 
The comparator variable Is the first subgroup of each of the key patient features. 
* percentage of patients from each subgroup referred for palliative treatment. 
** Odds Ratio adjusted for all other variables listed In this table. 
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4.3.4 Soclo-economic status and receipt of specific treatments 
Overall, the percentage of patients receiving surgery was 9%, but for the 
subgroup of patients with proven non-small cell lung cancer, the rate of surgical 
resection was 14%. Within this subgroup, logistic regression confirmed that 
Increasing age, a performance status of ~ 2 , , and a stage at diagnosis of lIb or 
worse were all linked with a reduced likelihood of receiving surgical treatment 
(table 4.5). However the soclo-economlc status of a patient did not affect the 
likelihood of receiving surgery (table 4.5). For the cohort overall, the percentage 
of patients receiving chemotherapy was 24%, but for the subgroup of patients 
with proven small cell lung cancer the figure was 61%. Logistic regression for 
the cohort overall revealed a stage at diagnosis of IlIa and over, was linked to a 
significant Increase In the likelihood of chemotherapy being used; whilst a 
performance status of 3 or worse was associated with a reduced likelihood of 
chemotherapy being used (table 4.6). Table 4.6 demonstrates that patients 
within the least affluent Townsend Qulntlle were found to have a reduced 
likelihood of receiving chemotherapy despite adjusting for stage and 
performance status (adjusted OR 0.85, 95% CI 0.79, 0.91, p for trend <0.01). 
The results for radiotherapy show that 20% of the cohort overall received this 
treatment modality. Logistic regression revealed that there was no effect of 
Increasing age, or soclo-economlc status on the likelihood of receiving 
radiotherapy (table 4.7). There was a progressive Increase In the likelihood of 
radiotherapy being used as stage of the disease Increased supporting the role 
radiotherapy plays In active palliative care; and only at performance status 4 
was there a reduction In the likelihood of It being used (table 4.7). 
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Table 4.5: Logistic regression for access to surgery In proven NSCLC (N=25,667) 
Nwho 
had AdJ OR** Pfor 
N suraerv (%)* OR (95% en .(95% ell trend 
Sex 
Male 15671 2170 14 
Female 9996 1507 15 1.10 (1.03,1.19) 1.05 (0.96, 1.14) 0.291\ 
Age qulntlle 
1 (30-61 years) 5620 941 17 <0.001 
2 (52-69 years) 6438 1114 17 1.04 (0.95, 1.14) 0.93 (0.83, 1.04) 
3 (70-74 years) 4723 722 15 0.90 (0.81, 1.00) 0.79 (0.69,0.89) 
4 (75-80 years) 5503 702 13 0.73 (0.65, 0.81) 0.65 (0.57, 0.74) 
5 (81-101 years) 3383 198 6 0.31 (0.26, 0.36) 0.27 (0.23, 0.33) 
Performance status 
PS 0 4454 1312 29 0.001 
PS 1 6862 1078 16 0.45 (0.41, 0.49) 0.51 (0.46, 0.57) 
PS 2 3702 202 5 0.14 (0.12, 0.16) 0.19 (0.16, 0.22) 
PS 3 2220 53 2 0.06 (0.04, 0.08) 0.10 (0.08, 0.14) 
PS 4 540 8 1 0.04 (0.02, 0.07) 0.08 (0.04, 0.16) 
"missing" 7889 1024 13 0.36 (0.33,0.39) 0.42 (0.37, 0.47) 
Stage 
Stage Ia 931 599 64 <0.001 
Stage Ib 1582 795 50 0.56 (0.47, 0.66) 0.58 (0.48, 0.69) 
Stage lIa 162 105 65 1.02 (0.72, 1.45) 0.96 (0.65, 1.42) 
Stage lIb 1061 415 39 0.36 (0.30, 0.43) 0.35 (0.29, 0.43) 
Stage IlIa 1987 262 13 0.08 (0.07, 0.10) 0.07 (0.06, 0.09) 
Stage I1Ib 3807 190 5 0.03 (0.01, 0.04) 0.03 (0.02, 0.03) 
Stage IV 7554 197 3 0.01 (0.01,0.02) 0.02 (0.01,0.02) 
Occult 35 12 34 0.32 (0.14, 0.59) 0.36 (0.17,0.77) 
"Missing" 8548 1102 13 0.08 (0.07, 0.10) 0.09 (0.08, 0.11) 
Townsend qulntlle 
1 (most affluent) 3838 539 14 0.235 
2 4772 710 15 1.07 (0.95, 1.21) 1.13 (0.98, 1.32) 
3 4960 719 14 1.04 (0.92, 1.17) 1.18 (1.02, 1.37) 
4 5348 744 14 0.99 (0.88, 1.11) 1.01 (0.87, 1.16) 
5 (least affluent) 6698 955 14 1.02 (0.91, 1.14) 1.11 (0.96, 1.27) 
"missing" 51 10 20 1.49 (0.74 3.00) 1.76 (0.78 3.99) 
Legend: N who had surgery, Number who had surgery from each subgroup. 
(%)* percentage of each subgroup who had surgery. 
Adj OR** Odds ratio adjusted for all features In the table. 
A p value 
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Table 4.6: Logistic regression for chemotherapy for whole cohort (N=60,059) 
Nwho Adj OR** P for 
N had CTx (%l* OR (95% ell (95% Ol trend 
Sex 
Male 35693 8367 23 
Female 24366 5820 24 1.02 (0.99, 1.06) 1.02 (0.97, 1.06) 0.431\ 
Age qulntlle 
1 (30-61 years) 11895 4807 40 <0.001 
2 (52-69 years) 13866 4471 32 0.70 (0.67, 0.74) 0.73 (0.69, 0.77) 
3 (70-74 years) 10378 2543 25 0.48 (0.45, 0.51) 0.52 (0.49, 0.55) 
4 (75-80 years) 13077 1865 14 0.25 (0.23, 0.26) 0.28 (0.26, 0.30) 
5 (81-101 years) 10843 501 5 0.07 (0.06, 0.08) 0.10 (0.09, 0.11) 
Performllnce stlltus (PS) 
PS 0 7434 2951 40 <0.001 
PS 1 11808 4389 37 0.90 (0.85, 0.95) 0.93 (0.87, 1.00) 
PS 2 7611 1644 22 0.42 (0.39, 0.45) 0.43 (0.39, 0.46) 
PS 3 6026 416 7 0.11 (0.10,0.13) 0.13 (0.11,0.14) 
PS 4 2068 44 2 0.03 (0.02, 0.04) 0.03 (0.03, 0.05) 
"Missing" 25122 4743 19 0.35 (0.33, 0.37) 0.46 (0.43, 0.49) 
Histology 
NSCLC 25667 7122 28 
Small cell 5921 3589 61 4.01 (3.78, 4.25) 5.31 (4.94, 5.70) 
Carcinoid 197 11 6 0.15 (0.08, 0.28) 0.12 (0.06, 0.21) 
Mesothelioma 2071 302 15 0.44 (0.39, 0.50) 0.41 (0.36, 0.47) 
Other 958 179 19 0.60 (0.51, 0.71) 0.80 (0.73, 0.89) 
"Missing" 25245 2984 12 0.35 (0.33, 0.37) 0.50 (0.47, 0.52) 
Stage 
Stage Ia 1689 116 7 0.095 
Stage Ib 2481 247 10 1.50 (1.19, 1.89) 1.58 (1.25, 2.01) 
Stage IIa 273 38 14 2.19 (0.48, 3.24) 1.79 (1.18, 2.72) 
Stage lIb 1570 275 18 2.88 (2.29, 3.62) 2.83 (2.23, 3.60) 
Stage lIla 3059 986 32 6.45 (5.26, 7.90) 7.44 (6.01, 9.20) 
Stage IIIb 5980 2042 34 7.03 (5.78, 8.55) 8.49 (6.92, 10.42) 
Stage IV 13278 3544 27 4.94 (4.07, 5.98) 6.35 (5.19, 7.76) 
Occult 65 8 12 1.90 (0.89, 4.08) 2.23 (1.01, 4.94) 
"Missing" 31664 6931 22 3.80 (3.14, 4.60) 5.19 (4.25, 6.34) 
Townsend qulntlle 
1 (most affluent) 8946 2222 25 0.005 
2 11009 2702 25 0.98 (0.92, 1.05) 0.97 (0.90, 1.04) 
3 11911 2715 23 0.89 (0.84, 0.95) 0.89 (0.83, 0.96) 
4 12867 2880 22 0.87 (0.82, 0.93) 0.83 (0.77,0.89) 
5 (least affluent) 15219 3649 24 0.95 (0.90, 1.01) 0.85 (0.79, 0.91) 
"mlsslno" 107 19 18 0.65 (0.40 1.08) 0.67 (0.39 1.17) 
L ~ g ~ D d : : N who had CTx, Number who had chemotherapy from each subgroup. 
(%)* percentage of each subgroup who had chemotherapy 
Adj OR** Odds ratio adjusted for all features In the table. 
/\, p value. 
95 
Table 4.7: Logistic regression for radiotherapy for the whole cohort (N=60,059) 
Nwho AdJ OR* P for 
N had RTx (%)* OR (95% CIl (95% CIl trend 
Sex 
Male 35693 7454 21 
Female 24366 4642 19 0.89 (0.86, 0.93) 0.94 (0.90, 0.98) 0.001'" 
Age qulntlle 
1 (30-61 years) 11895 2378 20 0.521 
2 (52-69 years) 13866 2826 20 1.02 (0.96, 1.09) 1.00 (0.94, 1.06) 
3 (70-74 years) 10378 2199 21 1.08 (1.01, 1.15) 1.06 (0.99, 1.13) 
4 (75-80 years) 13077 2827 22 1.10 (1.04,1.17) 1.11 (1.04, 1.18) 
5 (81-101 years) 10843 1866 17 0.83 (0.78,0.89) 0.90 (0.83,0.96) 
Performance status (PS) 
PS 0 7434 1417 19 <0.001 
PS 1 11808 3098 26 1.51 (1.41, 1.62) 1.48 (1.38, 1.60) 
PS 2 7611 2196 29 1.72 (1.60, 1.86) 1.79 (1.66, 1.94) 
PS 3 6026 1043 17 0.89 (0.81, 0.97) 0.96 (0.88, 1.06) 
PS 4 2068 148 7 0.33 (0.27, 0.39) 0.38 (0.32, 0.45) 
"Missing" 25122 4194 17 0.85 (0.80, 0.91) 1.02 (0.95, 1.10) 
Histology 
NSCLC 25667 6438 25 
Small cell 5921 883 15 0.52 (0.48, 0.57) 0.56 (0.52, 0.61) 
Carcinoid 197 8 4 0.13 (0.06, 0.26) 0.15 (0.08, 0.31) 
Mesothelioma 2071 556 27 1.10 (0.99, 1.21) 1.24 (1.12, 1.38) 
Other 958 191 20 0.74 (0.63, 0.87) 0.82 (0.74, 0.91) 
"Missing" 25245 4020 16 0.57 (0.54, 0.59) 0.69 (0.65, 0.72) 
Stage of tumour 
Stage Ia 1689 222 13 <0.001 
Stage Ib 2481 514 21 1.73 (1.45, 2.05) 1.63 (1.37, 1.94) 
Stage IIa 273 53 19 1.59 (1.15, 2.22) 1.60 (1.15, 2.24) 
Stage lIb 1570 379 24 2.10 (1.75, 2.52) 1.95 (1.63, 2.35) 
Stage IlIa 3059 865 28 2.61 (2.21, 3.06) 2.44 (2.08, 2.88) 
Stage I1Ib 5980 1624 27 2.46 (2.11, 2.87) 2.34 (2.01, 2.73) 
Stage IV 13278 3100 23 2.01 (1.74, 2.33) 2.03 (1.75, 2.36) 
Occult 65 11 17 1.35 (0.69, 2.61) 1.15 (0.59, 2.25) 
"Missing" 31664 5328 17 1.34 (1.16, 1.54) 1.57 (1.36, 1.82) 
Townsend qulntlle 
1 (most affluent) 8946 1728 19 0.359 
2 11009 2259 21 1.08 (1.00, 1.16) 1.08 (1.01, 1.16) 
3 11911 2470 21 1.09 (1.02,1.17) 1.12 (1.04, 1.20) 
4 12867 2655 21 1.09 (1.01, 1.16) 1.12 (1.04, 1.20) 
5 (least affluent) 15219 2967 19 1.01 (0.95, 1.08) 1.02 (0.95, 1.09) 
"missing" 107 17 16 0.79 (0.47 1.33) 0.80 (0.47 1.36) 
Legend: N who had RTx, Number who had radiotherapy from each subgroup. 
(%)* percentage of each subgroup who had radiotherapy 
Adj OR** Odds ratio adjusted for all features in the table. 
/\. p value 
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4.3.5 Patient Survival 
The median survival from diagnosis for the whole cohort was 203 days 
(Interquartile range 62 to 545 days), with 32% of patients surviving one year 
from diagnosis. Table 4.8 Illustrates that socio-economlc status had no 
Independent Influence on survival, once adjusted for all patient features. Table 
4.9 Illustrates the hazard ratios of specific patient features as well as the strata 
of NHS Trust case ascertainment, and the year of diagnosis. It shows that 
females had a slightly lower relative mortality compared with men, (adjusted HR 
0.89, 95% CI 0.88, 0.91, p<0.01)i and the mortality of patients with a 
performance status of 3 was more than three times that of patients with 
performance status 0, (adjusted HR 3.32, 95% CI 3.13, 3.53, p<0.01). Patients 
with stage IV disease had a more than five-fold Increase In mortality compared 
with patients who were stage Ia (adjusted HR 5.57, 95% CI 4.73, 6.56, 
p<0.01). There was no variation In hazard ratio based on the level of case 
ascertainment at NHS Trusts, nor based on the year of diagnosis. There was no 
evidence that the proportional hazards assumption was Incorrect. 
Table 4.8: Results of Cox regression based on soclo-economlc status 
Absolute no. Univariate HR Adjusted HR** 
deaths (0/0)* (950/0 CI) (950/0 CI) 
Townsend qulntlle 
1 (most affluent) 7139 (80) 
2 8896 (81) 1.03 (1.00, 1.07) 1.03 (1.00, 1.06) 
3 9668 (81) 1.05 {1.02, 1.08 1.02 (0.99, 1.05) 
4 10420 (81) 1.06 (1.02, 1.09) 1.03 (0.99, 1.06) 
5 (least affluent) 12250 (80) 1.03 (0.97, 1.09) 1.00 (0.95, 1.06) 
Legend: (%)* percentage of deaths for each variable subgroup. 
Adj HR ** Hazard ratio adjusted for sex, age qulntlle, performance status, 
histology, and stage at diagnosis. 
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Table 4.9: Results of unl and multivariate Cox regression analyses; using NHS 
Trust strata and key patient features. 
Absolute number Univariate HR Adjusted HR** 
deaths (010)* (95% CI) (95% CI) 
Trust strata based on OlE ratio 
Highest O:E 19825 (82) 
2 14553 (81) 0.99 (0.96-1.01) 1.01 (0.99-1.03) 
3 9983 (80) 0.95 (0.93-0.98) 0.99 (0.97-1.02) 
Lowest O:E 4092 (77) 0.94 (0.90-0.97) 1.07 (1.03-1.11) 
Sex 
Male 29218 (82) 
Female 19235 (79) 0.92 (0.90-0.94) 0.89 (0.87-0.90) 
Age qulntlle 
1 (30-61 years) 8800 (74) 
2 (62-69 years) 10731 (77) 1.13 (1.10-1.17) 1.11 (1.08-1.15) 
3 (70-74 years) 8337 (80) 1.26 (1.22-1.30) 1.18 (1.15-1.22) 
4 (75-80 years) 10982 (84) 1.45 (1.41-1.50) 1.31 (1.27-1.35) 
5 (81-101 years) 9603 (89) 1.78 (1.73-1.83) 1.41 (1.37-1.46) 
Performance status (PS) 
PS 0 4660 (63) 
PS 1 9022 (76) 1.50 ( 1.45-1.55) 1.31 (1.26-1.35) 
PS 2 6776 (89) 2.44 (2.35-2.53) 1.88 (1.81-1.95) 
PS 3 5736 (95) 4.06 (3.90-4.22) 2.88 (2.76-3.00) 
PS 4 2032 (98) 7.35 (6.97-7.76) 4.91 (4.64-5.19) 
PS not known 8578 (81) 1.95 (1.88-2.02) 1.73 (1.67-1.80) 
"Missing" 11629 (80) 1.74 (1.68-1.80) 1.66 (1.60-1.73) 
Histology of tumour 
Non Small Cell 18538 (80) 
Small cell 5175 (90) 1.34 (1.30-1.38) 1.24 (1.20-1.28) 
Carcinoid 25 (16) 0.11 (0.08-0.17) 0.17 (0.12-0.26) 
Mesothelioma 1626 (82) 0.98 (0.93-1.03) 0.90 (0.85-0.95) 
"Other" histology 1785 (75) 0.91 (0.87-0.96) 0.97 (0.92-1.02) 
"Missing" 21304 (80) 1.06 (1.04-1.08) 0.95 (0.92-0.98) 
Stage of tumour 
Stage IA 661 (39) 
Stage IS 1319 (53) 1.46 (1.33-1.60) 1.44 (1.31-1.58) 
Stage IIA 114 (42) 1.10 (0.91-1.35) 1.10 (0.90-1.34) 
Stage lIB 985 (62) 1.98 (1.80-2.19) 1.90 (1.72-2.09) 
Stage lIlA 2280 (75) 2.63 (2.41-2.87) 2.25 (2.06-2.46) 
Stage IllS 5074 (85) 3.74 (3.45-4.06) 2.96 (2.72-3.21) 
Stage IV 12348 (93) 5.98 (5.52-6.47) 4.37 (4.04-4.73) 
Occult 45 (69) 2.15 (1.58-2.92) 1.98 (1.46-2.69) 
Uncertain 3183 (75) 3.21 (2.95-3.49) 2.55 (2.34-2.78) 
"Missing" 22444 (82) 3.55 (3.28-3.83) 2.90 (2.67-3.13) 
MDT treatment Intent 
No specific anti-cancer Rx 2626 (90) 
Curative Intent 2548 (47) 0.23 (0.22-0.25) 0.47 (0.44-0.50) 
Palliative Intent 18879 (88) 0.83 (0.80-0.86) 1.01 (0.97-1.05) 
Best Supportive Care 6792 (92) 1.22 (1.16-1.27) 1.26 (1.20-1.32) 
Don't know 4046 (80) 0.65 (0.62-0.68) 0.85 (0.81-0.90) 
"MIssing" 13562 (76) 0.59 (0.57-0.62) 0.87 (0.84-0.92) 
Year of diagnosis 
2007 15774 (72) 
2006 15199 (83) 1.03 (1.00-1.05) 1.03 (1.00-1.05) 
2005 11248 (87) 1.01 (0.98-1.03) 1.01 (0.99-1.04) 
2004 or earlier 6232 (90) 1.02 (0.99-1.05) 1.02 (0.99-1.05) 
Legend: (%)* percentage of the total number of patients within each subgroup 
of each variable who have died. 
** Hazard ratios are mutually adjusted for all variables In the table. 
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4.3.6 Results of NHS Trust stratification using different data sources 
NHS Trust stratification using these three sources of data showed a high level of 
agreement. The level of concordance between Registry derived strata and ONS 
and HES derived strata are depicted in tables 4.10 and 4.11 respectively. The 
weighted kappa value for agreement between Registry and ONS derived 
stratification was 0.85, and between Registry and HES derived NHS Trust 
stratification was 0.75. 
Table 4.10: Concordance between ONS and Registry derived NHS Trust strata. 
NHS Trust strata calculated using ONS data 
SO) 1 2 3 4 'Missing' Total 
,.,5 
1 25 11 3 0 0 39 
- m t;=» 
2 11 17 11 0 0 39 
t; S ,. 3 3 8 21 7 0 39 i!l'a 
....... ~ ~ 4 0 0 6 34 0 40 
.!!It; 
en =».- 'Missing' 0 0 0 0 11 11 :c £ 0) z ~ ~ ~ Total 39 36 41 41 11 168 
Table 4.11: Concordance between HES and Registry derived NHS Trust strata. 
NHS Trust strata calculated using HES data 
Sf 1 2 3 4 'Missing' ,..- 1 24 13 0 1 1 loom t;;=» 
2 10 18 7 4 0 
t; S ,. 3 3 8 20 8 0 i!'a'a 
... .s ~ ~ 4 1 0 11 26 2 
.!!It; (I)=»- 'Missing' 0 0 0 0 11 
:c £ r z ~ a = = Total 38 39 38 39 14 
NHS Trust stratum; 1=quartlle with highest observed:expected ratiO, 
4=quartlle with lowest observed:expected ratio. 
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Total 
39 
39 
39 
40 
11 
168 
4.4 Discussion 
4.4.1 Overall summary 
I have found that despite variation In the NHS Trust level of case ascertainment 
within the NLCA dataset, there was little variation related to this In patient 
demographics, access to treatment and survival. This suggests that overall the 
data within the NLCA are unbiased and are representative of people with lung 
cancer in England, which implies the NLCA is a useful dataset for health service 
research. 
I have found that although only a minority of patients undergo surgery, for the 
subgroup of patients with proven non-small cell lung cancer this figure is 14%, 
which is approaching the figure of 17% amongst comparable European countries 
(5). Less than a third (32%) of all patients are surviving for one year after their 
diagnosis, which is below the standard of 'good practice' stated as 37%, In the 
Cancer Reform Strategy - second annual report (37). This figure is based on the 
highest rate of one year survival amongst countries with 100% registration in 
EUROCARE-4 (21). Overall survival is affected by several patient features; 
namely Increasing age, poor performance status and advanced stage of the 
disease at diagnosis. Of note socio-economlc deprivation does not affect overall 
survival, or the likelihood of receiving surgery or radiotherapy; but it did have a 
small effect on reducing the likelihood of receiving chemotherapy, even after 
allowing for variation In stage and performance status. 
4.4.2 Strengths and weaknesses 
The strength of the NLCA dataset lies in the fact it Is the largest (non Registry), 
contemporary, and unselected cohort of Individuals with lung cancer In Europe, 
Including both surgical and non-surgical patients. Data collection is on-going 
and the production of an annual report (35) allows policy changes to be 
evaluated and the audit cycle to be completed. The weaknesses of the NLCA 
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dataset are that it does not contain detailed Information on patient co-morbidity, 
nor Information regarding the treatment facilities available at Individual NHS 
Trusts, and that a number of the data fields have missing data. These results 
have shown that In general NHS Trusts that submitted a lower proportion of 
cases also tended to have higher levels of missing data for Individual variables. 
There Is evidence that the proportion of missing data Is decreasing progressively 
and that the quality of the dataset Is therefore improving each year (35). 
Furthermore my aim is to link the NLCA dataset with other healthcare datasets 
and thereby to evaluate the Influence of overall and individual co-morbidities on 
treatment received and overall survival. Despite these limitations the NLCA is 
the largest available dataset for lung cancer health services research and my 
results suggest it Is a valid resource tool which should now be used to answer 
important service provision questions. 
Finally It is reassuring to note that there was a good level of correlation between 
the strata of NHS Trusts based on case ascertainment calculated using cancer 
Registry data, and those created using ONS and HES data. 
4.4.3 Comparison with other studies 
Whilst there are few published national studies of health service research 
involving lung cancer in England, there have been smaller audits at a regional 
level which have described geographical variation in treatment and survival for 
people with lung cancer (51, 67). Jack et al (2003) (51) found that a deprived 
socio-economic status was linked to a reduced likelihood of receiving 
chemotherapy, but that it had no Impact on 1 or 3 year survival, findings 
conSistent with my results. In 1998 an audit (23) was carried out by the Clinical 
Effectiveness and Evaluation Unit of the Royal College of Physicians (London) 
which comprised 1600 patients across 48 hospitals In England, Wales and 
Northern Ireland. Information was collected retrospectively and prospectively 
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about clinical presentation, treatment received and survival at six months post 
procedure on patients who had undergone a bronchoscopy. There was 
geographical variation In the timing of and Intervals between several pOints 
along the diagnostic pathway. Variation was also reported between hospitals in 
terms of the treatments used; rates of surgical resection (excluding known small 
cell cancers) ranged from 3-33%, of chemotherapy (small cell cancers only) 
ranged from 14-100%, and for radiotherapy ranged from 20-77%. However, 
within a small cohort like this, small changes In patient numbers will dramatically 
alter the percentages reported. Within this small cohort, 46% of patients had 
died within six months of bronchoscopy, which Is In keeping with our finding that 
median survival from diagnosis Is only 203 days (interquartile range 62 to 545 
days). Some of these Inequalities In the patient lung cancer pathway may be 
mitigated by Implementation of the NHS Cancer Plan (2000) (24), and the 
Cancer Reform Strategy (2007) (27). Standards for the treatment of Individuals 
diagnosed with lung cancer In England and Wales have also been set by the 
National Institute for Clinical Excellence (NICE) in 2005 (26). 
The second annual report since the Cancer Reform Strategy (37) described 
regional variation In lung cancer one year survival at the level of primary care 
trusts. Given these results confirm that Individual level soclo-economlc status 
does not affect the likelihood of receiving surgery nor overall survival, It seems 
unlikely that Individual soclo-economlc status explains the regional variation In 
treatment received by Individuals with lung cancer (23, 35) nor their survival 
(37). This in turn suggests that the factors underpinning these Trust level 
variations are more likely to be related to primary or secondary care practice, 
and not Individual patient features. 
There are two International comparators, namely the EUROCARE-4 study (21), 
and the ongOing SEER (22) (Surveillance, Epidemiology and End Results) 
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programme in America. Both of these are registry linked datasets; the former is 
a European collaboration involving 47 cancer registries from 21 countries (and 
includes 4 regional registries for England), whilst the latter represents 26% of 
the overall American population. Neither of these large data sets are specific for 
lung cancer, but they do contain information on incidence, treatment and 
survival for all major cancers including lung. The NLCA dataset contains more 
patient specific details, including stage of disease at diagnosis (not present in 
EUROCARE-4) but the survival data within the NLCA are currently inadequate to 
calculate 5 year survival, although this will be possible by the end of 2011. 
Comparison between this cohort and results from SEER show good agreement on 
age and stage at diagnosis. As the NLCA database increases over time, more 
comprehensive comparisons will be possible with these International datasets. 
4.4.4 Implications of this study 
The Implications of this study are two-fold; firstly the validation of the NLCA 
dataset on the basis of data completeness suggests that these data reflect the 
current state of lung cancer in England. As such, It Is a unique dataset which 
has enormous potential to Inform and Influence policy change and to Improve the 
standard of care for lung cancer patients. 
Secondly these analyses provide contemporary estimates of treatment received 
and overall survival In people with lung cancer in England, and they provide 
reassurance that an individual's socio-economic status has little Influence on 
either of these outcome markers. Future studies of geographical variation in 
lung cancer care should focus mainly on potential variation in NHS Trust level 
features. 
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Chapter five: Linking the National Lung Cancer Audit with Hospital 
Episode Statistics (HES) 
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5.1 Introduction 
The analyses so far have established there Is no evidence of bias in the 
demographic features of patients entered Into the dataset, nor their outcome, 
based on case ascertainment at NHS Trusts. Therefore the National Lung Cancer 
Audit is a contemporary dataset, which can be used to investigate the 
geographical Inequalities In lung cancer care In England. However, the Audit 
does not contain robust data on co-morbidity, and so this chapter will describe 
the process of cleaning a dataset from the NLCA linked to Hospital Episode 
Statistics; and the creation of a composite score of co-morbidity, the Charlson 
Index. 
My aim was to study the Influence of both patient level and NHS Trust level 
features on the management and clinical outcome of people with lung cancer. In 
order to try and quantify the influence of the NHS Trust where a patient was first 
seen on outcome measures, details relating to facilities at every NHS Trust were 
obtained. These include whether or not it Is a cardlo-thoracic surgical centre, 
and/or a radiotherapy centre, the level of participation in clinical trials and the 
individual NHS Trust results from Peer Review (2003-2007). 
This chapter will describe the results of basic patient features for the whole 
cohort, including the relationship between socio-economic status and 
performance status, stage of disease and co-morbidity at diagnosis. I have used 
logistic regression to investigate whether the composite score of co-morbidity, 
the Charlson Index, or the individual component disease groups, influenced the 
likelihood of receiving certain treatment modalities. I have also looked at the 
time spent in hospital prior to the diagnosis of lung cancer, to assess If this Is an 
Independent predictor of the likelihood of having certain treatments. From the 
perspective of an NHS Trust I will discuss the results of the Peer Review data 
(2003-2007) and the incorporation of these data, which theoretically reflect the 
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performance of a lung cancer multi-disciplinary team, into logistic regression 
analyses Investigating treatment use. The same four variables will be analysed 
using multivariate Cox regression to assess their Influence on overall survival In 
this cohort of patients with lung cancer. 
The influence of patient and NHS Trust features on the likelihood of receiving 
surgery in patients with non-small cell lung cancer, and chemotherapy for those 
with small cell lung cancer have been Investigated In detail and will be described 
In chapters 6 and 7 respectively. 
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5.2 Methods 
5.2.1 Patient features within National Lung Cancer Audit (NLCA) 
The dataset used for this section of research was the second download received 
from the Information Centre (downloaded 17th November 2009), and linked to 
Hospital Episode Statistics. The NLCA component of the linked dataset required 
cleaning to ensure that the statistical package Stata 11 could process the data, 
and this was described In chapter 3. 
The National Lung Cancer Audit dataset contains the following patient features: 
sex, age at diagnosis, performance status (ECOG), histological subtype, and 
stage of the disease at diagnosis. The NLCA dataset also contains the details of 
each Individual patient's Lower Super Output Area (LSOA), which can be 
converted to a Townsend score for deprivation, generating a marker of socio-
economic status (see section 4.2.4). The Townsend qulntlle was the marker of 
soclo-economlc status used throughout the remainder of this research. 
5.2.2 Patient features within Hospital Episode Statistics (HES) 
Co-morbidity 
Hospital Episode Statistics Is a national database that all NHS Trusts use which 
records the ICD-10 diagnostic codes assigned to every patient who attends an 
NHS Institution, and also the operation codes (OPCS4) for any procedures 
performed. This coding practice Is one element of the administration process by 
which an NHS Trust can Invoice Primary Care Trusts. In-patient data were 
available from 1997 to 2007 (Inclusive), so all patients within the NLCA dataset 
as of the 17th September 2009, with a date first seen before 31st December 
2008, were linked to HES. This provided 11 files (following the financial years 
between 1997 and 2007) with In-patient details Including all diagnoses assigned, 
the frequency and duration of admissions, the operations performed and also 
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ethnlclty of each Individual. Within an admission, every patient can have 
multiple 'episodes' which should represent any change In the management of the 
patient, for example If a consultant from a different discipline takes over the 
patient's care. For each episode, a patient can have up to 20 diagnoses 
recorded. This level of detail can allow the Influence of specific co-morbidities to 
be examined, and also allows the creation of a composite score of co-morbidity. 
The composite score of co-morbidity chosen for this research, and used 
throughout the remainder of this project was the Charlson Index. It was first 
described by Dr ME Charlson In 1987 (34) as a method of creating a composite 
score of co-morbid severity In hospital within a cohort of breast cancer patients, 
which was then used to predict ten year survival. It has since been validated In 
other groups of patients, often with a malignant disease (68, 69), and has been 
found to be strongly predictive of survival, independent of age. For this reason It 
Is an appropriate composite score to use in a cohort of Individuals with lung 
cancer. The Charlson Index Is composed of 16 disease groups each with an 
Individual 'score' which are weighted according to the Influence this disease 
group Is deemed to have on survival, see table 5.1. However, the Charlson 
Index does not score on the severity of a condition, therefore two patients with 
COPD would contribute 1 to their overall score, and yet one patient could be on 
reliever Inhalers only, and the other on full medical therapy Including long-term 
oxygen. It Is worth noting that when the Charlson Index was created, a 
diagnosis of AIDS was essentially a terminal Illness and hence It carries the same 
'weight' as metastatic disease. However, over the past 20 years, the 
development of Highly Active Antl-Retrovlral Treatment (HAART) has meant that 
a diagnosis of AIDS Is no longer a terminal event. Within this cohort of 
Individuals with lung cancer, AIDS Is unlikely to be a common co-morbidity, and 
so the Charlson Index remains an appropriate composite score of co-morbidity. 
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Table 5.1: Illustrates the diseases used within the Charlson Index and the score 
assigned to each disease group. 
Disease 
Myocardial Infarction/heart failure 
Cerebrovascular disease 
Chronic pulmonary disease 
Dementia 
Peptic ulcer disease 
Diabetes (without complications) 
Peripheral vascular disease 
Connective Tissue disorder 
Mild liver disease 
Cancer (solid organ) 
Haematologlcal Malignancy 
Diabetes with complications 
Hemiplegia and paraplegia 
Renal disease 
Moderate or severe liver disease 
Metastatic cancer 
AIDS 
Individual score 
1 
1 
1 
1 
1 
1 
1 
1 
1 
2 
2 
2 
2 
2 
3 
6 
6 
In order to create a composite co-morbidity score, the first challenge was to 
merge the 11 files with details of In-patient admissions, and create a master file. 
This dataset contained all patients held within the National Lung Cancer Audit, 
between January 2004 and the end of December 2008, and details of all 
diagnoses recorded for those who had been admitted to hospital since 1997. 
There were more than 1.5 million lines of data. 
In order to assess the Influence of co-morbidity on the treatment decision of the 
multi-disciplinary team, a Charlson Index was created for each patient within this 
NLCA/HES linked dataset at the time of diagnosis. The date of diagnosis Is held 
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within the NLCA dataset. Where the date of diagnosis was missing the date of 
first clinic appointment was Interpolated, adjusting for the median Interval 
between clinic appointment and diagnosis within the whole cohort, which was 10 
days. Only admissions before the date of diagnosis were considered. 
Not all patients within this linked dataset had an In-patient record reflecting their 
diagnosis of lung cancer. Therefore in order to remove this discrepancy all seven 
ICD-l0 codes for lung cancer were deleted from the dataset. Consequently, only 
patients who had a 'non-lung' malignancy prior to their diagnosis of lung cancer 
would contribute two points to their overall Charlson Index. However, It could 
be that patients with metastatic lung cancer contributed six points to their 
composite score on the basis of metastatic disease, rather than a specific 
diagnosis of lung cancer. 
It was Important to ensure that every diagnosis pertinent to a Charlson Index 
should contribute only once to the overall score (appendix 5). Therefore, 
duplicate ICD-10 codes were dropped after their first appearance In the 
NLCA/HES linked dataset. For example an Individual with renal failure generated 
a Charlson Index of more than 700, when every time she attended for 
haemodlalysls she added two pOints to her overall score. Furthermore, should 
an Individual have more than one diagnosis (ICD-10 code) within the same 
Charlson disease group, only the first diagnosis should contribute to their overall 
score. 
'Bed days' 
Hospital Episode Statistics contains details of In-patient duration, 'bed days', and 
this has been studied previously In relation to survival from cancer (70, 71). 
Therefore a variable 'bed days' was created which was the sum of all the time 
spent In hospital over a twelve month period prior to the diagnosis of lung 
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cancer. However, so as to exclude the possibility of reverse causation, I.e. that 
In the Immediate period of time leading up to the diagnosis of lung cancer (say 
three months) an Individual may attend hospital for seemingly unrelated 
problems, which may In fact relate to the underlying malignancy, the period of 
time chosen for analysis should not Include this 'lead time' period. Therefore It 
was decided to examine the time spent in hospital by patients between 15 and 3 
months (I.e. a 12 month period) prior to the diagnosis of lung cancer. The 
number of days spent In hospital was then converted to a categorical variable, 
by creating quartlles. 
Ethnlclty 
Finally, HES contains Information regarding the ethnic origin of In-patients, and 
this Information was coded and grouped Into the following categories; White, 
Black (African and Caribbean), ASian, Mixed race, other ethnlclty, and missing. 
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5.2.3 NHS Trust features 
In order to Investigate the role of the hospital where a patient Is first seen In 
determining the clinical outcomes of Individuals with lung cancer, I have 
quantified the services pertinent to lung cancer care available at every NHS 
Trust, and the performance of the lung cancer MDT within every Trust. 
5.2.3.1 Cardlo-thoraclc surgical centres 
The National Society of Cardiothoraclc Surgeons has shared Information 
regarding which NHS Trusts are also Cardlo-thoraclc surgical centres. This was 
used to create a binary variable for each NHS Trust, based on whether the Trust 
Is a surgical centre or not. 
5.2.3.2 Radiotherapy centres 
Based on a report from the National Cancer Action Team (NCAT) (2007/2008) It 
has been possible to Identify which NHS Trusts within England have radiotherapy 
facilities. This Information was used to create a binary variable for each NHS 
Trust, based on whether the Trust Is a radiotherapy centre or not. 
5.2.3.3 Clinical trial entry data 
All NHS Trusts can provide chemotherapy, and all multi-disciplinary teams are 
encouraged to consider patients for clinical trials. Clinical trials will 
predominantly Involve chemotherapy, but not exclusively; some are related to 
surgery, radiotherapy, and palliative care. The National Cancer Research 
Network (NCRN) kindly supplied trial entry figures, specific to lung cancer, for 
2008-09. In order to allow comparison between NHS Trusts with different 
caseloads, the proportion of patients being entered Into clinical trials was 
calculated by dividing the number of patients entered Into trials by the expected 
number of patients at each NHS Trust according to Cancer Registry data (2007). 
There was a wide range of values for the proportion of expected patients entered 
Into trials at Individual NHS Trusts. Having evaluated the results (figure 5.1) a 
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cut-off of 5% (0.05) was made, as this accounted for an above average 
proportion of patients being entered into clinical tria ls; but yet an achievabl e 
target, as approximately a third of all patients were first seen in NHS Trusts who 
entered 5% or more of their expected lung cancer patients into clinical trial s. 
Hence, a binary variable reflecting trial entry at the level of an NHS Trust was 
created, a high trial centre entered 5% or more of Its expected lung cancer 
patients into clinical trials, and a low trial centre did not achieve this. 
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Figure 5.1: Histogram showing range In proportion of patients entered Into 
clinica l trials 
5.2.3.4 Peer Review 
The National Cancer Action Team, Department of Hea lth, performs a Peer review 
evaluation process of all cancer services at NHS Trusts In England and Wales. 
Originally this was every 4 years, but It has now become an annual process . 
Therefore all lung cancer multidisciplinary teams (MOTs) are Inspected and 
required to demonstrate evidence of how they perform ed when measured 
against 32 key standards (appendix 6). The results of the Peer review process 
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2004-2007 were made available for this research project. The overall score 
achieved by each NHS Trust was included as a marker of NHS Trust 
performance, and to establish if this influenced lung cancer outcomes. 
5.2.4 Outcome measures 
5.2.4.1 Treatment received 
Of the three treatment modalities used for lung cancer, surgery has the greatest 
number of variables within the National Lung Cancer Audit dataset, namely: the 
NHS Trust where the surgery took place, the date of the operation and the 
primary procedure (OPCS4) code. The degree of overlap between these three 
surgical variables was explored (figure 5.2). I decided to use the date of surgery 
as a reliable marker that surgery had taken place, which captured almost 80% of 
patients with any reference to surgery. 
NHS Trust where 
surgery occurred 
Date of 
surgery 
N=311 
10 surgical 
procedure 
N=26 
Figure 5.2: Relationship between Audit variables pertaining to surgery. 
Radiotherapy and Chemotherapy have variables recording the NHS Trust where 
these took place and the date the therapy started. There is di screpancy in th e 
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completeness of these data fields, but again It was felt the date of treatment was 
the most reliable piece of data. Therefore the presence of a 'date of treatment' 
was used to create a binary variable for whether treatment had actually taken 
place. 
5.2.4.2 Overall survival 
The start date was taken as the date of diagnosis as per the National Lung 
cancer Audit, and, If missing, the date of the first clinic appOintment was 
Interpolated, adjusting for the median Interval between these two dates on the 
patient pathway for the whole cohort (10 days). The end date was taken as the 
date of death as per NLCA (obtained from the Patient Demographics Service), or 
the date the dataset was downloaded, which was the 30th September 2009. 
Patients with a date of diagnosis on or after the date of death were excluded 
from survival analyses, and represent patients diagnosed by death certificate 
only. 
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5.2.5 Analysis plan 
One aspect of this stage of the research has simply been the creation of key 
variables based on important patient features and pertinent features of an NHS 
Trust. These are outlined in Table 5.2 below. Each patient feature was analysed 
for the cohort as a whole and the results are shown in section 5.3 
Table 5.2: Final set of patient and NHS Trust features 
Patient feature Source Comment 
Sex NLCA 
Age at diagnosis NLCA 
Histology NLCA 
Performance status NLCA Based on ECOG 
Spirometry NLCA Absolute value (L/min) 
Stage NLCA UICC version 6 
Townsend quintile NLCA derived Mapped via LSOA 
Ethnlcity HES 
Charlson Index HES derived Generated usi ng ICD-10 codes for 
in-patient admissions between 
1997 and 2007. 
Bed days HES derived Total days spent In hospita l In 12 
month period prior to diagnosis of 
lung cancer. 
Date of surgery NLCA 
Date of radiotherapy NLCA 
Date of chemotherapy NLCA 
Date of diagnosis NLCA 
Start date NLCA derived Date of diagnosis or Interpolated 
from date of clinic appointment. 
Date of death NLCA Patient Demographics Service 
" 
, ·,'4 !I .. 
, ' , 
Surgical centre CT Society Binary variable 
Radiotherapy centre NCAT Binary variable 
Trial entry data NCRN Binary variable created with 5% 
of expected lung cancer patients 
entered Into tria ls as the 
threshold for a high trial centre. 
Peer Review NCAT Overall score 
Legend: 
NLCA 
HES 
National Lung Cancer Audit dataset (LUCADA) 
Hospital Episode Statistics 
CT Society 
NCRN 
NCAT 
ECOG 
UICC 
LSOA 
Cardio-Thoracic Society 
National Cancer Research Network 
National Cancer Action Team 
Eastern Cooperative Oncology Group 
Union International Contre Ie Cancer (version 6) 
Lower Super Output Area 
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In order to evaluate the Influence on treatment received for the following 
variables: Charlson Index, the Individual component disease groups of the 
Charlson Index, 'bed days' and the overall score from Peer Review, multivariate 
logistic regression analyses were performed. The models were adjusted 
mutually for all patient features. 
Multivariate Cox regression analyses were performed to assess the Influence on 
overall survival of the same variables, namely: Charlson Index, the Individual 
component disease groups of the Charlson Index, 'bed days' and the overall 
score from Peer Review. The proportional Hazards assumption was checked 
using Nelson-Aaleen plots. 
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5.3 Results 
The NLCA/HES linked dataset (2nd dataset made available for this research) 
contained 87,254 patients who were first seen at an English NHS Trust between 
January 2004 and 31st December 2008. Two patients had no database Identifier 
and were excluded, and 6,286 (7%) were excluded on the basis there was no 
record of the NHS Trust at which they were first seen. This left 80,966 
unselected English patients with lung cancer, all of whom had either a date of 
diagnosis or date of first appointment. 
5.3.1 Patient features within NLCA 
The basic demographic features of this second cohort of English lung cancer 
patients were very similar to those of the original dataset. The sex ratio, 
male:female was 60:40, and the median age at diagnosis was 72 years 
(Interquartlle range 62 to 79 years). The histological subtypes at diagnosis are 
depicted In Table 5.3 and were broadly grouped Into non-small cell lung cancer 
(NSCLC) 40%, small cell 10%, and mesothelioma 3%. Within the subset of 
patients with NSCLC, 33% had proven squamous cell carcinoma, 27% had 
adenocarcinoma, and 34% had non-small cell lung cancer not-otherwlse-
specified (NOS). 
Table 5.3; Histological subtypes at diagnosis {N=80 966) 
HistoloGY N 0/0 
Squamous 11,487 14.2 
Adenocarcinoma 9,257 11.5 
NSCLC, NOS 11,531 14.2 
Mixed NSCLC 138 0.2 
Small cell 7,845 9.7 
Carcinoid 240 0.3 
Neuroendocrine 
Carci noSarcoma 
Large cell/other 
Bronchoalveolar cell 
Carclnoma-In-sltu 
Mesothelioma 
Missing 
Total 
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244 0.3 
39 0.1 
3,001 3.7 
525 0.7 
167 0.2 
2,772 3.4 
33,964 42.0 
80,SUS6 
Stage Is recorded in the NLCA dataset as per the sixth version of the Union 
International Contre Ie Cancer (UICC). Table 5.4 Illustrates the variation In 
stage of disease at diagnosis, and demonstrates the large subgroup of patients 
who present with metastatic disease (Stage IV), for whom a cure Is not possible. 
Table 5.4: Stage at diagnosis (N=80,966) 
Stage N 0/0 %* 
IA 2,439 3.0 5.9 
IB 3,591 4.4 8.7 
I1A 376 0.5 0.9 
lIB 2,217 2.7 5.4 
IlIA 4,351 5.4 10.6 
I1IB 8,627 10.7 20.9 
IV 19,547 24.1 47.3 
Occult 92 0.1 0.2 
Missing 39,726 49.1 NA 
Total 80,966 
Legend: * percentage of patients with each stage of disease excluding those 
with 'missing' data 
performance status 
Data on Performance Status (PS) at diagnosis were missing In 31,890 (40%) 
patients, but the variation In PS at diagnosis In those with these data Is 
Illustrated in the figure 5.3 below. It demonstrates the large group of patients 
(26,357) who have a good performance status (PS 0-1) at diagnosis. This 
suggests their co-morbidities, If they have any, should not preclude potentially 
curative treatment. 
20,000 
16,290 
15,000 
10,000 
5,000 
o 
PSO PS 1 PS 2 PS3 PS4 
Figure 5.3; Illustrates performance status at diagnosis If recorded (N==49,076). 
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Lung function 
Results of basic spirometry were available on 22,233 patients, and these data 
demonstrate a wide range of values of pre-operative FEV1 (see figure 5.4). 
However, this is unlikely to be a representative sample, as those patients with 
significant co-morbidities or a poor performance status may not be sent for basic 
spirometry. For this reason, FEV1 was not included in multivariate logi stic and 
Cox regression analyses in the remainder of this research. 
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Figure 5.4: Histogram illustrating the variation in basic spirometry. 
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4 
Socio-economic status 
Almost all patients within the National Lung Cancer Audit dataset have a lower 
super output area (LSOA) code based on th eir residential postcode. The LSOA 
was missing in 170 patients within this cohort, therefore it was not possible to 
derive a Townsend score for these individuals. The distribution of Townsend 
quintile scores (N = 80,796) for the remaining cohort are Illustrated in figure 5.5 . 
• 1 (15%) Most afflu ent 
. 2 (18%) 
.3 (20%) 
.4(21%) 
.5 (26%) Leas t affluent 
Figure 5.5: Distribution of socio-economlc status using Townsend qulntlles In thi s 
English cohort of patients with lung cancer. 
Figure 5.5 demonstrates that there were more Individuals from the lowest soclo-
economic stratum within this cohort of patients with lung ca ncer, and fewest 
from the most affluent subgroup. Whether the socia-economic stratum of an 
Individual was linked to any other differences In terms of clinica l features has 
also been Investigated. 
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1 
0.8 
0.6 
0.4 
0.2 
o 
1 (most 
affluent) 
2 3 4 5 (least 
affluent) 
Figure 5.6: Distribution of performance status across each Townsend qulntile. 
There was a small reduction in the proportion of patients with performance 
status 0, normal physical function, in the least affluent compared to the most 
affluent quintile of socio-economlc status. 
1 
0.8 
0.6 
0.4 
0.2 
o 
1 (most 
affluent) 
2 3 4 5 (I ast 
afflu ent) 
Figure 5.7: Distribution of stage across each Townsend qulntlle. 
• miss ing 
• Stag IV 
• St g III 
• Stage II 
• Stag I 
There was very little variation In the data on stage at diagnosis of these patients 
based on their socio-economlc status . Data within the National Lung Cancer 
Audit have been analysed previously (chapter 4), to assess the Influence of 
socioeconomic status on access to treatment, and the results are depicted in 
tables 4.5, 4.6 and 4.7. Socioeconomic status had no Influence on the likelihood 
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of receiving surgery in patients with non-small cell lung cancer, nor radiotherapy 
for the cohort overall, but there was evidence that those patients In the least 
affluent stratum were less likely to receive chemotherapy compared with those 
patients in the most affluent stratum. 
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5.3.2 Patient features within Hospital Episode Statistics (HES) 
Charlson Index 
For the cohort of 80,966 patients, there were >1.5 million episodes over the 11 
years of in-patient data supplied. The median Charlson Index at diagnosis for 
this cohort was 1, with an interquartile range of 0 to 4. This reflects the fact 
that whilst 39,537 (45%) patients had been in-patients prior to their diagnosis of 
lung cancer being made, the diagnostic ICD-10 codes assigned were not 
pertinent for the Charlson Index composite co-morbidity score. Hence they had 
a Charlson Index at diagnosis of zero. Figure 5.8 shows the distribution of 
Charlson Indices at diagnosis. Note that 979 patients had a Charlson Index at 
diagnosis of greater than or equal to 10 (n =576); the number of patients with a 
Charlson Index at diagnosis of 11 was 222, of 12 was 112, of 13 was 38, of 14 
was 18, of 15 was 9, of 16 was 3 and one patient had a Charlson Index at 
diagnosis of 17. The maximum score possible Is 34. 
50 
Perce age of patients within cohort 
40 
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Charlson Index at diagnosis 
Figure 5.8: Histogram showing the distribution of Charlson Indices at diagnosis . 
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The Charlson Index was divided into quintiles to allow regression analyses of this 
continuous variable, but in view of the large number of patients with a Charlson 
Index at diagnosis of zero, this group actually comprised two qulntiles. The 
division of the cohort on the basis of co-morbidity is shown in the Table 5.5 
below. 
Table 5.5: Division of cohort into Charlson Index qulntiles 
Charlson quintile 
1 (+2) 
3 
4 
5 
N (0/0) 
34,711 (43) 
15,915 (20) 
15,085 (19) 
15,255 (19) 
Charlson Index at diagnosis 
° 1 
2 or 3 
4+ 
Figure 5.9 illustrates that in this cohort of patients with lung cancer there was no 
evidence that the level of co-morbidity increased as affluence declined. 
1 
0.8 
0.6 
0.4 
0.2 
o 
1 (most 
affluent) 
2 3 4 5 (least 
affluent) 
Figure 5.9: Distribution of Charlson Indices across Townsend qulntiles. 
The results of logistic regression analyses assessing the Influence of the Charlson 
Index on access to treatment are illustrated In table 5.6. 
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Table 5.6: Logistic regression for Charlson Index and access to treatment 
N N* 0/0** 
Surgery (NSCLC only: N=34,31S) 
Charlson Index 
o 15573 2341 15 
1 6951 985 
752 
Radiotherapy (N=80,966) 
Charlson Index 
14 
13 
o 34711 7668 22 
1 15915 3376 21 
21 
Chemotherapy (small cell only; N=784S) 
Charlson Index 
o 3482 2441 70 
1 1492 904 61 0.66 (0.58, 0.74) 
2 or 3 1090 625 57 0.57 (0.50, 0.66) 
1781 850 48 0 0.35 0.44 
Adj OR*** p for 
trend 
< 0.001 
0.748 
<0.001 
Legend: N* Number of patients within each subgroup who have had trea tment. 
%** percentage of patients within each subgroup who have had treatment. 
Adj OR*** ; adjusted Odds Ratio, mutually adjusted for sex, age qulntlle, 
hi stology (radiotherapy only), stage, performance status, ethnic group and 
soclo-economic status. 
NSCLC; non -small cell lung cancer 
Table 5.6 shows that the Charlson Index has a strong Influence on the likelihood 
of receiving surgery and chemotherapy. If the composite co- morbidity score Is 4 
or more, then the patient Is 31% less likely to receive surgery and 50% less 
likely to receive chemotherapy compared with patients with a Charlson Index of 
zero. There did not appear to be any evidence that Increasing co-morbidity was 
associated with a reduced likelihood of receiving radiotherapy. Thi s Is a 
t reatment used in both radical (potentially curati ve) and palliative settings, and 
this may be why individuals with Increasing co-morbidity do not appear to be at 
a disadvantage In accessing radiotherapy. 
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Table 5.7: Results of Cox regression illustrating the Influence of the Charlson 
Index on overall mortality (N=80,264) 
N N died 0/0* Unadj HR Adj HR** P for 
(95% cn (95% CIl trend 
Charlson Index 
0 34,556 27,125 78 <0.001 
1 15,806 12,655 80 1.15 (1.13, 1.18) 1.08 (1.06, 1.11) 
2 or 3 14,937 12,393 83 1.26 (1.23, 1.28) 1.14 (1.12, 1.17) 
4+ 14965 14,218 95 2.19 (2.14 2.23) 1.76 (1.72 1.80) 
Legend; %* percentage of patients within each subgroup who have died. 
Adj HR**i adjusted Hazard Ratio, mutually adjusted for sex, age qulntlle, 
histology, stage, performance status, ethnic group and soclo-economlc status. 
Table 5.7 demonstrates that as the Charlson Index rises, so the patient Is more 
likely to die. The adjusted Hazard RatiO for Individuals with a Charlson Index of 
4 or more was 1.76 (95% CI 1.72, 1.80), suggesting that these Individuals are 
almost 80% more likely to die than those with a Charlson Index of zero. Even 
patients with a single co-morbid Illness, scoring one pOint, had a statistically 
significant Increased likelihood of death compared with those patients with a 
Charlson Index of zero. 
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IndiVIdual diseases 
The frequency of each component disease of the Charlson Index within this 
cohort of lung cancer patients Is Illustrated In table 5.8 below. 
Table 5.8: Number of patients within each disease group. 
Component disease group Number % cohort 
Myocardial Infarction/heart failure 8,552 11 
Cerebrovascular disease 4,628 6 
Chronic pulmonary disease 18,087 22 
Dementia 839 1 
PeptiC ulcer disease 2,745 3 
Diabetes (without complications) 7,497 9 
Peripheral vascular disease 7,020 9 
Connective tissue disease 1,558 2 
Cancer (solid organ) 11,588 14 
Haematologlcal malignancy 631 1 
Diabetes with complications 642 1 
Hemiplegia/paraplegia 1,002 1 
Renal disease 1,972 2 
Severe liver failure 112 1 
Metastases 11,762 14 
AIDS 31 0.04 
The commonest co-morbidity Is respiratory disease (22% of cohort) which 
Includes primarily chronic obstructive pulmonary disease (COPD), and Interstitial 
lung fibrosis. Given the link between smoking and lung cancer, and smoking 
with both Ischaemlc heart disease and other malignancies, It Is expected that a 
significant proportion of this cohort of patients with lung cancer will have both 
these co-morbidities. It Is also worth noting that 14% of this cohort of patients 
with lung cancer had metastatic disease at diagnosiS as per Hospital Episode 
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Statistics which Is not dissimilar to the percentage of patients recorded as having 
Stage IV disease In the National lung Cancer Audit (24%). 
Treatment received and surviyal 
The results of logistic regression analyses regarding surgery and chemotherapy If 
the patient had known non-small cell, and small cell lung cancer respectively, 
are illustrated in Tables 5.9 and 5.10. Table 5.9 shows that Individuals with 
certain conditions were less likely to have surgery than those without. Dementia 
was a strong negative predictor, with an adjusted Odds ratio of 0.26 (95% CI 
0.08, 0.88) compared with those without the Illness. A total of 4 patients out of 
a total of 150 with non-small cell lung cancer and dementia had surgery. The 
presence of cardiac and renal disease also played a strong negative predictive 
role. Individuals with cardiac disease were 21% less likely to have surgery 
compared with those without (adjusted Odds ratio 0.79, 95% CI 0.96, 0.91). 
Individuals with renal disease were 31% less likely to have surgery than those 
without this disease (adjusted Odds ration 0.69, 95% CI 0.50, 0.96). Cardiac 
and renal Impairment would be Important from an anaesthetic perspective, as 
well as recovery In the post-operative period. Diabetes with complications also 
had a negative Influence on the likelihood of having surgery. Individuals with 
this condition were almost half as likely to have surgery as those without this 
disease (adjusted Odds ratio 0.51, 95% CI 0.30, 0.87). 
Table 5.10 shows the results of logistic regression on access to chemotherapy for 
those patients with proven small cell lung cancer. It shows that several diseases 
had a negative Influence Including: chronic respiratory disease (adjusted Odds 
Ratio 0.84, 95% CI 0.75, 0.95), cerebrovascular disease (adjusted Odds Ratio 
0.77, 95% CI 0.61, 0.97), peptic ulcer disease (adjusted Odds RatiO 0.65, 95% 
CI 0.50, 0.84) and renal failure (adjusted Odds Ratio 0.60, 95% CI 0.42, 0.88). 
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Table 5.9: Logistic regression for surgery In patients with NSCLC (N=34,513). 
D'.ea.e aroUD N N* %** UnadJ OR (95% CIl Adj OR**. (95% Cll P 
cardiac 
No 31223 4173 13 
Yes 3290 312 9 0.68 (0.6, 0.77) 0.79 (0.68, 0.91) <0.01 
Stroke 
No 32843 4311 13 
Yes 1670 174 10 0.74 (0.63, 0.88) 0.85 (0.70, 1.03) 0.10 
Peripheral vascular disease 
No 31547 4161 13 
Yes 2966 324 11 0.82 (0.73, 0.93) 0.88 (0.77, 1.02) 0.09 
Dementia 
No 34363 4481 13 
Yes 150 4 3 0.14 (0.04, 0.44) 0.26 (0.08, 0.88) 0.03 
Respiratory 
No 27178 3623 13 
Yes 7335 862 12 0.88 (0.81, 0.95) 0.83 (0.76, 0.92) <0.01 
Connective tissue diseases 
No 33832 4371 13 
Yes 681 114 17 1.34 (1.08, 1.65) 1.11 (0.87, 1.43) 0.40 
Ulcer 
No 33409 4335 13 
Yes 1104 150 14 1.06 (0.89, 1.27) 1.06 (0.86, 1.31) 0.58 
Diabetes 
No 31403 4131 13 
Yes 3110 354 11 0.83 (0.74, 0.94) 0.90 (0.78, 1.03) 0.12 
Hemiplegia 
No 34163 4459 13 
Yes 350 26 7 0.55 (0.37, 0.83) 0.64 (0.40, 1.02) 0.06 
Diabetes with complications 
No 34251 4465 13 
Yes 262 20 8 0.54 (0.34, 0.87) 0.51 (0.30, 0.87) 0.01 
Renal failure 
No 33817 4425 13 
Yes 696 60 9 0.63 (0.48, 0.82) 0.69 (0.50, 0.96) 0.03 
Haematologlcal malignancy 
No 34210 4445 13 
Yes 303 40 13 1.05 (0.75, 1.47) 1.03 (0.69, 1.52) 0.90 
Cancer (not lung) 
No 30053 3963 13 
Yes 4460 522 12 0.88 (0.79, 0.97) 1.01 (0.90, 1.13) 0.93 
Severe liver failure 
No 34472 4480 13 
Yes 41 5 12 1.18 (0.49, 2.81) 0.82 (0.29, 2.33) 0.71 
Metaatases 
No 29633 4201 14 
Yes 4880 284 6 0.38 (0.33, 0.43) 0.73 (0.63, 0.84) <0.01 
AIDS 
No 34494 4481 13 
Yes 19 4 21 1.48 (0.5 4.39) 1.08 (0.21 5.46) 0.92 
Legend: N* number of patients within each disease group who had surgery. 
%** percentage of patients within each disease group who had surgery. 
Adj OR*** adjusted Odds Ratio adjusted for sex, age qulntJle, stage, 
performance status, Townsend qulntlle and ethnic group. 
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Table 5.10; Logistic regression for chemotherapy In patients with small cell lung 
cancer (N=784s). 
DI.88.e group N N* %** Unad) OR (95% cn Ad) OR*** (95% cn 
Cardiac 
No 
Yes 
Stroke 
No 
Yes 
7127 4437 
718 388 
7472 4644 
373 176 
Peripheral vascular disease 
No 7229 4498 
Yes 616 322 
Dementia 
No 7816 4813 
Yes 29 7 
Respiratory 
No 
62 
53 
62 
47 
62 
52 
62 
24 
63 
0.71 (0.61,0.82) 
0.55 (0.45, 0.68) 
0.68 (0.58, 0.8) 
0.2 (0.9, 0.48) 
Yes 
6225 3941 
1620 879 54 0.71 (0.63,0.79) 
Connective Tissue Disease 
No 7722 4756 62 
Yes 123 64 52 0.7 (0.49, 1.00) 
Peptic Ulcer disease 
No 7567 4680 62 
Yes 278 140 50 0.63 (0.49, 0.80) 
Diabetes 
No 7131 4442 62 
Yes 714 378 53 0.7 (0.60, 0.81) 
Hemiplegia 
No 7772 4788 62 
Yes 73 32 44 0.51 (0.32, 0.81) 
Diabetes with complications 
No 7789 4795 62 
Yes 56 25 45 0.52 (0.30, 0.88) 
Renal failure 
No 7708 4768 62 
Yes 137 52 38 0.38 (0.27, 0.54) 
Haematologlcal malignancy 
No 7787 4787 61 
Yes 58 33 57 0.85 (0.50, 1.42) 
cancer (not lung) 
No 7020 4370 62 
Yes 825 450 55 0.74 (0.64, 0.85) 
Severe liver failure 
No 7835 4815 61 
Yes 10 5 SO 0.64 (0.19, 2.22) 
Metastases 
No 6283 4060 65 
Yes 1562 760 49 0.53 (0.48, 0.59) 
AIDS 
No 7842 4820 61 
Yes 3 0 o **** 
0.97 (0.82, 1.15) 
0.77 (0.61, 0.97) 
0.86 (0.71, 1.03) 
0.47 (0.18, 1.23) 
0.84 (0.75, 0.95) 
0.69 (0.47, 1.02) 
0.65 (0.50, 0.84) 
0.82 (0.70, 0.98) 
0.76 (0.45, 1.28) 
0.61 (0.34, 1.09) 
0.60 (0.42, 0.88) 
0.98 (0.56, 1.71) 
0.85 (0.72, 1.00) 
0.57 (0.15, 2.17) 
0.58 (0.51, 0.66) 
p 
0.74 
0.03 
0.10 
0.13 
0.01 
0.06 
<0.01 
0.03 
0.31 
0.10 
0.01 
0.93 
0.05 
0.41 
<0.01 
Legend; N* number of 
chemotherapy. 
patients within each disease group who had 
%** percentage of patients within each disease group who had chemotherapy. 
Adj OR*** adjusted Odds Ratio adjusted for sex, age qulntlle, stage (limited or 
extensive), performance status, Townsend qulntlle and ethnic group. 
**** Unable to calculate Odds RatiO as number of patients with AIDS too small. 
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Table 5.11 shows the results of Cox regression analyses for the Individual 
disease groups. These results demonstrate that for every disease the socio-
economic status and ethnlclty of a patient had little effect on the Hazard Ratio. 
Instead It was the adjustment for sex, age qulntlle, histology, stage and 
performance status which had the greatest effect on the Hazard Ratio. The 
adjusted Hazard Ratio for the majority of diseases was approximately 1.20, 
Indicating that should an Individual with lung cancer also have this disease they 
are 20% more likely to die compared with those patients with lung cancer who 
do not have this disease. These diseases Include: cardiac disease, stroke, 
peripheral vascular disease, respiratory disease, gastric ulcers, and hemiplegia. 
Certain diseases had an adjusted Hazard Ratio of less than 1.20, and these 
were: connective tissue disease, diabetes with and without complications, and 
haematologlcal malignancy. Individuals with metastatic disease at diagnosis 
were at the greatest risk of death, with an adjusted Hazard Ratio of 2.10. Very 
few patients had AIDS but those that did had an Increased likelihood of death 
(adjusted HR 1.87, 95% CI 1.34, 2.62). Severe liver failure and renal failure 
also led to an Increased likelihood of death (adjusted HR 1.59, 95% CI 1.30, 
1.94 and adjusted HR 1.36, 95% CI 1.29, 1.42 respectively). Therefore, with 
the exception of metastatic disease, which Is Incorporated Into the stage of 
disease at diagnosis, no single component disease within the Charlson Index was 
the predominant Influence on overall survival. 
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Table 5.11: Cox regression evaluating the influence of Individual disease groups 
within the Charlson Index on overall survival (N = 80,264). 
Individual disease 
Cardiac disease 8552 7349 86 
Unadjusted 1,41 1.38 1,45 
Adjusted for age and sex 1.31 1.28 1.34 
Adj for age, sex, histo, stage, PS 1.24 1.21 1.27 
Adjusted for SES and ethnic 1,41 1.38 1,45 
Full 
Stroke 4628 4010 87 
Unadjusted 1,48 1,43 1.53 
Adjusted for age and sex 1.37 1.33 1,42 
Adj for age, sex, histo, stage, PS 1.22 1.18 
Adjusted for SES and ethnic 
Full 
Peripheral Vascular disease 7020 5917 84 
Unadjusted 1.33 1.30 1.37 
Adjusted for age and sex 1.27 1.24 1.30 
Adj for age, sex, histo, stage, PS 1.21 1.18 1.25 
Adjusted for SES and ethnic 1.33 1.30 1.37 
Full 
Dementia 839 785 94 
Unadjusted 2.1 2 1.98 2.28 
Adjusted for age and sex 1.78 1.65 1.91 
Adj for age, sex, histo, stage, PS 1.38 1. 28 1.48 
Adjusted for SES and ethnic 2.1 2 1.97 2.27 
Ful 
Respiratory disease 18,087 15,068 83 
Unadjusted 1.31 1. 28 1.33 
Adjusted for age and sex 1. 28 1.26 1.30 
Adj for age, sex, histo, stage, PS 1. 23 1. 21 1.25 
Adjusted for SES and ethnic 1.31 1. 28 1.33 
d for all 1.23 1.21 6 
Legend: N* Number of patients with each Individual disease who have died 
% ** percentage of individuals with each disease who have died. 
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Table 5.11: continued 
Individual disease N N* % ** HR 95% CI 
Connective Tissue Disorders 1558 1269 81 
Unadjusted 1.16 1.25 1.35 
Adjusted for age and sex 1.18 1.11 1.24 
Adj for age, sex, hlsto, stage, PS 1.17 1.11 1.24 
Adjusted for SES and ethnic 1.09 1.22 
Full 
Ulcer disease 2745 2297 84 
Unadjusted 1.30 1.25 1.35 
Adjusted for age and sex 1.25 1.20 1.30 
Adj for age, sex, histo, stage, PS 1.22 1.17 1.27 
Adjusted for SES and ethnic 1.30 1.25 1.35 
Full 
Diabetes (no complications) 7497 6295 84 
Unadjusted 1.31 1.27 1.34 
Adjusted for age and sex 1.26 1.22 1.29 
Adj for age, sex, histo, stage, PS 1.17 1.14 1.20 
Adjusted for SES and ethnic 1.31 1.27 1.34 
Full 
Hemiplegia 1002 899 89 
Unadjusted 1.57 1.47 1.67 
Adjusted for age and sex 1.50 1.41 1.60 
Adj for age, sex, hlsto, stage, PS 1.19 1.12 1.27 
Adjusted for SES and ethnic 1.57 1.47 1.68 
Full 
Diabetes with complications 642 555 86 
Unadjusted 1.36 1.25 1.48 
Adjusted for age and sex 1.29 1.19 1.41 
Adj for age, sex, hlsto, stage, PS 1.16 1.07 1.26 
Adjusted for SES and ethnic 1.36 1.25 1.48 
Full ad sted for a 1.16 
Legend: N* Number of patients with each Individual disease who have died 
% * percentage of Individuals with each disease who have died. 
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Table 5.11 : continued 
Individual disease 
Renal failure 
Unadjusted 
Adjusted for age and sex 
Adj for age, sex, histo, stage, PS 
Adjusted for SES and ethnic 
Full 
Haematological malignancy 
Unadjusted 
Adjusted for age and sex 
Adj for age, sex, histo, stage, PS 
Adjusted for SES and ethnic 
Full 
Cancer (non Lung ) 
Unadjusted 
Adjusted for age and sex 
Adj for age, sex, hlsto, stage, PS 
Adjusted for SES and ethnic 
Severe Liver fail ure 
Unadjusted 
Adjusted for age and sex 
Adj for age, sex, histo, stage, PS 
Adjusted for SES and ethnic 
Metastases 
Unadjusted 
Adjusted for age and sex 
Adj for age, sex, histo, stage, PS 
Adjusted for SES and ethnic 
Full 
AIDS 
Unadjusted 
Adjusted for age and sex 
Adj for age, sex, hlsto, stage, PS 
Adjusted for SES and ethnic 
N ** 
1972 1762 89 
631 514 81 
11588 9864 85 
112 96 86 
11762 11207 95 
31 27 87 
HR 
1.61 1.54 1.69 
1.41 1.38 1.51 
1.36 1.30 1.43 
1.61 1.54 1.69 
1.13 1.04 1.23 
1.12 1.03 1.23 
1.16 1.06 1.26 
1.13 1.04 1.23 
1.31 1.28 1.34 
1.27 1.25 1.30 
1.28 1.25 1.31 
1.34 
1.49 1.22 1.83 
1.59 1.30 1.94 
1.59 1.30 1.95 
2.45 
2.58 
2.10 
2.45 
1.81 
2.15 
1.84 
1.81 
2.40 
2.53 
2.06 
1.29 
1.54 
1.32 
1.29 
1.81 
2.50 
2.64 
2.14 
2.50 
2.53 
3.01 
2.58 
2.53 
Fu l sted above .62 
Legend: N* Number of patients with each Individual disease who have died 
%** percentage of individuals with each disease who have died. 
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Bed days 
The majority of patients within this cohort, 66,952 (83%), were not admitted to 
hospital within the 12 month period leading up to their diagnosis of lung cancer. 
A small group (914, 1%) were admitted for more than 30 days. A categorical 
variable for admission time was created and Is Illustrated In table 5.12. 
Table 5.12: Admission time 
Admission time Number (%) 
Zero 66,952 (83) 
1-5 days 7,910 (10) 
6-10 days 2,521 (3) 
11-30 days 2,699 (3) 
>30 days 914 (1) 
In order to assess the Influence of 'admission time' pre-diagnosis on the 
likelihood of receiving treatment, logistic regression (unl and multivariate) was 
used. Only patients with histologically proven non-small cell lung cancer were 
used for analysis of access to surgery, and only those with small cell lung cancer 
were used for analysis of access to chemotherapy. The whole cohort was used 
to assess the likelihood of receiving radiotherapy based on admission time pre-
diagnosis. The results are Illustrated In table 5.13. There Is evidence that those 
patients with a prolonged admission time (more than 30 days) were 26% less 
likely to receive radiotherapy than those without an admission, even after 
adjusting for all other patient features. Although there appeared to be a similar 
trend In the access to chemotherapy for those patients with small cell lung 
cancer, It did not achieve statistical significance. There was no evidence that 
admission time pre-diagnosis Influenced the likelihood of having surgery for 
those patients with non-small cell lung cancer. 
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Table 5.13: Results of multivariate logistic regression illustrating the influence of 
time in hospital pre-diagnosis with lung cancer on access to treatment. 
Time N N Rx (0/0)* Unadj OR Adj OR** P for 
(days) (950/0 CI) (950/0 Cll trend 
Surgery (NSCLC only; N=34,315) 
Zero 29,178 3705 13 0.162 
1-5 3,198 490 15 1.24 (1.12,1.38) 1.17 (1.03,1.32) 
6-10 964 153 16 1.30 (1.08, 1.55) 1.20 (0.97, 1.49) 
11-30 898 102 11 0.88 (0.71, 1.09) 0.99 (0.77,1.26) 
>30 275 35 13 1.00 (0.70 1.43) 0.94 (0.61, 1.45) 
Radiotherapy (N=80,966) 
Zero 66,952 14684 22 < 0.001 
1-5 7,910 1645 21 0.93 (0.88, 0.99) 0.97 (0.91, 1.02) 
6-10 2,521 500 20 0.88 (0.80, 0.97) 0.94 (0.85,1.04) 
11-30 2,669 468 18 0.76 (0.68,0.84) 0.83 (0.75, 0.92) 
>30 914 132 14 0.6 0.50, 0.72) 0.74 (0.61 0.90) 
I ~ ~
Chemotherapy (small cell only; N=7,84S) 
Zero 6,691 4170 62 0.1 38 
1-5 689 405 59 0.86 (0.73, 1.01) 1.02 (0 .86, 1.22 ) 
6- 10 208 116 56 0.76 (0.58, 1.01) 0.97 (0.72, 1. 32) 
11-30 203 110 54 0.72 (0.54, 0.95) 0.91 (0 .67, 1.23 ) 
> 30 54 19 35 0.33 (0.19 0.57) 0.45 (0. 24 0.85) 
Legend: Rx; treatment 
(% )* percentage of patients who received treatment from each subgroup of 
admission time. 
Adj OR** adjusted Odds Ratio for sex, age qulntile, performance status, 
histology (radiotherapy only), stage (limited or extensive In chemotherapy), 
Townsend quintile and ethnic group. 
NSCLC; non-small cell lung cancer. 
If an Individual has been In hospital for a total of less than a month In the yea r 
prior to diagnosis with lung ca ncer, there appea rs to be very litt le effect on the 
likelihood of receiving treatment for th ei r ca ncer. 
Cox regression analyses showed that time spent In hospital prior to the diagnosis 
of lung cancer had no Impact on overall survival once th e diagnosis had been 
made (Table 5.14). Thi s Is almost certainly related to the poor prognosis from 
the condition, with a median survival of just 203 days. 
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Table 5.14: Cox regression evaluating the Influence of admission time pre-
diagnosis on overall survival (N=80,264). 
N N died Ofo* 
Bed days' (days) 
UnadJ HR 
(95% cn 
AdJ HR** 
(95% cIl 
p for 
trend 
zero 66474 54309 82 0.738 
1-5 7817 6348 81 1.01 (0.98, 1.03) 0.97 (0.95, 1.00) 
6-10 2474 2023 82 1.02 (0.97, 1.06) 0.96 (0.92, 1.01) 
11-30 2611 2229 85 1.17 (1.12, 1.22) 1.05 (1.01, 1.09) 
>30 888 780 88 1.28 (1.19, 1.37) 1.01 (0.94, 1.09) 
Legend: %* percentage of patients within each subgroup who have died. 
Adj HR**i adjusted Hazard Ratio, mutually adjusted for sex, age qulntlle, 
histology, stage, performance status, ethnic group and soclo-economlc status. 
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Ethnicity 
Data on ethnicity revealed the vast majority of patients were White, with Asians 
comprising the second largest group with 4,627 patients (6%). Within this 
ethnic subgroup Pakistani patients were the most common representing 87%. 
Ethnicity data were missing in 18% of the cohort. Figure 5.10 illustrates the 
distribution of ethnic groups. 
70000 
60899 
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40000 
30000 
20000 
10000 4627 
442 195 365 
0 
White Black Asian Mixed Other MiSSi ng 
Figure 5.10: Histogram illustrating the ethnic composition of this cohort. 
Table 5.15: Illustrates the detailed breakdown of ethnic group amongst thi s 
cohort of English lung cancer patients. 
Ethnic group N % 
White 57,986 72 
Irish/white 786 1 
Other white 2,127 3 
African 87 0.1 
Caribbean 272 0.3 
Other Biack 83 0.1 
Pakistani 4,051 5 
Indian 317 0.4 
Bangledeshi 102 0.1 
Chinese 73 0.1 
Other Asian 84 0.1 
White/Black Caribbean 50 0.1 
White/Black African 48 0.1 
White/Asian 41 0.1 
Other mixed race 56 0.1 
Other Ethniclty 365 0.5 
Not stated 14,438 18 
Total 80,966 
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5.3.3 NHS Trust features 
There were 31 cardlothoracic surgical centres, and 49 Radiotherapy centres at 
the time of this research. There were 44 NHS Trusts who fulfilled the criteria for 
high trial centre status. 
peer Review results 
The process of Peer review incorporates an element of self evaluation and 
independent external assessment of every cancer multidisciplinary team. There 
are 32 standards to which each MDT is measured (appendix 6). For each target 
an NHS Trust will score 0 or 1, however If there Is more than one lung cancer 
multidisciplinary team within an NHS Trust, it Is possible for a Trust to score 
between 0 and 1. In other words, If an NHS Trust has three lung cancer MDTs 
then It could score either: 0, 0.33, 0.67 or 1 for each target. Every NHS Trust 
will have a total score between 0 and 1 for their overa ll attainment of Peer 
Review targets. Figure 5.11 Illustrates the variation In success at Peer Review 
across all NHS Trusts for the period 2003-2007. 
o .2 .4 .6 .8 
Overall proportion of Peer Review targets met 
Figure 5.11 : Histogram illustrating the variation In success at Peer Review. 
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The median overall Peer Review score was 0.80, with an interquartile range of 
0.71 to 0.84. In order to allow inclusion in regression analyses, a binary variable 
for the overall score was created with 0 .84 as the cut-off. This represented the 
top quarter of NHS Trusts, who had entered 25,672 (32%) patients into the 
cohort. The remaining NHS Trusts who scored <0.84 In their Peer Review 
overall score, accounted for 75% of Trusts, and had entered 55,294 (68%) 
patients. The results of uni and multivariate logistic regression analyses 
assessing the influence of the overall Peer Review score on the likelihood of 
receiving treatment for lung cancer are depicted in table 5.16. 
Table 5.16: Results of logistic regression assessing the influence of an overall 
Peer Review score on the likelihood of receiving treatment for lung cancer. 
N N* (%) ** 
Surgery (NSCLC only: N=34,513) 
Peer Review score 
Unadj OR 
95% CI 
Adj OR*** 
95 0/0 CI 
p for 
trend 
<0.84 23461 3114 13 0.204 
>0.84 11052 1371 12 0.93 0.86, 0.99 0.95 (0.88, 1.03) 
Chemotherapy (small cell only: N=7845) 
Peer Review score 
<0.84 5275 3221 61 
>0.84 2570 1599 62 1.05 0.95, 1.16) 1.00 0.90, 1.12) 
Radiotherapy (whole cohort: N=80,966) 
Peer Review score 
<0.84 55294 11377 21 
> 0.84 25672 6052 24 1.19 1.15 1.23 1.15 1.24 
Legend: N* number of patients within each subgroup who received treatment 
(%) percentage of patients within each subgroup who received treatment 
0.949 
<0.001 
Adj OR *** adjusted for sex, age quintile, performance status, histo logy 
(radiotherapy only), stage (UICC version 6 if NSCLC, and limited vs extensive for 
small cell lung cancer), Townsend quintile, ethnic group, Charlson Index and 
admission time pre diagnosis. 
NSCLC: non-small cell lung cancer 
Table 5.16 shows that a high overall score In the Peer Review process was not 
associated with an increased likelihood of receiving surgery or chemotherapy in 
those patients with non-small ce ll and sma ll cell lung cancer respectively . But 
there is evidence that patients flrst seen in those NHS Trusts which scored >0.84 
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In the Peer Review process, were almost 20% more likely to receive radiotherapy 
than patients first seen In those NHS Trusts scoring less than 0.84 (adjusted 
Odds Ratio 1.19, 95% CI 1.15, 1.24). 
Cox regression analyses found that the overall score at Peer Review had no 
Influence on survival. The adjusted Hazard Ratio for death for those patients 
first seen In an NHS Trust which scored >0.84 at Peer Review was 1.01 (95% CI 
0.99, 1.03) compared with those patients first seen In an NHS Trust scoring 
<0.84 (table 5.17). This will be related to the poor prognosis of lung cancer, but 
It could also highlight the Inadequacies of the current Peer Review process. It 
could be that the Indicators measured are Inappropriate or Inadequate to detect 
a difference In patient survival based on the NHS Trust where that Individual was 
first seen. 
Table 5.17: Cox regression for overall score at Peer review and overall mortality 
N N died %* 
Peer Review score 
Unadj HR 
{t5% Cll 
AdJ HR ** 
(95% Cll 
p for 
trend 
<0.84 55294 44981 81 0.179 
>0.84 25672 21410 83 1.01 (0.99, 1.02) 1.01 (0.99, 1.03) 
Legend: %* percentage of patients within each subgroup who have died. 
AdJ HR**; adjusted Hazard RatiO, mutually adjusted for sex, age qulntlle, 
histology, stage, performance status, ethnic group and soclo-economlc status. 
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Individual patient survival is determined by several key clinical features, as well 
as pre-existing co-morbidities and the treatment given. Figure 5.12 shows the 
good prognosis of carcinoid disease, in contrast to the poor outlook for 
individuals with small cell lung cancer and mesothelioma. Figure 5.13 shows the 
variation in observed survival based on stage at presentation . 
Kaplan-Meier curve: stage 
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Figure 5.13: Kaplan-Meier (KM) survival curve based on stage at diagnosis. 
Figure 5.14 shows the survival curves for those patients with no evidence of co-
morbid illness in HES, compared with those with a Charlson Index of 4 or more. 
Kaplan-Meier; Charlson Index at diagnosis 
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Figure 5.14: KM survival curve based on Charlson Index (CI) at diagnOSis. 
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Individual patient survival is determined by several key clinical features, as well 
as pre-existing co-morbidities and the treatment given. Figure 5.12 shows the 
good prognosis of carcinoid disease, in contrast to the poor outlook for 
individuals with small cell lung cancer and mesothelioma. Figure 5.13 shows the 
variation in observed survival based on stage at presentation. 
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Figure 5.13: Kaplan-Meier (KM) survival curve based on stage at diagnosis. 
Figure 5.14 shows the survival curves for those patients with no evidence of co-
morbid illness in HES, compared with those with a Charlson Index of 4 or more. 
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Figure 5.14: KM survival curve based on Charlson Index (CI) at diagnosis. 
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5.3.5 Summary of results 
Basic demographic features for the cohort as a whole: 
• 60% of the cohort were male 
• Median age 72 years (Interquartlle range 62 to 79 years) 
• Histology (40% missing): 40% non-small cell lung cancer, 10% small cell,3% 
mesothelioma and 7% other histological subtypes. 
• Stage (49% missing): 11% Stage I and II, 16% stage III, and 24% stage IV 
• Performance status (40% missing): 32% PS 0 or 1 
• FEV1: median 1.55 L1mln (Interquartlle range 1.14 to 2.06 L1mln) 
• Soclo-economlc status: 26% cohort from least affluent qulntlle 
Slightly fewer patients with PS 0 In least compared with most affluent qulntlle 
Very little variation In stage based on soclo-economlc status 
• Charlson Index: median score 1 (Interquartlle range 0 to 4) 
45% patients had no diagnoses relevant to Charlson Index pre-diagnosis. 
No evidence that Charlson Index varied with soclo-economlc status. 
• Individual disease groups: high prevalence of smoking related pathologies 
22% respiratory disease, 14% non-lung malignancy and metastatic disease, 
and 11% cardiac disease. 
• 'Bed days': 83% of the cohort were not admitted to hospital In the 12 month 
period prior to their diagnosis with lung cancer. 
No evidence that 'bed days' Influence the likelihood of having surgery 
Only more than 30 'bed days' prior to diagnosiS led to a reduced likelihood of 
receiving chemotherapy and radiotherapy. 
• Peer Review: the overall score from this evaluation was not linked to an 
Increased likelihood of receiving treatment nor an Improved prognosis. 
145 
5.4 Discussion 
5.4.1 Treatment received 
The proportion of Individuals within this cohort who underwent surgery for their 
lung cancer was 10%, which Improved to 13% In those with proven NSCLC. For 
those patients with small cell lung cancer the chemotherapy rate was 61%. And 
the overall rate of radiotherapy, regardless of underlying histology, was 22%. 
One of the main alms of this research has been to Investigate co-morbidity In a 
cohort of patients with lung cancer. The linked NLCA/HES dataset provided the 
opportunity to Investigate three markers of co-morbid Illness. The time spent In 
hospital In the 12 month period prior to diagnosis was provided by HES already, 
but the Charlson Index was calculated from the record of ICD-10 disease codes. 
As well as the overall composite score, the Individual component diseases were 
Investigated to see If anyone disease group played the dominant role In 
Influencing disease outcome. The results show that the Charlson Index had a 
strong Influence on access to treatment and overall survival, Independent of 
other clinical features such as stage and performance status. As the level of co-
morbid Illness Increased, the likelihood of having surgery or chemotherapy fell. 
There was no affect on the likelihood of receiving radiotherapy as co-morbid 
Illness Increased, but this could be because radiotherapy Is used with both 
potentially curative and palliative Intent, for example Individuals with significant 
co-morbid Illness may receive single fraction palliative radiotherapy to a bone 
metastasis when they would not be suitable for chemotherapy or surgery. The 
NLCA does not currently have the capability to differentiate between the 
treatment Intent of the radiotherapy given, and for this reason, access to 
radiotherapy was not evaluated for Individual histological subtypes. The NLCA 
will soon be linked to the national radiotherapy database, and so It will be 
possible to analyse details regarding the number of fractions etc that a patient 
with lung cancer has received, and the Influence on survival too. 
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In terms of socioeconomic status, this cohort had an Increased proportion of 
Individuals from the lowest Townsend qulntlle, but there was no evidence of wide 
variation In stage or co-morbidity between strata of socioeconomic status. In 
contrast to published literature, there was no evidence that as socioeconomic 
status declined the stage at presentation was more advanced (45,49). Previous 
publication using the NLCA dataset (36) has not shown any evidence that 
resection rate falls as soclo-economic status declines, In contrast to the paper 
from Pollack et al (50). 
Analysis of the Individual component diseases found that certain diseases were 
Important in determining the likelihood of patients receiving surgery and 
chemotherapy. With regard to surgery, the presence of dementia was the 
strongest negative predictor but it was only present In 150 of the 34,513 
patients with non-small cell lung cancer. Cardiac disease, renal failure and 
diabetes with complications were all linked with a reduced likelihood of receiving 
surgery. These conditions would all pose an increased anaesthetic and operative 
risk, and this result makes clinical sense. With regard to chemotherapy, 
dementia again appeared to have a strong Influence but because only 29 of the 
7845 patients with small cell lung cancer also had dementia, It did not achieve 
statistical Significance. Renal failure was a strong negative predictor for 
receiving chemotherapy, and given the need for renal clearance of chemotherapy 
agents, this result again makes good clinical sense. No Individual disease group, 
with the exception of dementia which was uncommon In this cohort, had a 
stronger Independent Influence on the likelihood of receiving surgery or 
chemotherapy than the Charlson Index. Therefore I did not Include Individual 
disease groups amongst the patient features used In chapters 6 and 7, when 
looking at the Influence of patient and NHS Trust features on surgery and 
chemotherapy for non-small cell and small cell lung cancer respectively. 
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The evaluation of the Influence of 'bed days' on access to treatment revealed 
heterogeneity amongst the treatment types. No effect was demonstrated for 
surgery. In those patients with more than 30 days In hospital, there was a 
reduced likelihood of both chemotherapy and radiotherapy. However, only for 
radiotherapy was the p for trend Significant. It appears that the observation of 
time spent In hospital, 'bed days', as a marker of co-morbid Illness has too much 
error within It. For example, an Individual may have a heart attack but only be 
In hospital five days, whilst another may have a total hlp replacement and be an 
In-patient for two weeks. Only, once a high threshold was reached, I.e. 30 days, 
was an influence on outcome observed for both chemotherapy and radiotherapy. 
Variables which are prone to error are unlikely to demonstrate significant results 
from regression analyses, as the Odds Ratio will converge with the comparator. 
Therefore, 'bed days' was not used In the remainder of this thesis as a marker of 
co-morbid Illness. This variable has been used as a marker of co-morbidity In 
Scottish studies before but with inconsistent results. Brewster et al found that 
as 'bed days' Increased there was no Increased likelihood of dying within 30 days 
of diagnosis for Individuals with either breast or colorectal cancer (70). In 
contrast Parks et al found that the Hazard Ratio for death In Individuals with 
pancreatic cancer Increased If the number of 'bed days' In the six months prior to 
diagnosis was more than five days (71). 
The overall score from Peer Review for each NHS Trust was only found to 
Influence the likelihood of receiving radiotherapy. No effect was demonstrated 
for surgery or chemotherapy. I had antiCipated that as a marker of Trust 
performance rather than facilities per se, this would prove a potentially useful 
Indicator of outcome from lung cancer. However, given the lack of Influence 
demonstrated during regression analyses, the overall Peer Review score was not 
used In the remainder of my thesis. 
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5.4.2 Survival 
Lung cancer continues to have a very poor prognosis, and the median survival 
for the entire cohort (dataset 2) was 198 days (Interquartlle range 59 to 532). 
In spite of the disappointing survival from the disease as a whole, the Charlson 
Index was found to be an Independent marker of prognosis. As the composite 
score of co-morbidity Increased so the likelihood of death Increased too. 
Amongst Individual disease groups, the presence of metastases had the greatest 
Influence on overall survival. Other Individual diseases which were shown to 
affect survival were, AIDS (n=31 only), liver failure, renal failure and dementia. 
Only metastatic disease had an adjusted Hazard Ratio above that of the Charlson 
Index of 4 or more. Time spent In hospital prior to diagnosis was not found to 
Influence overall survival, even amongst those patients who had been In hospital 
for more than a month In the year before their lung cancer was diagnosed. 
Finally the overall score from Peer Review for each NHS Trust did not Influence 
overall survival. This result along with the fact that Peer Review did not 
Influence access to treatment, suggests that It Is not a good discriminator of MDT 
performance. 
In order to look more closely at the Influence of patient and NHS Trust features, 
I decided to look at the access to treatment and survival for two distinct 
histological subgroups, namely non-small cell lung cancer (surgery) and small 
cell lung cancer (chemotherapy). The Indicator of co-morbidity used for the 
remainder of this research was the Charlson Index, rather than Individual 
diseases or 'bed days'. In terms of NHS Trust features, the binary variables of 
cardia-thoracic surgical centres, radiotherapy centres, and high vs low trial 
participation, have been used. The overall scores from Peer Review have not. 
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Chapter six: Inequalities In outcomes for non-small cell lung cancer: the 
Influence of clinical characteristics and features of the local lung cancer 
service 
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fi.llntroductlon 
In this chapter I have looked specifically at non-small cell lung cancer. Non-
small cell lung cancer accounts for more than 80% of all lung cancers (72, 73), 
and for these people surgical resection represents the best chance of cure (74). 
The National Institute for Health and Clinical Excellence (NICE) recommended 
surgical resection for all patients with stage I and II disease who had no medical 
contra-Indications and adequate lung function (26). At present only a small 
minority of people with non-small cell lung cancer will have disease which Is 
suitable for surgical resection (75). There Is evidence that surgical resection 
rates for lung cancer and survival from the disease vary between and within 
countries (37, 73, 76, 77). This variation Is anecdotally attributed to 
geographical differences In patient features, for example Individuals from one 
area being older, presenting with late stage disease, or having significant co-
morbidities which preclude an anaesthetic. My Intention was to adjust for all 
patient features and Investigate whether the variation In outcomes at a hospital 
level were still evident. 
In this chapter I have used the National Lung Cancer Audit (NLCA) dataset linked 
to Hospital Episode Statistics (dataset 2) to quantify the Influence of patient and 
National Health Service (NHS) Trust level features on access to surgery and 
survival for people with non-small cell lung cancer In England. There are 157 
NHS Trusts In England and only 31 have thoracic surgery available on-Site. 
There are 28 cancer Networks In England. Within each one there Is a 'hub and 
spoke' system whereby specialist cancer centres, with thoracic surgeons 
available on-site, act as the 'hub' and provide speCialist cancer services, such as 
surgery and radiotherapy, for the hospitals that compose the 'spokes'. Some 
thoracic centres are purely thoracic, others are cardlo-thoraclc, but I have used 
the term thoracic surgical centre as a means of describing the service they 
provide regardless of the sub-speciality of the surgeons. 
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6.2 Methods 
The NLCA-HES linked dataset (dataset 2) was used for this piece of research and 
Included all English patients first seen between January 2004 and 31st December 
2008. For this chapter I restricted my analyses to people with a proven 
histological diagnosis of non-small cell lung cancer. The NLCA dataset Includes 
the following Information on all patients: 
sex, 
age at diagnosis, 
histological sub-type, 
Lower Super Output Area (census derived), 
performance status (as classified by ECOG), 
stage at presentation (as classified by UICC version 6), 
details of the NHS Trust where a patient was first seen 
and whether surgical resection had occurred (date of surgery). 
Although the National Lung Cancer Audit records Information on co-morbid 
Illness, these data are incomplete, and are limited to only six disease groups. 
The audit records only whether or not the presence of this co-morbid Illness 
Influenced the treatment decision. I created a composite score of co-morbidity, 
the Charlson Index (34), as described In section 5.2.2. I also used data from the 
Hospital Episode Statistics dataset to provide Information on ethnlclty. 
In order to describe variation in the facilities available at NHS Trusts I created 
three binary variables, as described in section 5.2.3. These were, whether or 
not a Trust is a thoracic surgical centre, whether or not it is a radiotherapy 
centre, and whether or not the centre was actively entering patients Into clinical 
trials for lung cancer. A fourth binary variable thought to quantify lung cancer 
MDT performance was also created based on the results of the Peer Review 
process 2004-2007, as described in section 5.2.3.4. However, I dropped this 
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from multivariate regression analyses, given the lack of evidence to support the 
assumption that It was influential (table 5.16). 
6.2.1 Surgery 
I performed logistic regression analyses to estimate the odds ratios for receiving 
surgery, adjusting these analyses for all patient and NHS Trust level features 
and clustering on NHS Trusts. In order to look more specifically at variation In 
access to surgery In patients In whom I would have expected a high chance of 
undergoing surgery, I repeated the analyses In a subgroup of patients with stage 
lor II disease. 
6.2.2 Survival 
For the survival analyses I used a start and end date as described In section 
5.2.4.2. Because some patients with lung cancer are diagnosed at post-mortem 
I excluded people from the survival analysis when the date of death was the 
same as, or earlier than, the date of diagnosis. I performed Cox regression 
analyses to calculate Hazard ratios and then constructed a multivariate model to 
adjust mutually for all patient and NHS Trust features. The final Cox regression 
model Included clustering by NHS Trusts. I then repeated the survival analysis 
for the subgroup of patients with stage I and II disease as outlined above. I 
checked the proportional hazards assumption for the model by Inspecting 
Nelson-Aaleen plots. 
Finally, to determine whether people first seen at a thoracic surgical centre were 
different to those seen at a non-surgical centre, I compared the demographic 
features of the two patient groups and, for the subgroup of people who had an 
operation, I estimated survival according to where the person was first seen. 
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6.3 Results 
The NLCA-HES linked dataset contained a total of 87,252 patients who were first 
seen at an English NHS Trust between January 2004 and 31st December 2008. 
Histological diagnosis was based on a pre-treatment histology as this would be 
the Information available to multidisciplinary teams. Data In the early years of 
the NLCA were poorly completed, and so 33,964 (42%) of this dataset have no 
pre-treatment histology recorded. Small cell lung cancer accounts for 7845 
(10%) of patients, 2772 (3%) have mesothelioma and 1872 (2%) had other 
diagnoses. There were 34,513 (43%) patients with a histological diagnosis of 
non-small cell lung cancer. 33% of patients had squamous cell carcinoma, 27% 
adenocarcinoma, 33% non-small cell lung cancer not-otherwise specified and the 
remaining 7% had large cell tumours, bronchoalveolar cell carcinoma and 
carcinoma-In-situ. The median age at diagnosis was 71 years (Interquartlle 
range 63 to 77 years) and 60% were male. A total of 4,485 patients (13%) 
underwent a surgical procedure. The median Charlson Index at diagnosis was 1 
(Interquartile range 0 to 2), with a minimum score of 0, and maximum of 17. 
There are 31 cardlothoraclc surgical centres In England, 49 radiotherapy centres, 
and 44 NHS Trusts which were defined as high trial participation, which was 
equivalent to putting 5% or more of their expected lung cancer patients Into 
clinical trials. Amongst the thoracic surgical centres, 19 were radiotherapy 
centres too, and 15 were trial active. Twelve NHS Trusts possessed all three 
features. Of the 34,513 patients 9,168 (27%) were first seen In thoracic surgical 
centres. 
6.3.1 Surgery 
Table 6.1 shows the results of univariate and multivariate logistic regression 
analyses for the associations between having surgery and both patient and NHS 
Trust features. As the Charlson Index Increased, Indicating a higher level of co-
morbid Illness, the likelihood of having surgery decreased. The odds ratio for 
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having surgery, mutually adjusted for all patient and NHS Trust features, for 
patients with a Charlson Index of 4 or more compared with patients with a 
Charlson Index of 0, was 0.67 (95% confidence Interval 0.56, O.BO). Patients In 
the 4th age qulntile (76-BO years) were almost half as likely to undergo surgery 
as those In the youngest qulntile (adjusted Odds Ratio 0.56, 95% confidence 
Interval 0.49, 0.56). People with more advanced disease stage and poorer 
performance status were also less likely to have an operation. There was no 
evidence that ethnic group or socio-economic status Influenced the likelihood of 
receiving surgery. 
If a patient was first seen In a thoracic surgical centre, they were 51% more 
likely to have surgery, even after adjusting for all of the patient level features 
(adjusted Odds Ratio 1.51, 95% confidence Interval 1.16, 1.97). There was 
some evidence that this difference between surgical and non-surgical centres 
varied year on year (test for interaction p=0.003) - but there was no obvious 
trend over time as the odds ratios for 2004, 2005, 2006, 2007 and 200B were 
1.5B (95% confidence Interval 0.B2 to 3.05), 2.50 (1.57 to 3.88), LBO (1.18 to 
2.72), 1.11 (0.76 to 1.64) and 1.47 (1.09 to 1.99) respectively. In the 
multivariate analyses, whether the NHS Trust was a radiotherapy centre or a 
high trial centre did not Influence the likelihood of having surgery. 
I Identified 4,966 patients who had stage I or II disease and In this subgroup 
2,387 (4B%) had surgery. In these patients the likelihood of having surgery was 
53% higher In patients first seen at NHS Trusts that were thoracic surgical 
centres compared with those seen In non-surgical centres (adjusted Odds Ratio 
1.53, 95% confidence Interval 1.09, 2.13). 
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Table 6.1: Results of logistic regression regarding the Influence of patient 
features on likelihood of having surgery (clustered by NHS Trust) 
Nwho 
N had (%)* UnadJ OR AdJ OR** 
suraerv 
Sex 
Male 20,945 2637 13 
Female 13,568 1848 14 1.09 (1.02, 1.17) 1.06 (0.99,1.15) 
Age qulntlle 
1 (30-62 years) 8221 1290 16 
2 (63-69 years) 7635 1232 16 1.03(0.95,1.13) 0.95 (0.85, 1.05) 
3 (70-75 years) 7693 1050 14 0.85 (0.78, 0.93) 0.79 (0.71, 0.89) 
4 (76-80 years) 6115 652 11 0.64 (0.58,0.71) 0.56 (0.49, 0.65) 
5 (81-100 years) 4849 261 5 0.31 (0.27,0.35) 0.26 (0.22, 0.32) 
Stage 
IA 1178 722 61 
IB 2138 1029 48 0.59 (0.51,0.68) 0.63 (0.52, 0.76) 
IIA 202 121 60 0.94 (0.70, 1.28) 0.96 (0.72,1.28) 
liB 1448 515 35 0.35 (0.30, 0.41) 0.35 (0.28, 0.43) 
lilA 2777 380 14 0.10 (0.09, 0.12) 0.09 (0.07, 0.11) 
IIIB 5427 297 5 0.04 (0.03, 0.04) 0.03 (0.03, 0.04) 
IV 10,968 271 2 0.02 (0.01, 0.02) 0.02 (0.01, 0.02) 
Occult 50 15 30 0.27 (0.15,0.50) 0.26 (0.13, 0.52) 
missing 10,325 1135 11 0.08 (0.07, 0.09) 0.09 (0.07, 0.12) 
Performance status 
0 5847 1651 28 
1 9282 1372 15 0.44 (0.41, 0.48) 0.52 (0.46, 0.59) 
2 5317 264 5 0.13 (0.12, 0.15) 0.19 (0.15,0.24) 
3 3251 67 2 0.05 (0.04, 0.08) 0.10 (0.08,0.14) 
4 760 13 2 0.04 (0.03, 0.88) 0.11 (0.06, 0.18) 
missing 10,056 1118 11 0.32 (0.29, 0.35) 0.40 (0.32, 0.49) 
Ethnic group 
White 26,511 3443 13 
Black 234 27 12 0.87 (0.58, 1.31) 0.84 (0.47, 1.49) 
Asian 1905 262 14 1.07 (0.93, 1.22) 1.13(0.96,1.33) 
Mixed race 103 10 10 0.72 (0.37, 1.38) 0.77 (0.33, 1.78) 
Other 161 29 18 1.47 (0.98, 2.20) 1.41 (0.88, 2.27) 
missing 5599 714 13 0.98 (0.90, 1.07) 1.04 (0.92, 1.17) 
Townsend qulntlle 
1 (most affluent) 5184 701 14 
2 6393 856 13 0.99 (0.89, 1.10) 0.99(0.88,1.11) 
3 6660 872 13 0.96 (0.87, 1.07) 1.04(0.92,1.19) 
4 7148 942 13 0.97, 0.87, 1.08) 0.98 (0.84,1.13) 
5 (least affluent) 9051 1110 12 0.89 (0.81, 0.99) 0.86 (0.71,1.04) 
missing 77 4 5 0.35 (0.13,0.96) 0.43 (0.15, 1.23) 
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Pvalue 
0.086 
<0.001*** 
0.001*** 
<0.001*** 
0.39" 
0.132*** 
Table 6.1 continued. 
Nwho 
N had (%)* Unadj OR AdJ OR** P 
surgery 
Charlson Index 
0 15,573 2341 15 <0.001*** 
1 6951 985 14 0.93 (0.86, 1.01) 0.95 (0.86, 1.04) 
2or3 5828 752 13 0.83 (0.77, 0.91) 0.89 (0.80,0.99) 
4+ 6161 407 7 0.40 (0.36, 0.45) 0.67 (0.56, 0.80) 
Surgical centre 
No 25,248 2947 12 
Yes 9265 1538 17 1.51 (1.41, 1.61) 1.51 (1.16, 1.97) <0.001 
Radiotherapy centre 
No 21,646 2614 12 
Yes 12,867 1871 15 1.24 (1.16,1.32) 1.02 (0.83,1.27) 0.854 
Trial entry 
Low 23,136 2817 12 
High 11,377 1668 15 1.24 (1.16, .32) 1.15 (0.88,1.50) 0.34 
Legend: N=total number of patients in each variable. 
(%)* percentage of each variable who had surgery. 
Adj OR** Odds ratio for surgery adjusted for all other variables in the table. 
*** p for trend 
1\ this Is the result of a log likelihood ratio test 
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6.3.2 Survival 
A small number of patients (148) had a date of death on or before the date of 
diagnosis and so were excluded from the survival analyses. In my survival 
analyses females had a better prognosis than males but as age, stage and 
performance status Increased prognosis worsened (table 6.2). Patients with a 
Charlson Index of 4 or more had an adjusted Hazard Ratio of death of 1.59 
(95% confidence Interval 1.52, 1.66) compared with those with a Charlson Index 
of zero. There was no evidence that social deprivation was linked to worse 
survival. Whether the NHS Trust where a patient was first seen was a thoracic 
surgical centre or not had no significant effect on overall mortality. The results 
of Peer Review had no effect on overall mortality (adjusted Hazard Ratio 1.01, 
95% confidence Interval 0.98, 1.04). There was no evidence that my 
proportional hazards assumption was Incorrect. 
Patients who had surgery had an almost 60% lower overall mortality, (adjusted 
Hazard Ratio 0.41, 95% confidence Interval 0.39, 0.44), compared with those 
who did not have surgery, even after adjusting for a" patient features. In the 
subgroup of people with stage I or II disease where 48% had surgery, the fully 
adjusted Hazard Ratio was very similar at 0.41 (95% confidence Interval 0.37 to 
0.46). The median survival for patients stage I or II disease who had surgery 
was 774 days (Interquartlle range 305 days to 2150 days), compared with a 
median survival of just 174 days (Interquartlle range 63 to 394 days) for those 
who did not have surgery. 
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Table 6.2: Results of Cox regression analyses using all patient features, all NHS 
Trust level features, surgical Intervention or not, and clustering by NHS Trust. 
Nwho 
N died (%)* Unadl HR AdJ HR** P 
Sex 
Male 20,848 17,144 82 
Female 13,517 10,616 79 0.90 (0.88, 0.92) 0.90 (0.88, 0.92) <0.001 
Age qulntlle 
1 (30-62 years) 8183 6372 78 <0.001*** 
2 (63-69 years) 7616 5897 77 1.02 (0.98, 1.06) 1.04 (1.00, 1.07) 
3 (70-75 years) 7660 6210 81 1.15 (1.11,1.19) 1.10(1.06,1.14) 
4 (76-80 years) 6084 5068 83 1.28 (1.24, 1.33) 1.17 (1.13,1.22) 
5 (81-100 years) 4822 4213 87 1.57 (1.51,1.64) 1.32 (1.26, 1.39) 
Stage 
IA 1177 448 38 <0.001*** 
IB 2137 1062 50 1.43 (1.28, 1.60) 1.27 (1.11,1.46) 
IIA 202 79 39 1.03 (0.81,1.31) 1.00 (0.79,1.28) 
liB 1446 905 63 2.08 (1.85, 2.32) 1.71 (1.48, 1.99) 
iliA 2772 2083 75 2.82 (2.55, 3.13) 1.98 (1.73, 2.27) 
IIIB 5410 4564 84 4.09 (3.71, 4.50) 2.67 (2.33, 3.05) 
IV 10,913 10,106 93 6.37 (5.80, 7.01) 3.85 (3.35, 4.42) 
Occult 50 26 52 1.56 (1.05,2.31) 1.24 (0.83, 1.86) 
missing 10,258 8487 83 3.93 (3.57, 4.32) 2.53 (2.19, 2.91) 
Performance status 
0 5839 3804 65 <0.001*** 
1 9267 7226 78 1.49 (1.43, 1.55) 1.28 (1.22, 1.33) 
2 5300 4737 89 2.50 (2.40, 2.61) 1.87 (1.76, 1.99) 
3 3230 3103 96 4.51 (4.30,4.74) 3.12 (2.91, 3.35) 
4 737 722 98 7.62 (7.03, 8.25) 5.21 (4.39, 6.17) 
missing 9992 8168 82 1.82 (1.75, 1.89) 1.54 (1.45,1.62) 
Ethnic group 
White 26,408 21,488 81 0.0004" 
Black 231 177 77 0.84 (0.72,0.97) 0.81 (0.70,0.93) 
Asian 1897 1433 76 0.98 (0.93, 1.03) 0.95 (0.89, 1.02) 
Mixed race 103 84 82 0.86 (0.77,1.18) 0.96 (0.79,1.18) 
Other 160 115 72 0.83 (0.69, 1.00) 0.86 (0.73, 1.02) 
missing 5566 4463 80 1.03 (tOO, 1.06) 1.05 (1.01,1.09) 
Townsend qulntlle 
1 (most affluent) 5172 4161 80 0.661*** 
2 6363 5128 81 1.01 (0.97, 1.05) 1.00 (0.96, 1.05) 
3 6627 5345 81 1.03 (0.99, 1.06) 1.00 (0.96,1.05) 
4 7115 5671 80 1.01 (0.97, 1.05) 0.99 (0.94, 1.03) 
5 (least affluent) 9011 7390 82 1.04 (1.00,1.08) 0.99 (0.94, 1.05) 
missing 77 65 84 1.12 (0.87 1.42) 0.87 (0.67 1.14) 
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Table 6.2 continued. 
Nwho 
N died (%)* UnadJ HR AdJ HR** P 
Charlson Index 
0 15,536 12,105 78 <0.001*** 
1 6931 5431 78 1.10 (1.06,1.13) 1.06 (1.02,1.09) 
20r3 5795 4592 79 1.16 (1.12,1.20) 1.07 (1.03, 1.11) 
4+ 6103 5632 92 2.00 (1.93, 2.06) 1.59 (1.52, 1.66) 
Surgery 
No 29,887 25,940 87 
Yes 4478 1820 41 0.24 (0.23, 0.25) 0.41 (0.39,0.44) <0.001 
Surgical centre 
No 25,131 20,517 82 
Yes 9234 7243 79 0.91 (0.89, 0.94) 0.95 (0.89, 1.01) 0.09 
Radiotherapy centre 
No 21,536 17,550 81 
Yes 12,829 10,210 80 0.97 (0.95,0.99) 1.02 (0.96,1.09) 0.539 
Trial centre 
Low 23,043 18,642 81 
High 11322 9118 81 0.98 (0.95, 1.00) 1.01 (0.96 1.06) 0.734 
Legend 
N=total number of patients In each variable. 
(%)* percentage of patients In each variable who have died. 
Adj OR** Odds ratio for surgery adjusted for all other variables In the table. 
*** p for trend 
A this Is the result of a likelihood ratio test. 
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The demographic features of patients first seen at thoracic surgical and non-
surgical centres were similar (table 6.3) although the proportion of patients from 
the least affluent qulntile of SOCiety was higher for the thoracic surgical centres 
than the non-surgical centres (p<O.OOl). Of the 4,485 (13%) patients who had 
surgery 34% were first seen In a thoracic surgical centre. 
Table 6.3: Demographic features of patients with NSCLC based on where they 
are first seen. Total number with NSCLC Is 34,513. 
Thoracic surgical Non-surgical centre P 
centre value 
Number 0/0 Number 0/0 
Total 9,265 27 25,248 73 
Sex 0.529 
male 5,648 61 15,297 61 
female 3,617 39 9951 39 
Median age 70 years (IQR 63, 77) 71 years (IQR 63, 77) 
Performance status <0.001 
0 1804 19 4043 16 
1 2487 27 6795 27 
2 1388 15 3929 16 
3 824 9 2427 10 
4 169 2 591 2 
Missing 2593 28 7463 30 
Stage 0.003 
IA 372 4 806 3 
IB 582 6 1556 6 
IIA 62 0.7 140 0.5 
lIB 381 4 1067 4 
lIlA 746 8 2031 8 
IlIB 1388 15 4039 16 
IV 3003 32 7965 32 
Occult 16 34 
missing 2715 29 7610 30 
Charlson Index 0.074 
0 4221 46 11,352 45 
1 1784 19 5167 20 
2 or 3 1564 17 4262 17 
4+ 1696 18 4465 18 
Townsend qulntlle <0.001 
1 (most 
affluent) 1116 12 4068 16 
2 1602 17 4791 19 
3 1470 16 5190 21 
4 1724 19 5424 21 
5 (least 
affluent) 3339 36 5712 23 
Surgery <0.001 
No 7727 83 22,301 88 
Yes 1538 17 2947 12 
161 
Survival after surgery did not appear to be related to where the patient was first 
seen. Those patients with NSCLC who were first seen In a thoracic surgical 
centre and had surgery performed, had an adjusted Hazard Ratio of 1.01 (95% 
confidence Interval 0.87, 1.19). This demonstrates no Increased mortality after 
surgery In those patients first seen In a thoracic surgical centre (table 6.4). 
Table 6.4: Cox regression for patients with proven NSCLC who received surgery, 
based on where they were first seen. 
Nwho N 
had who Unadj HR 
surgery died (0/0)* (95% el) 
Surgical centre 
No 2947 1188 40 
Adj HR** (950/0 
e ~ l l p 
Yes 1538 639 42 1.06 (0.97, 1.171 1.01-'-0.87 1.19) 0.859 
Legend: (%)* percentage of patients who have died. 
** Hazard ratio adjusted for sex, age quintlle, performance status, stage, ethnic 
group, Townsend qulntlle, and Charlson Index. Analysis clustered by NHS Trust. 
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6.4 Discussion 
6.4.1 Principle findings 
My results demonstrate that the likelihood of having surgery for people with a 
histological diagnosis of non-small cell lung cancer Is Independently Influenced 
not only by patient level features, Including age, stage, performance status and 
co-morbidity, but also whether or not the patient Is first seen at a thoracic 
surgical centre. Even after allowing for patient level features people first seen at 
a surgical centre were 51% more likely to have an operation. This difference 
persisted amongst the subgroup of people with early stage disease, where 
surgery would be the preferred treatment modality and one might expect little 
variation In practice. 
These results also show that female sex, younger age, good performance status 
at diagnosis, and early stage disease were all associated with better survival. By 
linking In Information from Hospital Episode Statistics I was able to quantify co-
morbid Illness relating to hospital admissions by calculating a Charlson score, 
and show that as this score Increased, survival became poorer. Whether or not 
an Individual had surgery as part of their treatment plan was also an Important 
determinant of survival for that Individual, with those that did have surgery 
having a 60% reduction In their likelihood of death. This difference was Identical 
In the subgroup of patients with early stage disease. In order to determine 
whether the higher surgical resection rates for people first seen at thoracic 
surgical centres reflected these centres operating on people with more advanced 
disease and/or a worse prognosis I compared the patient features between 
people seen first at a thoracic surgical centre and those seen elsewhere and 
found no difference In either survival or patient level features with the exception 
that the thoracic surgical centres had a higher proportion of people from more 
deprived backgrounds. This suggests that If the clinical pathway was altered to 
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ensure that the 73% of people first seen at a non-surgical centre had the same 
chance of having surgery as those first seen at a thoracic surgical centre then 
this would Increase the overall resection rate in this patient group from 13% to 
17% with no detrimental impact on survival after surgery. The fact that there 
was no observed Improvement in survival in those patients who had surgery, If 
they were first seen In a surgical centre, reflects the difference between the 
survival advantage of surgery Itself conferred to the Individual; rather than an 
observed survival advantage of being first seen In a surgical centre, above and 
beyond the Increased likelihood of receiving surgery. 
6.4.2 Strengths and weaknesses 
Although the National Lung Cancer Audit Is not mandatory, there Is evidence 
within their annual reports that case ascertainment has Increased steadily and Is 
now In excess of 90% (35, 63, 78). In chapter 4 I studied the validity of this 
dataset, and found no evidence of bias dependent on the levels of reporting by 
Individual NHS Trusts (36) providing reassurance that the dataset reflects the 
full spectrum of lung cancer In England. Although a large proportion of this 
cohort had missing data for histology, I was still able to analyse a subgroup of 
more than 30,000 patients with histologically proven non-small cell lung cancer. 
Alongside case ascertainment, data completeness has Improved year on year 
(3S, 63). The marker of co-morbid illness that I used was derived from codes 
relating only to hospital admissions and so will not have captured details of 
conditions managed Independently by general practitioners. This means that, 
despite being a strong predictor of both survival and having surgery, the 
Charlson Indices I calculated may be too low and this raises the possibility of 
residual confounding by co-morbidity. However, when I adjusted the model for 
surgical resection and site first seen, the odds ratio for Charlson score did not 
change at all, suggesting that co-morbidity Is not a confounder for this 
association. The distribution of Charlson Indices In this cohort Is very similar to 
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those In both general practitioner data sets (55) and cohorts of patients with non-
small cell lung cancer (79, 80). One potential weakness Is that there Is no 
Information on whether some people who were offered surgery declined this 
Intervention. My research does not represent a randomlsed control trial looking 
at the Impact of surgery In patients with non-small cell lung cancer, and there 
has never been such a trial. The National Lung Cancer Screening Trial (U.S.A) 
was recently stopped because the primary outcome of a significant reduction In 
mortality from lung cancer was reached (more than 20%). This study compared 
chest X-ray with CT and patients found to have lung cancer at an early enough 
stage were treated surgically. This Is the first time that screening has been 
shown to reduce mortality (81). What I am able to report Is observational data 
from a large unselected cohort, which Illustrates the survival advantage of 
surgery In spite of adjusting for many patient features. It Is possible that my 
results are stili subject to some residual confounding or selection bias and this 
may mean that the marked benefit of surgery I have observed may be an over 
estimate of the true benefit. 
The main strengths of this study are the large size and the quality of the 
National Lung Cancer Audit dataset and the addition or an Independent co-
morbidity score In the form of the Charlson Index. The Charlson Index was 
originally developed and used prospectively In a cohort of people with breast 
cancer (34), and It has subsequently been validated In patient cohorts 
encompassing both malignant (68, 69) and non-malignant disease processes 
(82). Previous research has shown that the Charlson co-morbidity Index Is 
associated with lung cancer Incidence (83) and also survival (84). 
6.4.3 Comparison with other studies 
This study found that people with non-small cell lung cancer who are first seen In 
a thoracic surgical centre have an advantage over people with similar disease 
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seen at non-surgical centres with regards to access to surgery. I also found that 
having surgery had a large beneficial Impact on survival and this highlights the 
Importance of access to this Intervention. Previous research In this area In 
Scotland has shown that as distance from a cancer centre Increases survival 
decreases (85), suggesting that accessibility of services Is a key factor In lung 
cancer outcome. Other research has shown that being first seen In a 
radiotherapy centre Is associated with an Increased likelihood of receiving 'active 
treatment' (51); and that being first seen In a specialist 'cancer centre' Is 
associated with a small Improvement In overall survival (86, 87). There have 
been several large-scale reviews and policy documents In the UK designed to 
address Inequality In cancer outcome Including the Calman-Hlne report (88), the 
NHS Cancer Plan (24) and the Cancer Reform Strategy (27). Creating speCialist 
cancer centres has been pivotal to this programme of change, and whilst 
centralising services will create greater experience and expertise In one centre, It 
may potentially disadvantage Individuals In remote settings, and Increase 
geographical Inequalities. The results I have described suggest that more 
reforms are needed to ensure that all people with lung cancer have equal access 
to surgical Intervention where this Is appropriate. 
6.4.4 Implications of this study 
The Department of Health has published guidance that as many as 20% of 
patients with non-small cell lung cancer may be suitable for surgical resection 
(89). My findings suggest that If all people with non-small cell lung cancer had 
the same access to this Intervention as people first seen at a thoracic surgical 
centre then the English resection rates would Increase from 13% to 17% with no 
detrimental Impact on survival after surgery. However, what my research does 
not show Is what aspects of "being a surgical centre" are crucial to Increasing 
resection rates. It Is possible that this may simply be the presence of a surgeon 
'on-site', but other aspects of the lung cancer service within these speCialist 
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centres may also be Important, such as the composition of the multidisciplinary 
team, Improved access to speCialist radiological and cardiovascular Investigations 
and the geographical location of these thoracic surgical centres. Given the 
terrible prognosis of lung cancer In the UK, understanding the care pathways In 
more detail, and, In particular, the barriers to surgical Intervention that currently 
exist for people seen in non-surgical centres, Is a pressing priority. The Peer 
Review data available at the time of this research did not Influence clinical 
outcome measures In lung cancer, and It Is an area for further research In terms 
of what performance measures should be collected In order to accurately 
describe variation In practice. As the National Lung Cancer Audit matures the 
addition of more specific Information on the composition of local cancer centres 
and Networks Is essential to allow these questions to be answered. 
167 
Chapter seven: How do patient and hospital features Influence 
outcomes In small cell lung cancer In England? 
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7.1 Introduction 
Chemotherapy is recommended by the National Institute for Health and Clinical 
Excellence (NICE) for the treatment of Individuals with small cell lung cancer 
(26), but there Is evidence that geographical variation exists In Its use across 
England (35). The extent to which this variation Is due to patient features, 
Including co-morbidity and performance status, or features of the hospital where 
the patient Is first seen, Is not known; and establishing this Is a priority given the 
poor survival for people with lung cancer seen in the U.K (7, 21). 
The aim of this chapter was to use the NLCA together with co-morbidity data 
from Hospital Episode Statistics to study the impact of patient features and 
features of the NHS Trust on the use of chemotherapy In people with small cell 
lung cancer. In addition I have also studied survival In this cohort. Since data 
on radiotherapy are also available In the National Lung Cancer Audit I have 
evaluated the Impact on survival of radiotherapy use In addition to 
chemotherapy In patients with small cell lung cancer. 
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7.2 Methods 
The data used In this chapter were downloaded from the National Lung Cancer 
Audit (NLCA) and included all patients first seen between January 2004 and 31st 
December 2008 (dataset 2). The analyses were restricted to those patients with 
histologically-proven small cell lung cancer. As has been discussed In chapters 5 
and 6 the NLCA dataset contains the following details: 
sex, 
age at diagnosis, 
Lower Super Output Area (census derived), 
performance status (as classified by ECOG), 
stage at presentation (limited or extensive disease), 
details of the NHS Trust where a patient was first seen, 
and whether chemotherapy was given (date of chemotherapy). 
The data held by the National Lung Cancer Audit on co-morbidity were 
Incomplete and are limited to only six disease groups. Therefore I created a 
composite co-morbidity score, Charlson Index (34), as described In section 
5.2.2. I also used data from Hospital Episode Statistics to provide Information 
on ethnlclty. 
7.2.1 Chemotherapy 
All NHS Trusts can provide chemotherapy, and so to assess whether there was a 
range In the provision of chemotherapy across NHS Trusts during the study 
period, I calculated the proportion receiving chemotherapy In each Trust and 
then used logistic regression to assess the likelihood of receiving chemotherapy 
after adjusting for all patient features. I used the largest NHS Trust as the 
comparator In the regression model and I Included only NHS Trusts that had at 
least 30 patients with histologically-proven small cell lung cancer to ensure 
robust estimates. 
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To Identify the most Important factors associated with an Individual's treatment 
with chemotherapy, I performed logistic regression analyses to assess the 
likelihood of patients with histologically-proven small cell lung cancer receiving 
chemotherapy, adjusting for all patient features and clustering on NHS Trust. In 
this analysis I also adjusted for a marker of an NHS Trust's participation In 
clinical trials by estimating whether NHS Trusts were entering a certain 
proportion of their expected lung cancer patients Into clinical trials (described In 
section 5.2.3.3). I also tried to quantify lung cancer MDT performance by using 
the results of the Peer Review process 2004-2007 (described In section 5.2.3.4) 
This was subsequently dropped from multivariate regression analyses due to the 
lack of evidence to support the assumption that It Influenced the likelihood of a 
patient having chemotherapy (table 5.16) or survival (table 5.17). 
7.2.2 Survival 
For the survival analyses, I created a start and end date as detailed In section 
5.2.4.2. Because the objective was to assess the effect of chemotherapy on 
survival, patients with a date of death the same as, or earlier than, the date of 
diagnosis were excluded from the survival analyses. I performed Cox regression 
analyses to calculate hazard ratios for overall mortality In patients receiving 
chemotherapy compared with those receiving no chemotherapy and then 
constructed a multivariate model mutually to adjust for all patient features and 
NHS Trust trial Involvement. The flnal Cox regression model Included clustering 
by NHS Trusts. I then restricted this multivariate Cox regression model to 
Include only patients who had received chemotherapy, to assess whether chemo-
radiotherapy conferred any survival advantage over chemotherapy alone. The 
proportional hazards assumption for our models was checked by Inspecting 
Nelson-Aalen plots. 
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Finally, to determine whether patients first seen at a centre with high trial 
participation were different from those first seen In a centre with low trial 
participation, I compared the demographic features of patients between these 
two groups of NHS Trusts. For the subgroup of patients who had received 
chemotherapy, I used a Cox regression model to assess survival according to 
whether a patient had been first seen In a centre with high compared with low 
trial participation, adjusting for all patient features and clustering by NHS Trust. 
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7.3 Results 
This second dataset (NLCA-HES linked) contained a total of 87,252 patients who 
were first seen at an English NHS Trust between January 2004 and 31st 
December 2008. I excluded 6,286 patients (7%) because there were missing 
data for the NHS Trust where the patient had first been seen. There were 7,845 
(10%) patients with histologically-proven small cell lung cancer of whom 54% 
were male, and the median age of these patients was 69 years (lnterquartlle 
range 62 to 76 years), two years younger than for the cohort overall. In total 
1781 patients (23%) had evidence of co-morbid disease with a Charlson score of 
4 or more, compared with 19% of the cohort overall (table 7.1). 
Table 7.1: Distribution of Charlson Indices for the overall cohort of patients with 
lung cancer, and those with proven small cell lung cancer. 
Complete cohort Small cell only 
Charlson Index N (0/0) N (0/0) 
0 34,711 43 3482 44 
1 15,915 21 1492 19 
2 or 3 15,085 19 1090 14 
4+ 15255 19 1781 23 
There were 44 NHS Trusts with >5% of expected lung cancer patients being 
entered Into clinical trials, called centres with high trial participation. Of the 
7,845 patients with histologically-proven small cell lung cancer, 2,524 (32%) 
were first seen In centres with high trial participation which was a similar 
proportion to the cohort overall (31 %). 
7.3.1 Chemotherapy 
The analysis of the use of chemotherapy at each NHS Trust In England showed 
wide variation. In the NHS Trusts with more than 30 patients the overall 
proportion receiving chemotherapy was 0.61, the same as for the whole group 
with small cell lung cancer. The actual proportion ranged from 0.14 to 0.86 at 
Individual NHS Trusts (Interquartlle range 0.53 to 0.71). Adjusting for all patient 
features, there was significant variation (p<O.OOl) In the odds ratios for 
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receiving chemotherapy In the same group of NHS Trusts, with the largest Trust 
as comparator. The Individual NHS Trust level odds ratios ranged from 0.03 
(95% confidence Interval 0.014, 0.07) to 4.47 (95% confidence Interval 1.46, 
13.72), with an Interquartile range of 0.42 to 1.02. 
A total of 4,820 (61 %) patients with histologically-proven small cell lung cancer 
received chemotherapy, of whom 861 (18%) also received radiotherapy. Table 
7.2 shows the results of logistic regression analyses of likelihood of receiving 
chemotherapy. Age at diagnosis, performance status, stage and co-morbidity all 
showed Important Independent associations with the likelihood of receiving 
chemotherapy. As age Increased, the likelihood of receiving chemotherapy 
decreased, with an odds ratio of 0.74 (95% CI 0.64, 0.86) In the second qulntlle 
(63-69 years), and an odds ratio of 0.59 (95% CI 0.50, 0.69) In the 3rd qulntlle 
(70-75 years) compared with the youngest group. Patients with a performance 
status of 2 were less likely to receive chemotherapy compared with patients with 
a performance status of zero (adjusted odds ratio 0.58, 95% confidence Interval 
0.45, 0.74). Extensive stage disease at diagnosis was associated with a 
reduction In the likelihood of receiving chemotherapy compared with those 
patients with limited disease (adjusted odds ratio 0.61, 95% confidence Interval 
0.47, 0.78). A Charlson Index of 4 or more was associated with a reduced 
likelihood of receiving chemotherapy compared a Charlson Index of zero 
(adjusted odds ratio 0.50, 95% confidence Interval 0.42, 0.58). Sex, ethnlclty 
and soclo-economlc status were not associated with access to chemotherapy. 
If a patient was first seen In an NHS Trust defined as a centre with high trial 
participation, they were more likely to receive chemotherapy than those at a 
centre with low trial participation, even after adjusting for all patient features 
(adjusted odds ratio 1.42, 95% confidence Interval 1.06, 1.90). When I 
performed a restricted analysis with only those patients without missing data 
(N=3059), the results were very similar (adjusted odds ratio for centres with 
high v low trial participation 1.50, 95% confidence Interval 1.03, 2.16). 
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Table 7.2: Results of logistic regression analyses evaluating the Influence of 
patient features on the likelihood of receiving chemotherapy (CTx). 
N 
Total having UnadJ OR AdJ OR** 
N CTx (%)* (95% CIl (95% cn 
Sex 
Male 4245 2560 60 
Female 3600 2260 63 1.11 (1.01, 1.22) 1.08 (0.98, 1.19) 
Age qulntlle 
1 (30-62 years) 2174 1616 74 
2 (63-69 years) 1928 1292 67 0.70 (0.61, 0.80) 0.74 (0.64, 0.86) 
3 (70-75 years) 1771 1079 61 0.54 (0.47, 0.62) 0.59 (0.50, 0.69) 
4 (76-80 years) 1170 580 50 0.34 (0.29, 0.39) 0.39 (0.32, 0.47) 
5 (81-101 years) 802 253 32 0.16 (0.13, 0.19) 0.19 (0.15, 0.24) 
PS 
PS 0 977 779 80 
PS 1 1925 1504 78 0.91 (0.75, 1.10) 1.08 (0.87, 1.35) 
PS 2 1444 901 62 0.42 (0.35, 0.51) 0.58 (0.45, 0.74) 
PS 3 876' 341 39 0.16 (0.13, 0.20) 0.25 (0.19, 0.33) 
PS 4 284 30 11 0.03 (0.02, 0.05) 0.05 (0.03, 0.07) 
Missing 2339 1265 54 0.30 (0.25, 0.36) 0.42 (0.32, 0.55) 
Stage 
Umlted 1323 1025 77 
Extensive 3078 1873 61 0.45 (0.39, 0.52) 0.61 (0.47,0.78) 
Missing 3444 1922 56 0.37 (0.32, 0.42) 0.45 (0.34, 0.59) 
Townsend qulntlle 
1 (most affluent) 1087 675 62 
2 1385 876 63 1.05 (0.89, 1.24) 1.02 (0.85, 1.24) 
3 1530 922 60 0.93 (0.79, 1.09) 0.92 (0.77, 1.11) 
4 1669 1008 60 0.93 (0.80, 1.09) 0.87 (0.72, 1.09) 
5 (least affluent) 2154 1327 62 0.98 (0.84, 1.14) 0.85 (0.67, 1.08) 
Missing 20 12 60 0.92 (0.37, 2.26) 0.65 (0.25, 1.87) 
Ethnic group 
White 6061 3739 62 
Black 31 16 52 0.66 (0.33, 1.34) 0.38 (0.11, 1.29) 
As/an 399 240 60 0.94 (0.76, 1.15) 1.02 (0.80, 1.27) 
Mixed 14 10 71 1.55 (0.49, 4.96) 1.75 (0.58, 5.32) 
Other 38 20 53 0.69 (0.36, 1.31) 0.60 (0.34, 1.10) 
MIssing 1302 795 61 0.97 (0.86, 1.10) 0.94 (0.81, 1.09) 
Charlson Index 
0 3482 2441 70 
1 1492 904 61 0.66 (0.58, 0.74) 0.79 (0.69, 0.91) 
2 or 3 1090 625 57 0.57 (0.50, 0.66) 0.76 (0.65,0.90) 
4+ 1781 850 48 0.39 (0.35, 0.44) 0.50 (0.42, 0.58) 
Trial entry 
<5% 5321 3162 S9 
>5% 2524 1658 66 1.31 (1 18 1.44) 1.42 (1.06. 1.90) 
Legend: (%)* percentage of patients who received chemotherapy. 
** Odds ratio adjusted for all other variables In the table. 
Analysis clustered by NHS Trust. 
" this Is the result of a likelihood ratio test 
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p 
value 
0.106 
<0.001 
<0.001 
<0.001 
0.075 
0.107'" 
<0.001 
0.017 
7.3.2 Survival 
A small number of patients (63) had a date of death on or before the date of 
diagnosis and so were excluded from the survival analyses. The median survival 
for the remaining cohort of 7,782 patients with histologically-proven small cell 
lung cancer was 182 days (Inter-quartile range 44 to 368 days). Table 7.3 
shows the results of univariate and multivariate Cox regression analyses, and 
demonstrates that females had a better prognosis than males. As age, stage, 
performance status and co-morbidity Increased, prognosis worsened. The 
adjusted Hazard ratio for patients with a Charlson Index of 4 or more was 1.62 
(95% confidence Interval 1.49, 1.77) compared with those patients with a 
Charlson Index of zero. Soclo-economlc status and ethnlclty had no effect on 
overall survival. Whether the NHS Trust where a patient was first seen was a 
centre with high trial participation or not did not affect overall survival (adjusted 
Hazard ratio 0.99, 95% confidence Interval 0.88, 1.10). There was no evidence 
that our proportional hazards assumption was not met. 
Table 7.3 also shows that patients who received chemotherapy had a lower 
mortality compared with those who did not, In spite of adjusting for all patient 
features (adjusted Hazard ratio 0.51, 95% confidence Interval 0.46, 0.56). 
When I performed a restricted analysis with only those patients without missing 
data (N=3059), the results were very similar (adjusted Hazard ratio for yes v no 
chemotherapy 0.49, 95% confidence Interval 0.41, 0.58). The survival of 
patients over time who did and did not receive chemotherapy Is shown In figure 
7.1. In the subgroup of patients with limited disease (1,319 patients) where 
78% received chemotherapy there was a lower overall mortality rate compared 
with those who did not receive chemotherapy (adjusted Hazard ratiO 0.62, 95% 
confidence Interval 0.50, 0.76). The median survival for patients with limited 
stage disease who received chemotherapy was 399 days (Inter-quartile range 
241 to 686 days), compared with a median survival of just 139 deys (Inter-
quartile range 37 to 381 days) In those who did not receive chemotherapy. 
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Table 7.3: Cox regression analysis of patient features, NHS Trust trial-entry and 
the patient's receipt of chemotherapy on overall survival. 63 patients were 
death certificate only (N=7782). Total number that had died, 6,981. 
Total N Unadj HR Adj HR** 
patients died (%1* (95% cn (95% en 
Sex 
Male 4206 3838 91 
Female 3576 3143 88 0.84 (0.80, 0.88) 0.86 (0.82, 0.90) 
Age qulntlle 
1 (30-62 years) 2161 1859 86 
2 (63-69 years) 1917 1731 90 1.22 (1.14, 1.30) 1.12 (1.04, 1.21) 
3 (70-75 years) 1757 1561 89 1.31 (1.23, 1.40) 1.20 (1.11, 1.30) 
4 (76-80 years) 1159 1079 93 1.62 (1.51, 1.75) 1.31 (1.19, 1.44) 
5 (81-101 years) 788 751 95 2.07 (1.90, 2.25) 1.47 (1.32, 1.64) 
PS 
PS 0 975 772 79 
PS 1 1919 1653 86 1.39 (1.28, 1.52) 1.34 (1.24, 1.45) 
PS 2 1437 1344 94 2.19 (2.01, 2.40) 1.83 (1.67, 2.00) 
PS 3 868 847 98 3.82 (3.46, 4.21) 2.65 (2.36, 2.99) 
PS 4 269 265 99 8.63 (7.40, 9.95) 5.01 (4.05, 6.19) 
Missing 2314 2100 91 1.86 (1.71, 2.02) 1.63 (1.50, 1.77) 
Stage 
Limited 1319 1043 79 
Extensive 3053 2894 95 2.45 (2.28, 2.63) 2.07 (1. 92, 2.25) 
missing 3410 3044 89 1.74 (1.62, 1.87) 1.43 (1.31, 1.57) 
Townsend qulntlle 
1 (most affluent) 1075 947 88 
2 1378 1234 90 1.04 (0.96, 1.13) 1.07 (0.98, 1.17) 
3 1523 1365 90 1.08 (0.99, 1.17) 1.07 (0.97, 1.17) 
4 1650 1490 90 1.05 (0.97, 1.14) 1.07 (0.98, 1.18) 
5 (least affluent) 2138 1929 90 1.05 (0.97, 1.13) 1.07 (0.96, 1.19) 
Missing 18 16 89 1.13 (0.69, 1.85) 1.52 (1.15, 2.02) 
Ethnic group 
White 6015 5439 90 
Black 31 26 84 0.71 (0.49, 1.05) 0.79 (0.56, 1.11) 
Asian 396 344 87 1.06 (0.95, 1.19) 1.01 (0.88, 1.15) 
Mixed 14 11 79 0.69 (0.38, 1.24) 0.78 (0.47, 1.31) 
Other 37 32 87 1.00 (0.71, 1.42) 0.84 (0.46, 1.52) 
Missing 1289 1129 88 1.00 (0.93, 1.06) 1.04 (0.94, 1.14) 
Charlson Index 
0 3466 3015 87 
1 1483 1301 88 1.23 (1.15, 1.32) 1.07 (1.01, 1.14) 
2 or 3 1080 967 90 1.35 (1.25, 1.45) 1.11 (1.02, 1.22) 
4+ 1753 1698 97 2.09 (1.97, 2.22) 1.62 (1.49, 1.77) 
Chemotherapy 
No 2967 2825 95 
Yes 4815 4156 86 0.43 (0.41, 0.45) 0.51 (0.46, 0.56) 
Trial entry 
<5% 5282 4739 90 
>5% 2500 2242 90 0.96 (0.91 1.01) 0.99 (0.88 1.10) 
Legend: (%)* percentage of patients from each subgroup who have died 
** Hazard ratio adjusted for all other variables In the table. 
Analysis clustered by NHS Trust. 
'" this Is the result of a likelihood ratio test. 
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P value 
<0.001 
<0.001 
<0.001 
0.001 
0.341 
0.422'" 
<0.001 
<0.001 
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Figure 7.1; Kaplan-Meier survival curve comparing the observed survival in those 
who did, compared with those who did not, have chemotherapy. 
Table 7.4 demonstrates that those patients with limited stage disease who 
received chemo-radiotherapy had a better overall survival than those who 
received chemotherapy alone (adjusted Haza rd ratio 0.72, 95% confidence 
Interval 0.62, 0.84). 
Table 7.4: Results of Cox regression analyses assessing the Influence of chemo-
radiotherapy versus other treatment regimes. Clustered by NHS Trust. 
N who Unadj. HR Adj. HR** 
N died %* (95% CI) (95% CI) P value 
Whole cohort 7782 
CTx alone 3914 3463 88 <0.001 
CTx and RTx 861 670 78 0.66 (0.61, 0.72) 0.70 (0.65, 0.76) 
Limited stage 1319 
CTx alone 737 594 81 <0.001 
CTx and RTx 280 184 66 0.69 (0.58, 0.81) 0.72 (0.62, 0.84) 
Legend: N= Number of patients 
(%) * percentage of patients from each subgroup who have died 
** Hazard ratio adjusted for sex, age qulntile, performance status, stage (whole 
cohort only), ethnic group, Townsend qulntile, Charlson Index. 
Footnote: some patients had no record of any treatment received, and some 
received surgery, whilst others received radiotherapy only. 
Whole cohort; no treatment N=2360; surgery N= 148; radiotherapy only N=499. 
Limited stage: no treatment N=218; surgery N=20; radiotherapy only N= 64. 
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The demographic features of patients first seen In centres with high and low trial 
participation were similar (table 7.5), although the proportion of patients from 
the least affluent qulntlle of society was higher In centres with high compared 
with low trial participation. Although there were differences In stage and 
performance status between the two types of centres this will In part reflect the 
size of the cohort. The main difference between the high and low trial 
participation centres were In the missing data. Most Importantly In the group of 
patients likely to receive chemotherapy, good performance status (0-1) and 
limited stage disease the proportions were very similar (36% and 37% and 16% 
and 17% respectively between high and low centres). Of the 4820 (61%) 
patients who received chemotherapy, 34% were first seen In centres with high 
trial participation. Survival after chemotherapy was not affected by whether or 
not a patient had been first seen in a centre with high compared with low trial 
partiCipation, adjusted Hazard ratio 1.05 (95% confidence Interval 0.97, 1.13). 
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Table 7.5: Demographic features of patients with small cell lung cancer based on 
the where they were first seen. Total number of patients with small cell lung 
cancer is 7,845. 
Centre with high trial Centre with low trial 
participation participation P value 
(N=2,S24) (0/o) * (N=5,321) (Ofo)* 
Sex 0.446 
Male 1401 56 2844 53 
Female 1123 44 2477 47 
Median age 69 years (IQR 61 to 75) 69 years (IQR 62 to 76) 
Performance status 0.001 
0 331 13 646 12 
1 579 23 1346 25 
2 420 17 1024 19 
3 254 10 622 12 
4 74 3 210 4 
MIssing 866 34 1473 28 
Stage 0.001 
Limited 393 16 930 17 
Extensive 844 33 2234 42 
Missing 1287 51 2157 41 
Charlson Index 0.175 
0 1124 46 2358 44 
1 460 18 1032 19 
2 or 3 350 14 740 14 
4+ 590 23 1191 22 
Townsend qulntlle <0.001 
1 (most affluent) 351 14 736 14 
2 406 16 979 18 
3 460 18 1070 20 
4 483 19 1186 22 
5 (least affluent) 821 33 1333 25 
Chemotherapy <0.001 
No 866 34 2159 41 
Yes 1658 66 3162 59 
Legend: (%)* percentage 
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7.4 Discussion 
7.4.1 Principle findings 
These results demonstrate that there Is considerable variation In the use of 
chemotherapy In people with small cell lung cancer. Older age and the presence 
of co-morbidity were both associated with a decrease In the use of 
chemotherapy, but even after allowing for these there was wide variations In use 
between NHS Trusts In England. Trusts with an Interest In recruiting people Into 
lung cancer clinical trials In general were more likely to give chemotherapy to 
people with small cell lung cancer, and this difference was not explained by 
Individual patient features. 
My results show that male sex, Increasing age, co-morbidity, worsening 
performance status, and extensive stage disease were all Independently 
associated with a worse survival. Whether or not a patient received 
chemotherapy was also Independently associated with survival (adjusted Hazard 
ratio of 0.51, 95% confidence Interval 0.46, 0.56). The beneficial effects of 
chemotherapy on survival amongst the patients who were treated with 
chemotherapy were the same whether a patient was first seen In a high or low 
trial centre, suggesting that the Increased use of chemotherapy In centres with 
high trial participation was not associated with an Increase In chemotherapy 
related deaths. This In turn suggests that the high trial centres are not tending 
to over treat people and that there Is scope to Increase the use of chemotherapy 
In the centres with low trial participation. 
7.4.2 Strengths and weaknesses 
Although the National Lung Cancer Audit (NLCA) Is non-mandatory, I have 
previously shown that this Is a valid and representative dataset (36). There Is 
also evidence that the case ascertainment rate In the NLCA Is now In excess of 
90% (35, 63), and so this chapter Is based on one of the largest, contemporary 
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clinical lung cancer datasets In the world. One potential weakness of this 
research Is that my data on co-morbidity relate only to diagnoses associated 
with hospital admissions. As a result I may not have captured details of every 
condition managed independently by general practitioners, and so my derived 
Charlson Indices may be too low, and there may be some residual confounding 
by co-morbidity. However, I think that this Is unlikely to be the case, as the 
range of Charlson Indices observed In this cohort Is similar to those In cohorts of 
patients from a general practitioner dataset (55) and patients with lung cancer 
(79, 80). Furthermore my analyses showed that although co-morbidity was an 
Important predictor of survival It did not confound the association between the 
use of chemotherapy and survival. 
I acknowledge that using entry Into clinical trials as a surrogate for 
chemotherapy practice may In Itself explain the variation In access to 
chemotherapy described. However, the cut-off for the centres with high trial 
partiCipation was only 5% entry of expected patients Into clinical trials, and so 
the majority of Individuals with small cell lung cancer would have received 
chemotherapy outside a clinical trial. Furthermore, this study analyses the 
extent of variation amongst NHS Trusts having accounted for all patient features. 
It Is not possible to elicit from the dataset the number of patients who were 
offered chemotherapy but declined, nor the frequency of side-effects and toxicity 
from the chemotherapy. 
7.4.3 Comparison with other studies 
The annual reports from the National Lung Cancer Audit have described variation 
In chemotherapy use amongst Individuals with small cell lung cancer across 
England although they have not adjusted for co-morbidity. In the 2009 report 
(which assessed data from patients first seen In 2008) this proportion ranged 
from 0.00 to 1.00, which shows that the variation over the years 2004-2008 that 
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I have described in this chapter, still holds at the end of the study period. In a 
separate study Jack et al described variation In treatment rates and overall 
survival In lung cancer patients in South East England, but again no adjustment 
was made for performance status or co-morbidity (51). Patients first seen at a 
radiotherapy centre were more likely to receive 'active treatment', chemotherapy 
and radiotherapy (51). Several major policy documents have been published by 
the Department of Health over the past fifteen years (24, 27, 88). One of the 
major themes has been the creation of speCialist cancer centres, and there Is 
evidence that patients first seen by a lung cancer speCialist are more likely to 
receive 'active treatment', Including chemotherapy, than those who are not (67), 
and centralised referral for lung cancer has been associated with Improved 
survival rates (87). However, the creation of speCialist cancer centres will 
potentially generate greater Inequality In access to treatment as the distance 
and time spent travelling Increases. Jones and Crawford have both described a 
reduction In the likelihood of receiving chemotherapy In lung cancer patients as 
distance to hospital Increased (47, 86), and Campbell reported a poorer survival 
after diagnosis for Individuals with lung cancer as distance from a cancer centre 
Increased (85). Given chemotherapy Is available In all NHS Trusts, and 
recommended for the treatment of all patients with small cell lung cancer (26, 
89), It should be possible to make access to this treatment more equitable. My 
results have shown that the Increased use of chemotherapy In centres with high 
trial participation Is not at the detriment of overall patient survival. Therefore 
there Is reason to expect that Increasing the rate of chemotherapy use In small 
cell lung cancer would result In patient benefit. 
I have also been able to demonstrate In a large cohort, that chemo-radlotherapy 
has a survival advantage over chemotherapy alone. This supports the previously 
reported long-term survival gain of this multlmodallty treatment (90, 91), and 
would suggest that chemo-radlotherapy becomes the treatment of choice In 
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Individuals with good performance status and limited stage small cell lung 
cancer. 
My research also showed that as age Increased the use of chemotherapy 
decreased even after adjusting for stage, performance status and co-morbidity. 
This Is In keeping with several publications (92-94), despite evidence that overall 
response to chemotherapy Is not diminished In people with small cell lung cancer 
aged over 70 years (95). Janssen-Heljnen et al (1998) found that, In patients 
over the age of 70 years the presence of even a single co-morbid Illness reduced 
the use of chemotherapy (96), suggesting a reluctance to use these treatments 
In older patients. This supports my evidence that It Is not the associated co-
morbidity rise with age that Is wholly responsible for the observed decline In 
chemotherapy use as patients get older. The apparent reluctance to provide 
chemotherapy In elderly patients with small cell lung cancer Is not supported by 
evidence of a poor safety record (94, 97, 98). 
7.4.4 Implications of this study 
My results have shown evidence of the beneficial effects of chemotherapy for 
people with small cell lung cancer in England, but also the evidence of variations 
in access to this treatment dependent upon age and hospital attended. The 
main determinants of Trust level variation are not known and this Is an 
Important research question that needs addressing In the future development of 
the NLCA. The standards set In the 2004-2007 Peer Review process do not 
appear to have captured sufficient detail to distinguish between the performance 
of multi-disciplinary teams In different NHS Trusts. With regard to age It is clear 
that further debate Is needed In the lung cancer community about the decision to 
withhold treatment from older people with lung cancer. 
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Chapter eight: Lung cancer In young adults: a different disease entity? 
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8.1 Introduction 
Lung cancer Is primarily a disease of older age, but approximately 1-2% of 
patients are less than 40 years of age at diagnosis (99). Some studies have 
reported a poorer prognosis In this young adult subgroup (100, 101), although It 
Is not known if this reflects late presentation on behalf of the patient, or a more 
aggressive disease. Other studies have reported an equivalent prognosis 
following surgery for young adults with lung cancer and their older counterparts 
(102-104). However, these studies tend to be small case series In single centres 
evaluating one treatment modality, where the number of patients Is Inadequate 
to allow robust conclusions to be drawn. 
Young adults often have dependent children and are in paid employment and so 
a condition with such a poor prognosis will generate a significant soclo-economlc 
burden. Any research which can Influence the prompt diagnosis of lung cancer 
and optimise its management, will Improve clinical effectiveness. 
The aim of this chapter was to use the National Lung Cancer Audit dataset to 
examine the clinical and soclo-demographlc features of a large cohort of young 
adults (aged 20-40 years) with lung cancer, and to compare these findings with 
their older counterparts and with published literature on lung cancer In young 
adults. In particular I was keen to quantify the variation In access to treatment 
and post-operative survival In this young adult cohort. 
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8.2 Methods 
I used the third dataset downloaded from the National Lung Cancer Audit, which 
Included all patients first seen before 31st December 2008. Individuals without a 
sex recorded were excluded, as were those aged less than 20 years at diagnosis, 
and those patients In whom It was not possible to generate a start date. In 
order to assess the effect of age at diagnosis on clinical features and outcome 
measures, all patients aged between twenty and forty years (Inclusive) at 
diagnosis were grouped together. The remainder of the cohort were divided Into 
decades up to those aged 81 years and above. 
The dataset was examined for any variation In key clinical features, namely: 
sex, histology, performance status (as classified by the Eastern Cooperative 
Oncology Group), and stage at presentation (as classified by the American Joint 
Committee on Cancer and Union Internatlonale Contre Ie Cancer version 6). In 
order to evaluate socio-economlc status, the Townsend qulntlle for each patient 
was derived from the Lower Super Output Area (LSOA) based on their residential 
postcode. In order to create a binary variable for treatment received, I used the 
date of surgery, chemotherapy and radiotherapy as recorded In the NLCA. 
Multivariate logistic regression was performed to assess the likelihood of 
receiving each treatment modality across the age groups, adjusting for all the 
patient features mentioned above. 
Although the third dataset was the most up-to-date and contained the largest 
number of young adults, It did not contain Information regarding co-morbidities 
which had been derived from the HES linked dataset (dataset 2). Therefore I 
decided to perform a sensitivity analysis using a subset of this cohort of young 
adults. This subset Included all Individuals aged between 20 and 40 years 
(Inclusive) present In the HES linked dataset (dataset 2). This allowed me to 
record the distribution of disease groups pertinent to the Charlson Index as well 
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as calculating a composite score for co-morbidity, the Charlson Index, to 
determine the relevance of co-morbid Illness In this young adult subgroup. 
For the survival analyses a start date was created as described In section 
5.2.4.2. An end date was generated using either the date of death (obtained 
from the Personal Demographics Service), or the date the dataset was 
downloaded, 25 th January 2010. Those patients who were diagnosed on death 
certificate only, and had a date of death on or before their date of diagnosis 
were excluded from survival analyses. Cox regression analyses were performed 
to calculate Hazard ratios for mortality across the age groups, and then a 
multivariate model was constructed to adjust for all patient features. Nelson 
Aalen plots were Inspected. 
8.2.1 Non-small cell lung cancer 
In addition, within this cohort of young adult patients, I focussed on the 
subgroup with pre-treatment proven non-small cell lung cancer (NSCLC), and 
examined their clinical features (Including histological subtype), their likelihood 
of receiving surgery, and their post-operative survival. These features have 
been reported In the literature before and I was keen to see If our unselected, 
national Audit dataset would produce similar results. 
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8.3 Results 
The NLCA dataset Included a total of 95,932 patients seen at English NHS Trusts 
with their first hospital appointment before 31st December 2008. Figure 8.1 
describes the exclusion of certain Individuals on the basis that they had no sex 
recorded (2), were less than 20 years old at diagnosis (17), or that It was not 
possible to assign a start date (4,603, 5%). Therefore the overall cohort 
contained 91,310 Individuals with lung cancer of whom 583 patients (0.6%) 
were aged between 20-40 years, and this was the subgroup used for all 
subsequent analyses. Figure 8.2 illustrates the median interval between several 
pOints along the patient pathway, and figure 8.3 shows the distribution of the 
young adult subgroup based on age at diagnosis. 
The sex ratio In the young adult group was 1.3: 1, male:female. This was similar 
to that for the whole cohort, 1.4:1, male:female. Table 8.1 shows the variation 
In histological subtypes across the different age groups. The young adult group 
demonstrated a higher proportion of adenocarcinomas, and carcinoid tumours. 
Despite the long latency period from exposure to disease, there were 5 patients 
with proven mesothelioma In this young adult subgroup. 
189 
95,932 
Original patient cohort 
! 
9,542 
"Missing" date of diagnosis 
12; No sex recorded I 
86,388 
Date of diagnosis present 
4,146 117; less than 20 years I 
Date of first NHS Trust appointment 
248 
Date of referral from GP 
545 
Date of MDT meeting 
Summary; 
2 patients had no sex assigned. 
86,388 had date of diagnosis (17 were <20 years) 
4,939 have surrogate date of diagnosis 
Therefore 91,310 have a "start" date calculated 
4,603 (4.8%) are unable to have a start date calculated. 
Figure 8.1: Flow diagram depicting the method used to calculate start dates. 
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Date of 
referral 
from GP 
Date of first 
NHS Trust 
appointment 
9 days 
17 days 
Date of MDT 
meeting 
Date of •• ___ _ 
diagnosis 
5 days 
Figure 8.2: Median interval between dates along the patient pathway. 
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Fig 8.3: Histogram of age range for this young adult subgroup 
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I Treatment I 
Table 8.1: Histological subtypes based on age. 
Histol 20-40 Ofo 
Non Small Cell 227 1345 5746 12,009 
NOS 72 (12) 474 (16) 1979 (16) 3943 (15) 
Squamous 36 (6) 303 (10) 1593 (13) 4037 (15) 
Adenocarcinoma 102 (17) 468 (16) 1772 (14) 3237 (12) 
Large cell 11 (2) 72 (2) 268 (2) 484 (2) 
Mixed 0 4 (0) 29 (0) 45 (0) 
Bronchoalveolar cell 5 (1) 20 (1) 85 (1) 210 (1) 
Carcinoma-in-situ 1 (0) 4 (0) 20 (0) 53 (0) 
Small cell 29 (5) 327 (11) 1556 (13) 3005 (11) 
Carcinoid 34 (6) 29 (1) 52 (0) 82 (0) 
Other 40 (7) 100 (3) 297 (2) 571 (2) 
Mesothelioma 5 (1) 48 (2) 398 (3) 1076 (4) 
Missing 248 (43) 1079 (37) 4201 (34) 9553 (36) 
Total 583 2928 12250 26296 
Legend: (SNOMed codes for histology; SNOMed III (1992)/ICD-O-2) 
NOS: Not otherwise specified (M8046/3) 
Squamous cell carcinoma (M8070/3) 
Adenocarcinoma (M8140/3) 
Mixed: Mixed non-small cell lung cancer (M8940/3) 
Broncho-alveolar cell carcinoma (M8250/3) 
Carcinoma-in-situ (M8010/2) 
Other (induding Carcino-sarcoma): (M8980/3, M9999/9) 
Mesothelioma: (M9050/3, M905213, M9051/3) 
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70's >80 Total 
13,812 5260 (38,399) 
4594 (14) 1761 (10) 12824 
4884 (15) 1832 (11) 12685 
3479 (11) 1325 (8) 10385 
519 (2) 194 (1) 1548 
49 (0) 21 (0) 148 
223 (1) 88 (1) 631 
64 (0) 39 (0) 181 
I 
2882 (9) 854 (5) 8653 
64 (0) 23 (0) 284 
668 (2) 363 (2) 2039 
1133 (3) 462 (3) 3122 
13881 (43) 9851 (59) 38,813 
3 440 16813 91310 
The performance status at diagnosis was missing In 51% of this young adult 
subgroup. However, it was 0 or 1 in 80% of those individuals who had a 
performance status recorded. Only 4 patients were recorded with a performance 
status of 4 (1%), compared with 1,093 (7%) of the patients aged over 80 years 
( figure 8.4 ) . 
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Figure 8.4: Distribution of performance status across age groups (if recorded). 
Unfortunately 372 (64%) young adult patients did not have stage at diagnosis 
recorded. Of the remaining 211 patients, 116 (55%) had stage IV disease, and 
on ly 35 (17%) had stage I or II disease. The results for stage at diagnosis across 
the age groups are illustrated in Table 8.2. 
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Table 8.2: Distribution of stage (UICC version 6) at presentation across age groups 
Sta e 20-40 50's Ofo 60's 0/0 70's 010 >81 010 Total 
IA 11 321 (3) 793 (3) 1016 (3) 449 (3) 2667 
IB 16 81 389 (3) 1048 (4) 1587 (5) 816 (5) 3937 
IIA 0 (0) 9 (0) 58 (0) 133 (1) 144 (0) 62 (0) 406 
lIB 8 (1) 58 (2) 297 (2) 766 (3) 916 (3) 426 (3) 2471 
IlIA 24 (4) 143 (5) 574 (5) 1418 (5) 1793 (6) 825 (5) 4777 
IllB 36 (6) 303 (10) 1350 (11) 2813 (11) 3268 (10) 1809 (11) 9579 
IV 116 (20) 731 (25) 3228 (26) 6417 (24) 7666 (24) 3780 (22) 21938 ' 
Occult 0 0 3 0 9 0 33 0 37 0 12 0 94 
Missing 372 (64) 1523 (52) 6024 (49) 12875 (49) 16013 (49) 8634 (51) 45441 
Total 583 2928 12f 250 ____ 26,296 321440 16,813 911310 
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With respect to socio-economic status the data revealed a third of patients within 
this young adult subgroup were from the least affluent qulntlle, whilst only 9% 
were from the most affluent. In contrast, 21% of patients aged >80 years at 
diagnosis were from the least affluent, and 16% were from the most affluent 
quintile. This variation does reach statistical significance when tested using a 
chi2 test (p<O.OOl). Figure 8.5 illustrates the variation In soclo-economic status 
across the age groups. It was not possible to calculate a Townsend quintile In 
222 patients as they did not have data on their LSOA (N =91,088). 
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Figure 8.5: Distribution of Townsend qulntlles across age groups (N =91,088) 
Co-morbidity 
The earlier download from the NLCA which was linked to HES (dataset 2) had 
461 individuals with lung cancer aged between 20 and 40 years Inclusive. In 
this subgroup the median Charlson Index was zero, with an Interquartlle range 
of 0 to 1. Therefore only 25% of this cohort had a Charlson Index of 1 and 
above. The maximum Charlson Index was 12, and this was In a patient with 
AIDS who had metastatic disease at diagnosis. The distribution of disease 
groups is shown in table 8.3. 
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Table 8.3: Distribution of disease groups In young adult subgroup (N=461). 
Component disease group Number Ofo cohort 
Myocardial Infarction/heart failure 3 0.7 
Cerebrovascular disease 4 0.8 
Chronic pulmonary disease 43 9 
Dementia 0 
Peptic ulcer disease 1 
Diabetes (without complications) 9 2 
Peripheral vascular disease 9 2 
Connective tissue disease 3 0.7 
Cancer (solid organ) 36 8 
Haematologlcal malignancy 7 1.5 
Diabetes with complications 3 0.7 
Hemiplegia/paraplegia 1 
Renal disease 1 
Severe liver failure 0 
Metastases 66 14 
AIDS 2 0.4 
Table 8.3 demonstrates the low level of co-morbid Illness In this young adult 
subgroup, supporting the high proportion of Individuals with a good performance 
status. However, 8% of these young adults had had another malignant disease 
before being diagnosed with lung cancer, although this Is less than the cohort as 
a whole, described In chapter 5, when the proportion was 14%. The proportion 
of young adults with metastatic disease at diagnosis (14%) Is the same as for 
the whole cohort described In chapter S. 
8.3.1 Treatment received 
Within the cohort of young adult patients, 100 (17%) underwent surgical 
resection, of whom 3 received adjuvant chemotherapy and 10 adjuvant 
radiotherapy, and 3 adjuvant chemo-radlotherapy. Chemotherapy alone was 
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given to 158 (27%), and radiotherapy alone to 40 (7%) of the young adult 
cohort. A further 41 (7%) received combination chemo-radlotherapy. A total of 
247 (42%) Individuals within the young adult subgroup had no record of a 'date 
of treatment' within the NLCA dataset. Table 8.4 demonstrates the relationship 
between the age group of a patient and the Influence this may have on the 
likelihood of receiving treatment. For those patients with proven non-small cell 
lung cancer there was no significant variation In the likelihood of receiving 
surgery between the young adult group and patients over 40 years of age, until 
the subgroup of patients aged 71-80 years. This older age group were 40% less 
likely to receive surgery for their NSCLC than the young adult subgroup 
(adjusted OR 0.62, 95% CI 0.40, 0.96, p=0.03). Older patients with small cell 
lung cancer were less likely to receive chemotherapy compared with the young 
adults, although this only achieved statistical significance over the age of 60 
years (adjusted OR 0.29, 95% CI 0.09, 1.00, p=0.05). However the results for 
radiotherapy were quite different. This analysis Included all patients within the 
cohort, regardless of underlying histology or treatment Intent (palliative vs 
radical). Table 8.4 shows that as patients get older, up to the age of 80 years, 
they are more likely to receive radiotherapy compared with the young adult 
subgroup. Over the age of 80 years the adjusted Odds Ratio falls a little, 
although It remains significantly higher than In the young adult subgroup (adj OR 
1.39, 95% CI 1.09, 1,77). This may reflect the use of radiotherapy In both 
active palliative and potentially curative regimes, which suggests Individuals In 
the older age groups were perhaps receiving radiotherapy with palliative Intent. 
Although the treatment Intent Is recorded within the NLCA, It Is not clear 
whether this can reliably differentiate between palliative and radical 
radiotherapy. These results suggest that, with the exception of radiotherapy, 
patients In the young adult subgroup are no less likely to receive active 
treatment than older adults. 
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Table 8.4: Logistic regression analyses examining the influence of age on access 
to treatment. 
N Number (0/0) * Unadjusted 
who 
received 
treatment 
Surgery (NSCLC only; N=38,399) 
20-40 227 30 13 
41-50 1345 209 16 1.21 (0.80, 1.82) 
51-60 5746 896 16 1.21 (0 .82, 1.79) 
61-70 12009 1897 16 1.23 (0.84, 1.81) 
71-80 13812 1703 12 0.92 (0.63, 1.36) 
Chemotherapy (Small cell only; N=8653) 
20-40 29 26 90 
41-50 327 243 74 0.33 (0.10, 1.13) 
51-60 1556 1163 75 0.34 (0.10, 1.13) 
61-70 3005 2030 68 0.24 (0.07, 0.80) 
71-80 2882 1590 55 0.14 (0.04, 0,47) 
Radiotherapy (whole cohort; N=91,310) 
20-40 583 81 14 
41-50 2928 630 22 
51-60 12250 2828 23 
61 -70 26296 6001 23 
71-80 32440 7315 23 
>80's 16813 3052 18 
1.70 (1.32,2.18) 
1.86 (1,47, 2.36) 
1.83 (1,45, 2.32) 
1.80 (1.42, 2.28) 
Adjusted ** 
0.94 (0.59, 1,49) 
0.93 (0.60, 1.43) 
0.86 (0.56, 1.32) 
0.62 (0,40, 0.96) 
0.33 (0.10, 1.15) 
0.38 (0.11, 1.30) 
0.29 (0 .09, 1.00) 
0.18 (0.05, 0.61) 
1.59 (1.23, 2.05) 
1.68 (1.32, 2.15) 
1.65 (1.30, 2.10) 
1.67 (1.31, 2.13) 
Legend: (%)* percentage of each age group receiving specific treatment. 
** Odds Ratio (OR) adjusted for sex, performance status, histo logy (un less 
otherwise specified ), stage and Townsend quintlle. 
8.3.2 Survival 
Cox regression ana lysis for the whole cohort, revealed young adu lt patients were 
less likely to die than patients from all other age groups (table 8.5). Specifically, 
even patients In their forties were 57% more li kely to die than those between 
20-40 years of age at diagnosis (adjusted HR 1.57, p<O.Ol, 95% CI 1.40,1.77). 
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Table 8.5: Cox regression analyses assessing the Influence of age on overall 
survival. 
Age groups N Nwho (0/0)* HR (950/0 el) Adj HR** died (950/0 el) 
20-40 years 583 317 54 
40's 2928 2121 72 1.66 (1.47, 1.87) 1.57 (1.40, 1.77) 
50's 12250 9611 78 1.96 (1.75, 2.20) 1.79 (1.60, 2.01) 
60's 26296 21192 81 2.16 (1.93, 2.41) 1.97 (1.76, 2.21) 
70's 32440 27719 85 2.63 (2.35, 2.94) 2.30 (2.05, 2.57) 
>80's 16813 15250 91 3.38 (3.02, 3.78) 2.70 (2.41 3.02) 
Legend: (%)* percentage of each age group who have died. 
** Hazard Ratio (HR) adjusted for sex, performance status, histology, stage and 
Townsend qulntlle. 
However, given carcinoid disease does not have the typical prognostic profile of 
lung cancer per se, and given there was a high proportion of Individuals with 
carcinoid disease amongst the subgroup of young adults, I repeated the overall 
Cox regression analysis excluding all patients with carcinoid disease. The results 
are depicted In table 8.6. 
Table 8.6: Cox regression for all Individuals excluding those with carcinoid 
disease (N=91,026) 
Age groups N Nwho (0/0)* HR (95% el) Adj HR** died (95% ell 
20-40 years 549 316 58 
40's 2899 2118 73 1.55 (1.38, 1.74) 1.61 (1.43, 1.81) 
50's 12198 9606 79 1.96 (1.63, 2.04) 1.85 (1.66, 2.08) 
60's 26214 21174 81 2.00 (1.79, 2.24) 2.03 (1.82, 2.27) 
70's 32376 27701 86 2.43 (2.17, 2.72) 2.34 (2.09, 2.62) 
>80's 16790 15239 91 3.38 (2.79 3.49) 2.79 (2.41. 3.02) 
Legend: (%)* percentage of each age group who have died. 
** Hazard Ratio adjusted for sex, performance status, histology, stage and 
Townsend qulntJle. 
Table 8.6 shows that, even after a" those Individuals with proven carcinoid 
disease were excluded, the likelihood of death continued to rise considerably 
with age. Those Individuals who are In their forties were 60% more likely to die 
compared with those between the age of 20 and 40 years (adjusted Hazard RatiO 
1.61, 95% confidence Interval 1.43, 1.81). I repeated the analyses In those 
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Individuals with proven non-small cell lung cancer and small cell lung cancer, 
tables 8.7 and 8.8 respectively. These results show that once the histological 
subgroup Is defined, It is only really those Individuals In their seventies and over 
who have an Increased likelihood of death compared to those between 20 and 40 
years of age at diagnosis. 
Table 8.7: Cox regression for those individuals with proven non-small cell lung 
cancer (N=38,399) 
Age groups N Nwho (%)* HR (950/0 eI) Adj HR** died (95% eI) 
20-40 years 227 181 80 
40's 1345 1065 79 1.01 (0.86, 1.18) 1.13 (0.97, 1.33) 
50's 5746 4601 80 1.03 (0.89, 1.19) 1.13 (0.97, 1.31) 
60's 12009 9560 80 1.04 (0.90, 1.21) 1.17 (1.01, 1.35) 
70's 13812 11636 84 1.24 (1.07, 1.44) 1.31 (1.13, 1.52) 
>80's 5260 4703 89 1.60 (1.38, 1.86) 1.55 (1.34 1.81) 
Legend: (%)* percentage of each age group who have died. 
** Hazard Ratio adjusted for sex, performance status, stage and Townsend 
qulntlle. 
Table 8.8: Cox regression for those Individuals with proven small cell lung cancer 
(N=8653) 
Age groups N Nwho (0/0)* HR (95% eI) AdJ HR** died (95% eI) 
20-40 years 29 27 93 
40's 327 282 86 0.84 (0.57, 1.25) 1.01 (0.64, 1.60) 
50's 1556 1355 87 0.92 (0.63, 1.34) 0.95 (0.61, 1.48) 
60's 3005 2735 91 1.10 (0.76, 1.61) 1.07 (0.69, 1.67) 
70's 2882 2663 92 1.34 (0.92, 1.95) 1.26 (0.81, 1.96) 
>80's 854 827 97 1.91 (1.30 2.80) 1.73 (1.11, 2.71) 
Legend: (%)* percentage of each age group who have died. 
** Hazard Ratio adjusted for sex, performance status, stage (limited or 
extensive) and Townsend qulntlle. 
Finally, I decided to perform survival analyses for those Individuals without 
histology prior to treatment. In contrast to the analyses where histology Is 
known, non-small cell and small cell lung cancer (table 8.7 and 8.8 respectively), 
In the absence of known histology there Is a significant Increase In likelihood of 
death as age Increases. An Individual over the age of 80 years, with 'missing' 
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data for histology, Is more than 4 times as likely to die compared with someone 
between the ages of 20 and 40 years with 'missing' histology (adjusted HR 4.26, 
95% CI 3.48, 5.21) (table 8.9). 
Table 8.9: Cox regression for those Individuals with 'missing' data for histology 
(N=38,277) 
Age groups N Nwho (010)* HR (95010 CI) AdJ HR** died (95% CI) 
20-40 years 248 100 40 
40's 1079 681 63 1.97 (1.60, 1.97) 2.01 (1.63, 2.50) 
50's 4201 3144 75 2.71 (2.21, 3.32) 2.72 (2.22, 3.34) 
60's 9553 7603 80 3.20 (2.62, 3.91) 3.17 (2.59, 3.87) 
70's 13881 11898 86 4.03 (3.30, 4.93) 3.77 (3.09, 4.61) 
>80's 9851 8982 91 5.07 (4.15 6.20) 4.26 (3.48, 5.21) 
Legend: (%)* percentage of each age group who have died. 
** Hazard Ratio adjusted for sex, performance status, stage and Townsend 
qulntlle. 
8.3.3 Non-small cell lung cancer 
There were 227 patients with proven non-small cell lung cancer (NSCLC) In the 
young adult subgroup, of whom 45% were adenocarcinoma, 30% Non-small cell 
not-otherwlse-speclfled (NOS), and only 16% were squamous cell carcinoma. 
Within this young adult subgroup with proven NSCLC only 25 (11%) were staged 
IA to IlIA, and 94 (41%) had stage IV disease at diagnosis (table 8.10). Despite 
this advanced stage the performance status at diagnosis was good, with 118 
recorded as PS 0 or 1 (52%). The number of young adult patients with NSCLC 
having surgery was 30 (13%), of whom 13 had stage I to IlIA disease, 3 had 
stage I1IB and a further 3 had stage IV disease. The remaining 11 surgical 
patients had missing data for stage. 
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Table 8.10: Distribution of stage in proven NSCLC patients across age groups (N=38,399). 
Stage 20-40 (010) 40's (010) 50's (010) 60's (0/o) 70's (010) >80'5 {0/o) Total 
IA 2 (1) 38 (3) 187 (3) 443 (4) 473 (3) 146 (3) 1289 
IB 4 (2) 55 (4) 246 (4) 679 (6) 985 (7) 366 (7) 2335 
llA 0 (0) 6 (0) 38 (1) 72 (1) 72 (1) 30 (1) 218 
lIB 4 (2) 39 (3) 204 (4) 546 (5) 585 (4) 230 (4) 1608 
IlIA 15 (7) 103 (8) 403 (7) 987 (8) 1148 (8) 394 (7) 3050 
IIIB 28 (12) 208 (15) 922 (16) 1934 (16) 2103 (15) 860 (16) 6055 
I 
IV 94 (41) 504 (37) 2139 (37) 3941 (33) 4210 (30) 1475 (28) 12363 
Occult 0 (0) 1 (0) 6 (0) 23 (0) 17 (0) 3 (0) 50 
Missing 80 (35) 391 (29) 1601 (28) 3384 (28) 4219 (31) 1756 (33) 11431 
Total 227 1345 5746 12,009 13,812 5260 38,399 
- --_ .. -
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As previously mentioned, there was no evidence that young adults with proven 
NSCLC were less likely to receive surgery than any other age group. Cox 
regression for this specific subgroup of patients, with proven NSCLC who 
underwent surgery, revealed no variation In overall mortality across the age 
groups (table 8.11). There was no evidence that young adults had a worse 
prognosis after surgical resection than any other age group. 
Table 8.11: Cox regression analysis on the subgroup of patients with proven 
NSCLC who underwent surgical resection (N=5,013). 
N 
Age N who 
(years) died (0/0)* Unadj HR (95% CI) Adj HR** (95% CI) 
20-40 30 13 43 
40's 209 81 39 0.85 (0.47, 1.53) 1.10 (0.61, 1.97) 
50's 896 361 40 0.95 (0.55, 1.65) 1.08 (0.62, 1.89) 
60's 1897 757 40 0.94 (0.54, 1.63) 1.12 (0.64, 1.93) 
70's 1703 799 47 1.21 (0.70, 2.10) 1.42 (0.82, 2.46) 
>80'5 278 152 55 1.57 (0.89 2.77) 1.74 (0.98, 3.07) 
Legend: (%)* percentage of each age group who have died. 
** Hazard Ratio (HR) adjusted for sex, performance status, stage and Townsend 
qulntile. 
These results can also be Illustrated In a Kaplan-Meier survival curve. Figure 8.6 
shows that for those patients with NSCLC who had an operation, the order In 
which half an age subgroup had died, was as follows: >80 years, seventies, 
young subgroup, sixties, fifties and then those In their forties. 
203 
0 
C! 
Q) 
. ~ ~
m 1.0 ,.... 
~ ~ 0 II) 
II) 
-c:: Q) 
~ ~ 0 
ro 1.0 c.. 0 
.... 
0 
c: 
0 
:e 1.0 
0 N 
c.. 0 e 
c.. 
0 
0 
0 
0 200 400 600 800 1000 1200 1400 1600 
Survival time (days) 
--- Age 20-40 years --- Age 41-49 years 
--- Age 50-59 years --- Age 60-69 years 
--- Age 70-79 years --- Age >80 years 
Figure 8.6: Kaplan-Meier survival curve for individuals with NSCLC who have 
undergone surgical resection (N=5,013) . 
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8.4 Discussion 
8.4.1 Principle findings 
The results of this chapter have demonstrated that variation In clinical features 
exist between young adults with lung cancer and their older counterparts. 
Specifically, In the young adult subgroup, there was a greater proportion of 
patients with adenocarcinoma and carcinoid tumours, and a higher proportion of 
late stage disease at diagnosis. Despite this the performance status at 
diagnosis, where recorded, was 0-1 In 80% of this young adult cohort. There 
was no evidence that young adults were less likely to receive surgical resection 
for proven non-small cell lung cancer, than any other age group. In contrast 
there was a statistically significant reduction In the likelihood of receiving surgery 
over the age of 70 years (adjusted OR 0.62,95% CI 0.40, 0.96), which has been 
described elsewhere (53, 92). 
The likelihood of receiving chemotherapy for proven small cell lung cancer was 
reduced In all decades above the age of 40 years, although this did not reach 
statistical significance until the subgroup of patients In their sixties. This has 
also been reported by me In Chapter 7 and elsewhere (92-94), and may reflect 
the poorer performance status of patients as they got older (92), which can 
preclude the use of chemotherapy. 
The likelihood of receiving radiotherapy, regardless of histological subtype, was 
approximately equal amongst all patients aged between 40-80 years, and was 
Significantly higher than In the young adult subgroup. This may reflect the use 
of radiotherapy In palliative as well as potentially curative treatment regimes. 
The data recorded In the National Lung Cancer Audit at the time of my research 
were Inadequate to differentiate the treatment Intent. 
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Cox regression analyses revealed an Increased likelihood of death as age 
increased, regardless of histological subtype, despite adjusting for sex, 
performance status, stage, and socio-economic status. Subgroup analysis 
revealed that this effect persisted when all Individuals with carcinoid disease 
were excluded. However, when Individual histological subgroup analyses were 
performed (non-small cell and small cell), the effect was less marked. In those 
Individuals with 'missing' data for histology, the age related Increase In likelihood 
of death was greatest. It is worth noting that In none of these subgroup 
analyses did the young adult subgroup have a poorer prognosis than their older 
counterparts. 
In the subgroup of patients with proven non-small cell lung cancer who 
underwent surgical resection, there was no evidence of a reduction in overall 
survival amongst the young adult subgroup. 
8.4.2 Strengths and weaknesses 
The strength of this research lies in the large cohort of patients aged between 20 
and 40 years, which have been drawn from an unbiased, unselected, 
contemporary national cohort of patients with lung cancer (36). The size of the 
cohort provides robust clinical and demographic data, which can be used to 
assess potential Inequalities In patient care and survival based on age. The 
weaknesses of the NLCA dataset are that It does not contain detailed Information 
on patient co-morbidity, and that a number of the data fields have missing data. 
There is evidence that the proportion of missing data Is decreasing year on year 
and that the quality of the dataset Is therefore Improving (3S, 63). Furthermore 
when I used a slightly earlier download from the NLCA which had been linked to 
HES, I found that very few of these young adults had any co-morbid Illness, 
except 14% who presented with metastatic disease, although It Is not known 
whether or not this Is directly attributable to their underlying lung cancer. 
206 
Despite these limitations, this cohort of 583 young adult patients remains the 
largest cohort of young adults with lung cancer described In published literature. 
8.4.3 Comparison with other studies 
There Is very little published literature on lung cancer In a young adult 
population, and these studies are usually small, retrospective case series In the 
one medical Institution. This study Is not restricted to one histological subtype, 
one treatment modality, or one medical Institution. These data corroborate 
previously published evidence that adenocarcinoma and carcinoid tumours are 
more common In this young adult subgroup (99, 105-108). Retrospective 
studies have also demonstrated the low rate of early stage disease In the young 
adult subgroup observed here (100-102, 108). Of note, a study from Mexico In 
1987, found 46 of 48 young adult patients had stage IV disease at diagnosis 
(100). This may reflect the duration of symptoms prior to diagnosis, which has 
been reported as longer In young adults compared to older counterparts (108), 
but these data are not held In the NLCA dataset. 
The proportion of patients without evidence of treatment appears high (42%), 
but It may reflect poor data entry Into the NLCA dataset, In addition to late stage 
at presentation. Green et al described a population with a similar high 
proportion of late stage disease, and the rate of "no treatment" was also 42% 
(100). 
There was no evidence that survival was worse In the young adult subgroup 
overall, In contrast to some published data (100, 101), but In keeping with 
others (99, 102). Bourke et al published a multlcentre retrospective study 
looking at variation In clinical features, treatment received and survival In young 
adult patients In Chicago, Israel and northern Italy (l08). This paper allows 
comparison of young adult patients In three distinct geographical areas, and 
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found variation In survival of the young adult subgroup between countries. This 
Inequality Is not a result of histological subtype, differences In sex ratio, smoking 
history nor treatment received; but Is almost certainly a reflection of stage of 
disease at diagnosis. Within the Chicago cohort (n=83), only 7% were stage I, 
compared with 16% of the cohort In Israel (N=43), and five year survival In 
Chicago was 8% compared to 25% In the Israeli young adult subgroup. Within 
my cohort of 583 young adults, although there was a large amount of missing 
data for stage, only 5% of patients had stage I disease. Five year survival data 
for this cohort Is not yet available, but the results of Cox regression 
demonstrated no Increased rate of mortality In the young compared to older 
patient groups. 
Amongst published surgical case series, with between 22 and 110 young adult 
patients (103, 104), there does not appear to be any adverse survival affect of 
young age, which Is In keeping with these findings (n=30 with resected non-
small cell lung cancer). 
8.4.4 Implications of this study 
This research has demonstrated that amongst a large cohort of young adult 
patients with lung cancer In England, very few patients have early stage disease 
at diagnosis. This could suggest denial or Ignorance on the part of patients, and 
highlights the need for a public health response In terms of educating SOCiety, 
regarding the symptoms and signs of lung cancer and the Importance of early 
detection. There also needs to be a greater level of clinical suspicion amongst 
general practitioners, and hospital doctors to ensure lung cancer Is on the 
differential diagnosis of adults less than 40 years who present with relevant 
symptoms and signs. 
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Despite this, there was no evidence that survival overall, nor In the subgroup 
with proven NSCLC treated surgically, was adversely affected In the young adult 
subgroup. Given their good performance status, and the likelihood their co-
morbidities are few, it would seem reasonable to recommend a proactive, even 
aggressive approach In managing these young adults with lung cancer. 
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Chapter 9: Summary and future research 
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9.1 Summary 
During my period of research and demonstrated by this thesis I have been able 
to establish that the National Lung Cancer Audit dataset Is an unbiased and 
representative, unselected cohort of Individuals with lung cancer In England. I 
have also created, for the first time, a composite score of co-morbidity for every 
Individual with lung cancer, and to accurately assess the Influence this has on 
access to treatment and survival. This work has culminated In the publication of 
three papers In peer review journals, as well as several abstracts at national and 
International conferences. This has led to the acceptance of the National Lung 
Cancer Audit within the lung cancer clinical field, and reinforced the Importance 
of prospective audit In health service research. 
The main findings are: 
- that socio-economlc status does not affect the likelihood of an Individual going 
on to have either surgery or radiotherapy, but that as deprivation Increased the 
likelihood of having chemotherapy declined. 
- an Individual with NSCLC Is more likely to have surgery If they are first seen In 
an NHS Trust that Is a thoracic surgical centre, and surgery has a positive 
Independent Influence on overall survival. 
- an Individual with small cell lung cancer Is more likely to have chemotherapy If 
they are first seen In an NHS Trust that has a higher level of participation In 
clinical trials, and chemotherapy has a positive Independent Influence on overall 
survival. 
- a large proportion of young adults with lung cancer have advanced disease at 
diagnosis which makes curative treatment ImpOSSible, despite a good 
performance status. There was no evidence that young adults with NSCLC who 
underwent surgery had a poorer survival than their older counterparts. 
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In order to address the geographical variation previously reported for outcomes 
from lung cancer, I have tried to quantify the facilities and performance of MOTs 
in NHS Trusts across England. There Is wide variation in the practice observed 
which appears to be based on the facilities available. However, there needs to 
be a more detailed analysis of what It Is within a thoracic surgical centre which 
leads to the Increased likelihood of a patient undergoing surgery If first seen 
there. This will need to be a piece of qualitative research, evaluating the MOTs, 
the access to Investigations, the number of lung cancer nurse speCialists, and/or 
perhaps the personalities of the members of the MDT themselves. 
9.2 Future research 
The NLCA contains good data on patient features, but there is a need to collect 
more Information regarding the NHS Trusts, and the multi-disciplinary teams 
Involved In lung cancer care. Although the overall score from Peer Review 
appeared to be a poor marker of clinical outcomes for lung cancer it may be that 
Individual standards within the overall score are more discriminating. Further 
research needs to focus on speCific aspects of the lung cancer MDT, and the 
attendance of specific team members. It may also be Important to evaluate 
more recent results from the, now annual, Peer Review process, which will allow 
a more contemporaneous comparison with up-to-date data from within the 
NLCA. 
The following list contains features which may well contribute to the patient 
pathway and encourage both efficiency and a proactive approach to lung cancer 
management. 
- the number of clinical and medical oncologists, 
- the number of thoracic surgeons, 
- a dedicated lung cancer lead physician, 
- formal administrative support to the lung multi-disciplinary team, 
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- a dedicated radiologist, and on-site PET scanners, 
- a dedicated histopathologist, 
- ITU facilities on site, 
- the surgical capacity of the 'Trust, 
- the number of lung cancer specialist nurses 
- on-site cardiology/respiratory physiology assessment. 
The Influence of these features warrants further research and Is an area I am 
particularly Interested In. 
The National Lung Cancer Audit has huge research potential, and will allow 
detailed Investigation Into several key clinical questions. I am grateful to the 
RCP Clinical Effectiveness and Evaluation Unit for allowing me to use the 
remaining research grant to continue my research. This will allow me to 
dedicate 4 hours a week (lPA of my consultant job plan) to pursue my Interest 
In health service research. SpeCifically I Intend to: 
1: use the NLCA dataset and other data sources to evaluate In more detail the 
results of Peer Review and whether they reflect clinical outcomes for Individuals 
with lung cancer. I would also like to use the NLCA/HES linked dataset to 
Investigate clinical outcomes based on route of entry to hospital (emergency, 
out-patient or planned admission). 
2: aSSist Dr Helen Powell (a respiratory SpR), who starts a PhD continuing the 
research I started In lung cancer health service research In August 2011. WIthIn 
her PhD plan we Intend to Investigate: 
-What Is the current rate of death within 30 days of surgery or chemotherapy? 
-Which patient features help to predict survival post-operatively, or post-
chemotherapy? 
-What level of risk Is an Individual with lung cancer willing to accept? 
-Who sets the bar for an acceptable level of risk? 
-What reasons are given for refusing the treatment recommended by the MOTI 
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3: pursue my role as co-chair of the ERS taskforce In Quality Management of 
Lung Cancer Care. Within this role I have already produced, distributed and 
begun to collate the results of, a national questionnaire of lung cancer physicians 
from 42 European countries. I have also co-ordlnated the production of an on-
line survey of local lung cancer services In every European country, and we have 
had more than 400 responses so far. 
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Appendix 1: Tutorials 
The National Agenda for Lung Cancer and Mesothelioma 
Essential Documents In Lung Cancer and Mesothelioma 
The Cancer Reform Strategy 
Recent developments In lung cancer 
Running an MDT meeting 
Professional relationships and the MDT 
An effective lung cancer service 
Clinical Trials In Lung Cancer and Mesothelioma 
Clinical aspects 1 - selection for radical treatment 
Clinical aspects 2 - palliative chemotherapy 
Clinical aspects 3 - palliative radiotherapy 
Clinical aspects 4 - endobronchial therapy 
Clinical aspects 5 - Specialist Palliative Care 
Clinical aspects 6 - keeping patients Informed 
Clinical aspects 7 - The lung cancer clinical nurse specialist 
Clinical aspects 8 - approach to diagnosis 
Change management 
Managing Conflict 
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Appendix 2: Scoplng document for the NICE lung cancer update 
1 Guideline title 
The diagnosis and treatment of lung cancer (update of NICE clinical guideline 24) 
1.1 Short title 
Lung cancer update 
2 Background 
a) The National Institute for Health and Clinical Excellence ('NICE' or 'the 
Institute') has commissioned the National Collaborating Centre for Cancer to 
review recent evidence on the management of lung cancer and to update the 
existing guideline 'The diagnosis and treatment of lung cancer' (NICE clinical 
guideline 24, 2005) for use In the NHS In England and Wales. The update will 
provide recommendations for good practice that are based on the best available 
evidence of clinical and cost effectiveness. 
b) NICE clinical guidelines support the Implementation of National Service 
Frameworks (NSFs) In those aspects of care for which a Framework has been 
published. The statements In each NSF reflect the evidence that was used at the 
time the Framework was prepared. The clinical guidelines and technology 
appraisals published by NICE after an NSF has been Issued have the effect of 
updating the Framework. 
c) NICE clinical guidelines support the role of healthcare professionals In 
providing care In partnership with patients, taking account of their Individual 
needs and preferences, and ensuring that patients (and their carers and families, 
If appropriate) can make Informed decisions about their care and treatment. 
3 Clinical need for the guideline 
a) There are more than 38,000 new cases of lung cancer In the UK each year 
and more than 35,000 people die from the condltloni more than for breast 
cancer and colorectal cancer combined. 
b) Lung cancer Is now the leading cause of cancer death In women. 
c) About 90% of lung cancers are caused by smoking. Now that fewer men 
smoke, lung cancer deaths In men have decreased by more than a quarter In the 
UK (a 27% reduction between 1971 and 2006). However, the number of women 
who smoke has risen and deaths from lung cancer in women have increased. 
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d) Only about 5.5% lung cancers can be cured. Although the cure rate Is rising 
slowly, the rate of Improvement has been slower than that for other common 
cancers. 
e) Outcomes In the UK are worse than those In some European countries and 
North America. 
f) There Is evidence that outcomes vary within the UK, which - among other 
factors - may be explained by variations In the standard of care. 
g) NICE clinical guidelines are regularly reviewed, and updated as necessary. As 
part of its review of NICE clinical guideline 24, the National Collaborating Centre 
for Cancer convened a Lung Cancer Expert Advisory Group In June 2007 to 
discuss whether any part (or all) of the existing guideline needed updating. The 
advisory group comprised members of the original Guideline Development Group 
and other Invited speCialists Involved In the delivery of lung cancer services. 
h) The Advisory Group Identified significant progression and expansion of the 
evidence base since the publication of NICE clinical guideline 24, Indicating that a 
large number of recommendations would need to be updated. It also Identified 
new topics not Included In the original guideline. 
I) In September 2007 the NICE Guidance Executive agreed to a partial update of 
the guideline (Including new topics where appropriate) with an 18 month 
development time. In order to produce a high quality update within the allotted 
time, In line with the methods set out In 'The guidelines manual' (2009), It will 
not be possible to update the entire lung cancer guideline. Therefore we Intend 
to focus on topics: 
• for which there Is Important new published evidence 
• that are stili controversial or uncertain 
• In which there continues to be Identifiable variation In practice, and 
• that will have the most significant Impact on the clinical service and 
management of patients with lung cancer. 
j) A draft list of the prlorltlsed clinical topics to be Included In the updated 
guideline were then developed using advice from the Advisory Group, the GOG 
chair, the GOG clinical lead and attendees at the stakeholder scoplng workshop. 
These topics were Included as an Appendix In the draft scope that was Issued to 
stakeholders for consultation In November 2008. 
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4 The guideline 
a) The guideline development process is described In detail In two publications 
that are available from the NICE website (see 'Further Information'). 'The 
guideline development process: an overview for stakeholders, the public and the 
NHS' describes how organisations can become Involved In the development of a 
guideline. 'The guidelines manual' provides advice on the technical aspects of 
guideline development. 
b) This scope defines exactly what this guideline will (and will not) examine, and 
what the guideline developers will consider. 
c) The guideline update will include: 
• updated topics and recommendations, and supporting evidence 
• new topics and recommendations, and supporting evidence 
• 'old' topics and recommendations that do not need updating and are therefore 
stili valid. The evidence that supported these recommendations will not be 
updated. 
d) There will be some Important topics that need updating but are not part of the 
final prloritlsed list. These will be added to a holding list for future consideration 
and the final guideline will make this clear to the reader. 
e) The areas that will be addressed by the guideline are described In the 
following sections. 
4.1 PopulatIon 
4.1.1 Groups that will be covered 
a) Adults (18 years and older) with newly diagnosed non-small-cell lung cancer 
(NSCLC). 
b) Adults with newly diagnosed small cell lung cancer (SCLC). 
c) Adults with relapsed NSCLC. 
d) Adults with relapsed SCLC. 
4.1.2 Groups that will not be covered 
a) Adults with mesothelioma. 
b) Adults with lung metastases arising from primary cancers originating outside 
the lung. 
c) Children (younger than 18) with lung cancer. 
d) Adults with rare lung tumours (for example, pulmonary blastoma). 
e) Adults with benign lung tumours (for example, bronchial adenoma). 
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4.2 Healthcare setting 
a) Primary care - excluding population-based and opportunistic screening and 
prevention. 
b) Secondary care. 
c) Tertiary care by services offering specialist care (for example, thoracic 
surgery, radiotherapy and Interventlonal bronchoscopy). 
4.3 Clinical management (Including service delivery where appropriate) 
a) Diagnosis and staging. 
b) Information for patient and carers. 
c) Radical treatment of patients with NSCLC. 
d) Palliative endobronchial therapies. 
e) Management of patients with SCLC. 
f) Follow up. 
g) Service organisation and Inequality of management at key decision points to 
be addressed by the needs assessment Status 
4.3.1 Scope 
This Is the final scope. 
4.3.2 Guideline 
The development of the guideline recommendations will begin In February 2009. 
5 Related NICE guidance 
Published guidance 
The following guidance will be cross referred to as appropriate: 
• Bevaclzumab for the treatment of non-small-cell lung cancer (terminated 
appraisal). NICE technology appraisal 148 (2008). See www.nlce.org.uk/TA148 
• Erlotlnlb for the treatment of non-small cell lung cancer. NICE technology 
appraisal guidance 162 (2008). Available from www.nlce.org.uk/TA162 
• Endobronchial ultrasound-guided transbronchlal needle aspiration (EBUS-
TBNA) for mediastinal masses. NICE Interventlonal procedure guidance 254 
(2008). Available from www.nlce.org.uk/IPG254 
• Pemetrexed for the treatment of non-small-cell lung cancer. NICE technology 
appraisal guidance 124 (2007). Available from www.nlce.org.uk/TA124 
• Percutaneous radlofrequency ablation for primary and secondary lung cancers. 
NICE Interventlonal procedure guidance 185 (2006). Available from 
www.nlce.org.uk/IPG185 
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• Referral guidelines for suspected cancer. NICE clinical guideline 27 (2005). 
Available from www.nlce.org.uk/CG027 
• Photodynamic therapy for localised Inoperable endobronchial carcinoma. NICE 
Interventlonal procedure guidance 137 (2005). Available from 
www.nlce.org.uk/IPG137 
• Photodynamic therapy for advanced bronchial carcinoma. NICE Interventlonal 
procedure guidance 87 (2004). Available from www.nlce.org.uk/IPG087 
• Cryosurgery for malignant endobronchial obstruction. NICE Interventlonal 
procedure guidance 142 (2005). Available from www.nlce.org.uk/IPG142 
• Improving supportive and palliative care for adults with cancer. Guidance on 
cancer services (2004). Available from www.nlce.org.uk/csgsp 
• Docetaxel, paclitaxel, gemcltablne and vlnorelblne for the treatment of non-
small cell lung cancer. NICE technology appraisal guidance 26 (2001). 
(updated by and Incorporated Into NICE clinical guideline 24). 
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Appendix 3: NICE Lung cancer update 2010: 
Needs Assessment questionnaire 
1. MDT composition and attendance: 
a) What specialty Is the current named Lung cancer lead? (please circle) 
Resp physician Oncologist (Clinical/Medical) Radiologist Surgeon Pathologist 
b) Do you have a designated member of the MDT from the following disciplines? 
Do they form part of your MDT quorum? 
And approximately what percentage of MOTs did each member attend last year? 
Part of 010 
Designated How MDT meetings 
member? many? quorum? attended? 
Thoracic Surgeon Yes/no Yes/no 
Medical Oncologist Yes/no Yes/no 
Clinical Oncologist Yes/no Yes/no 
Histopathologist Yes/no Yes/no 
Radiologist Yes/no Yes/no 
Respiratory physicians Yes/no Yes/no 
Member of Palliative 
Care team Yes/no Yes/no 
Cancer Nurse specialist Yes/no Yes/no 
Cardlothoraclc Nurse Yes/no Yes/no 
c) Does this MDT discuss cases from outside the Immediate NHS Trust? 
Yes/no (please circle) 
2. Lung cancer nurses; 
a) How many Full-Time Equivalent (FTE) Lung cancer nurses are there In your 
NHS Trust? ___ _ 
b) Approximately how many new patients would each nurse be allocated per 
year? 
c) Are there any formal cover arrangements made for sick leave and annual 
leave? Yes/no 
d) Is there any secretarial support provided for the nurses? Yes/no 
e) Is there a designated lung cancer palliative care/Macmillan nurse? Yes/no 
f) Do the lung cancer nurses provide 'support groups' Yes/no 
To allow patients and carers to discuss the diagnosis and treatment etc 
g) Are there any nurse-led follow-up clinics? Yes/no 
h) Do the nurses provide telephone support for patients and carers? Yes/no 
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3. Cardlotboraclc (surgical) Nurse Specialist; 
a) Do you have access to a Thoracic Nurse specialist? Yes/no 
b) If so, do they see patients pre-operatively? Yes/no 
c) Does the patient get a telephone number to contact with post-operative 
concerns? Yes/no 
d) Are there nurse-led post-op clinics? Yes/no 
4. MDT decision making: 
a) How many patients were discussed at your MDT In 2009? 
b) How many/what percentage of these patients had a PET scan? ____ _ 
c) How many/what percentage of the total number actually received radical 
treatment? 
d) Of those patients receiving radical treatment, 
What percentage received surgery? 
What percentage received radical radiotherapy? 
e) What percentage of patients enter clinical trials? 
<5% 5-10% >10% 
5. Admlnlstratlye support; 
a) Does your Trust have an MDT co-ordinator? 
b) Does your Trust have an electronic database? 
c) Does your Trust have a data administrator? 
d) Does your Trust routinely upload Information to LUCADA? 
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Yes/no 
Yes/no 
Yes/no 
Yes/no 
6. Availability of specialist services; 
a) Please confirm which of the following services are available either within your 
hospital, your NHS Trust, your lung cancer network, or at a higher regional level. 
(please tick appropriate column) 
If services are not available at your hospital; please Indicate the distance from 
your hospital to the treatment site and the approximate waiting time to utilise 
the speCialist service (1, < 1 week; 2, 1-2 weeks; 3, >2 weeks) 
Available? 
Hospital NHS Trust Network Region Distance (miles) 
PET scanning 
I n t e r v e n ~ o n a l b r o n c h o $ c o p y y
TBNA 
EBUS 
EUS 
Endobronchial 
stenting 
Electrocautery 
Laser therapy 
Cryotherapy 
Photodynamic 
therapy (PDT) 
Brachytherapy 
Thoracoscopy 
Medical (LA) 
Surgical (VATS) 
Other services 
Mediastinoscopy 
Pulmonary 
rehabilitation 
Specialist SOB 
clinics 
Treatment options 
CHART 
Radical RTx 
Palliative RTX 
Chemotherapy 
Thoracic surgery 
Legend: TBNA; TransBronchlal Needle Aspiration; 
EBUS; EndoBronchial UltraSound (needle biopsy) 
EUS; Endoscopic UltraSound (needle biopsy) 
SOB; Shortness of breath 
RTx; Radiotherapy 
b) Please Indicate the pathology 'turn around' time; 
Diagnostic samples (days) 
Surgical samples (days) 
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Waiting time? 
Appendix 4: Letter sent to Lung cancer lead physicians 
Dear lung Cancer lead, 
Division of Epidemiology and Public Health 
University of Nottingham 
NG51PB 
anna,rlch@nottlngham.ac.uk 
5th March 2009 
We are a research team funded by the Royal College of Physicians to host a 
Fellow In lung Cancer (Dr Anna Rich) with the remit to examine the lUCADA 
dataset and look at ways In which it can be used to Influence a change In 
service. As part of the initial validation process, we are Investigating the 
completeness of LUCADA to ensure that lack of completeness does not bias 
future analyses. We have already completed some work In this area but need 
your help. 
We need to know the total number of lung cancer and mesothelioma patients 
'first seen' at your trust for the period 01/01/2007 to 31/12/2007. Your trust 
has been randomly selected, and this correspondence comes via Dr Roz Stanley 
at the Information Centre In leeds. She has kindly agreed to distribute these 
letters, and forward the responses to us. 
We are very grateful for your attention to this as the Information you provide will 
greatly assist In correlating LUCADA figures with your own. 
Yours faithfully, 
Dr Anna Rich, RCP Fellow. 
Dr David Baldwin, Consultant Physician, lung Cancer Lead, Hon Lecturer. 
Prof Richard Hubbard, BlF Professor of Respiratory Epidemiology. 
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Appendix 5: ICD-10 codes for diagnoses pertinent to the Charlson Index 
cancer 2 
ICD-10 d 2 
2 
ca nce r 
ca 
ca ncer 
aids ca ncer 
aids 
aids 
aids 
2 
2 
2 
2 
226 
C030 ncer 
C031 cancer 
C039 cancer 
CO cancer 
2 
2 
2 
cancer 2 
227 
C248 cancer 2 
cancer 2 
cancer 
cancer 
cancer 
cancer 
cancer 
cancer 
2 
2 
2 
2 
2 
228 
6 
6 
229 
C833 haem 
C834 hae 
C835 haem 
C836 hae 
haem 
haem 
haem 
r 
dm 1 
C910 haem dmcom 2 
230 
ha 2 
haem 
haem 
haem 
2 
2 
1 
1 
2 
haem 
haem 
haem 2 
haem 1 
2 
ca 1 
1 
1 
dementia 
dementia 
dementia 
1 
1 
1 
stroke 1 
231 
stroke 
stroke 
12 cardiac 
cardiac 
cardiac 
cardiac 1 
cardia 1 
cardiac 1 
cardiac 1 
1691 
1692 
1693 
1694 
1698 
1 
1 
1715 1 
232 
ulcer 1 
ulcer 1 
ulcer 1 
ulcer 
ulcer 
1 
J430 1 
J431 1 
J432 
renal 
renal 
renal 2 
renal 2 
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2 
2 
2 
2 
2 
2 
2 
2 
renal 
renal 
re I 
cancer 
ca 
ctd ca 2 
ctd 
ctd 
ctd 
ctd 
ctd 
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Appendix 6: The key standards used In the Peer Review process 2003-07 
08-2C-l-Lung Multidisciplinary Team (MDT) 
Measure Measure number 
08-2C-I0l Single named lead clinician 
08-2C-I02 Named core team members 
08-2C-I03 Team attendance at NSSG meetings 
08-2C-I04 If separate pre-diagnostic MDT membership named 
Meet fortnightly and record core attendance and protocols for 
08-2C-I05 referral to next scheduled meeting 
08-2C-I06 MDT agreed cover arrangements for core members 
08-2C-I07 Core member (or cover) present 2/3 of meetings 
08-2C-I08 Annual meeting to discuss operational policy 
08-2C-I09 Policy for all new patients to be reviewed by MDT 
OS-2C-110 Policy for communication of diagnosis to GP 
OS-2C-lll Operational policy for named key worker 
OS-2C-1l2 Core histopathology member taking part In histopathology EQA 
OS-2C-1l3 Core nurse member completed specialist study 
OS-2C-1l4 Agreed responsibility for core nurse members 
OS-2C-115 Agreed list of additional responsibilities for one core nurse member 
Attendance at national advanced communication skills training 
OS-2C-1l6 programme 
OS-2C-1l7 Extended membership of MDT 
OS-2C-1l8 Patient permanent consultation record 
OS-2C-119 Patient experience exercise 
08-2C-120 Presentation and discussion of patient experience exercise 
08-2C-121 Provision of written patient Information 
08-2C-122 Agree and record Individual patient treatment plans 
08-2C-123 NSSG agreed clinical guidelines 
08-2C-124 NSSG agreed referral guidelines 
08-2C-125 NSSG agreed diagnosis assessment Imaging guidelines 
08-2C-126 NSSG agreed diagnosis assessment pathology guidelines 
08-2C-127 MDT/Network agreed collection of minimum dataset 
MDT/NSSG agreed policy for the electronic collection of specific 
OS-2C-12S portions of MDS 
08-2C-129 MDT/NSSG agreed participation In network audit 
08-2C-130 MDT present results from participation In network audit 
08-2C-131 MDT/NSSG agreed list of approved trials 
08-2C-132 MDT/NSSG remedial action from MDT's recruitment results 
Legend: NSSG Network Site Specific Group (I.e. Lung) 
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Appendix 7: Postgraduate training courses 
Date Course Credits 
August 2008 Basic Epidemiology and Statistics 
September 2008 Advanced Epidemiology and Statistics 5 
Nov 26th 2008 Word 2007 1 
June 3rd 2009 Long documents in Word 2007 2 
June 17th 2009 Postgraduate Forum (poster presentation) 4 
Myers-Briggs 1 
Advanced Presentations skills (on-line) 2 
Getting Into thesis writing 1 
CV writing and Interview skills 1 
March is-17th 2010 Clinical management and Leadership 6 
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